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ABSTRACT 
The hypoxia signalling pathway controls the adaptation of cells to decreased oxygen 
availability. When oxygen becomes limiting, the central transcription factor of the pathway, 
hypoxia-inducible factor (HIF), is activated and induces the expression of a set of genes, which 
cause a glycolytic switch, enhance cell survival and induce angiogenesis. While those are 
necessary physiological adaptive processes, they are also hallmarks of cancer and hypoxia 
signalling is often found activated in cancer. However, current knowledge about the regulation 
of the hypoxia signalling pathway is not able to satisfactorily explain the deregulation found in 
cancer. 
Therefore, the aim of this work was to discover new regulatory mechanisms that could be 
responsible for sustained hypoxia signalling and therefore might represent future therapeutic 
targets. We focused on how post-translational modifications affected the properties of the 
central proteins of the pathway. Using standard biochemical approaches and fluorescence 
lifetime imaging, we found that the ubiquitin specific protease 29 (USP29) is a deubiquitinase 
for HIF-1α. Moreover, USP29 is the first ubiquitin protease towards HIF-2α. USP29 de-
conjugates poly-ubiquitin from HIF-α and prevents its proteasomal degradation, leading to its 
stabilisation even in normoxic conditions. Importantly, this action of USP29, while dependent 
on its catalytic activity, was not dependent on the classical prolyl-hydroxylation and pVHL-
mediated ubiquitination, and therefore we propose that USP29 is a non-canonical HIF activator. 
As hardly any reports about USP29 were available, we next aimed to characterise this 
maternally imprinted protein. We found that USP29 itself was subject to poly-ubiquitin-
mediated destabilisation, but was able to remove the ubiquitination itself and therefore auto-
stabilise in a catalytic activity-dependent way. Furthermore, we demonstrated that USP29 
formed homodimers in living cells. Finally, we found that USP29 mRNA levels correlated with 
disease progression and severity in prostate cancer and suggest that USP29 might become an 
attractive target for therapeutic targeting of hypoxia signalling in the future.   
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Chapter 1: Introduction 
1.1 Hypoxia signalling  
1.1.1 Oxygen 
In the lungs oxygen is extracted from the atmospheric air and is bound by haemoglobin in the 
erythrocytes. As the erythrocytes travel through the circulatory system they deliver molecular 
oxygen to the cells. Cells rely on oxygen during the last step of the respiratory chain in the 
mitochondria for the aerobic production of ATP. If oxygen levels drop below a cell-dependent 
critical level, cells experience hypoxia and cannot sustain aerobic respiration. A switch to 
glycolysis, the less efficient, but oxygen-independent way of producing ATP is required to 
ensure cell survival. The sensing of cellular oxygen levels, the increase of oxygen and ATP 
availability, the switch between the modes of energy generation and ultimately the adaption to 
the low oxygen environment, is controlled by the hypoxia signalling pathway.  
1.1.2 Discovery of the hypoxia signalling pathway 
A hypoxia inducible factor (HIF) was first described by Semenza et al. in 1992 as a nuclear 
factor that enhances transcription of the erythropoietin (EPO) gene in hypoxic conditions by 
binding to a 3’ enhancer sequence element (Semenza and Wang, 1992) that had previously been 
identified (Semenza et al., 1991). Wang and Semenza further showed that in response to 
hypoxia, HIF exhibited DNA binding activity also in cells that do not transcribe the EPO gene, 
suggesting that HIF and the sequence it binds to, might be involved in a general hypoxic 
response (Wang and Semenza, 1993). Further experiments showed that HIF consisted of a HIF-
α and HIF-β subunit and that both subunits contain a basic helix-loop-helix and a PAS domain 
(Wang et al., 1995; Wang and Semenza, 1995). While their mRNA levels were not regulated by 
hypoxia, HIF-α protein could be shown to be destabilised in normoxia (Huang et al., 1996; 
Salceda and Caro, 1997). Huang et al. showed that the destabilisation of HIF-α was mediated 
through the ubiquitin-proteasome pathway and that an oxygen dependent degradation (ODD) 
domain was controlling this process (Huang et al., 1998). Destabilisation depends on von-
Hippel-Lindau protein (pVHL) (Maxwell et al., 1999), which mediates the oxygen-dependent 
ubiquitination of HIF-α (Ohh et al., 2000). Binding of pVHL to HIF-1α’s ODD domain depends 
on the post-translational hydroxylation of two conserved proline residues (Pro-402 and Pro-564 
in the case of human HIF-1α) within the ODD (Ivan et al., 2001; Jaakkola et al., 2001) (Figure 
1.1). A so far unknown Fe
2+
-, 2-oxoglutarate- and oxygen-dependent prolyl-4-hydroxylase 
(called HIF-PH) was suggested to be responsible for this modification (Jaakkola et al., 2001). 
Shortly after, three human HIF-PHs designated PHD1, PHD2 and PHD3 were identified by 
Bruick et al. and Epstein et al. (Bruick and McKnight, 2001; Epstein et al., 2001). 
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Figure 1.1: The canonical hypoxia signalling pathway. In normoxia PHD proteins use 
molecular oxygen to hydroxylate HIF-α on two proline residues within the oxygen dependent 
degradation domain (blue). Hydroxylated HIF-α is recognised by the ubiquitin E3 ligase pVHL 
(von-Hippel Lindau protein), poly-ubiquitinated and degraded by the proteasome. When oxygen 
becomes limiting (hypoxia), HIF-α evades PHD/pVHL-mediated degradation, dimerises with 
HIF-1β and binds to hypoxia responsive elements (HRE) in the regulatory sequences of genes. 
HIF recruits co-activators (CoA) to transactivate the expression of its target genes. 
1.1.3 Hypoxia inducible factor HIF 
The hypoxia inducible factor consists of an α-subunit that is destabilised in normoxia and the β-
subunit (HIF-1β or ARNT) (Wang et al., 1995; Wang and Semenza, 1995) that was assumed to 
not underlie oxygen-dependent regulation but has recently been shown to be somewhat 
regulated by hypoxia (Wolff et al., 2013). HIF-α and HIF-1β heterodimerise via their basic 
helix-loop-helix (bHLH)/PAS domains (Figure 1.2) and the dimer binds to HRE enhancer 
motifs on the DNA (Jiang et al., 1996; Wang and Semenza, 1993). HIF then recruits the general 
co-activators CBP/p300 via the transactivation domain (TAD) (Arany et al., 1996), leading to 
the expression of a wide set of HRE-controlled genes. Apart from the erythropoietin gene, these 
are genes that enhance the glycolytic potential of the cell by increasing the expression of 
glucose transporters and of glycolytic enzymes, such as GLUT1 and phosphoglycerate kinase 1, 
respectively (Iyer et al., 1998). Among the HIF target genes are also vascular endothelial 
growth factor (VEGF), which induces angiogenesis (Iyer et al., 1998) and the anti-apoptotic 
protein BCL-xL (Chen et al., 2009). The hydroxylation of an asparagine residue in HIF-α’s C-
terminal transactivation domain (CTAD) by Factor Inhibiting HIF (FIH) negatively regulates 
the gene expression through inhibition of the binding of the co-activators, representing an 
additional layer of regulation (Lando et al., 2002; Mahon et al., 2001). 
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Three HIF-α subunits (HIF-1α, HIF-2α, HIF-3α) have been described (Ema et al., 1997; Gu et 
al., 1998; Semenza and Wang, 1992) of which HIF-1α and HIF-2α are the major activators of 
hypoxia induced gene transcription (Figure 1.2). 
 
Figure 1.2: Domain structures of the α-subunit of the hypoxia inducible factors 1-3. All 
three HIF-α isoforms contain an N-terminal basic helix-loop-helix (bHLH) domain and a PAS 
domain for dimerisation with HIF-β, and an oxygen dependent degradation domain (ODDD) 
with one or two proline residues that are subjected to hydroxylation by PHDs. While HIF-3α 
only contains one transactivation domain (TAD) followed by a leucine zipper domain, HIF-1α 
and HIF-2α contain an N-terminal (NTAD) and a C-terminal (CTAD) transactivation domain 
for recruitment of transcriptional coactivators. The CTAD contains an asparagine residue that 
can be subjected to FIH-mediated hydroxylation, leading to impaired recruitment of the 
transactivators CBP/p300. From (Duan, 2016) 
1.1.4 Prolyl-hydroxylase domain containing proteins (PHDs) 
Prolyl-hydroxylase domain containing proteins (PHDs) act as intracellular molecular oxygen 
sensors. In the presence of sufficient molecular oxygen and the cofactors Fe
2+
 and α-
ketoglutarate, PHDs hydroxylate two proline residues within the oxygen dependent degradation 
domain (ODDD) of the α-subunit of HIF, leading to its pVHL-dependent subsequent 
degradation. The PHD family consists of four PHDs, called PHD1, PHD2, PHD3 and PHD4 
(Bruick and McKnight, 2001; Epstein et al., 2001; Koivunen et al., 2007; Oehme et al., 2002). 
While the latter is bound to the membrane of the endoplasmic reticulum and its functions are 
only poorly understood, PHD1-3 have been characterised much more extensively (Table 1.1). 
They all share a similar domain structure but show differences in tissue expression pattern (Lieb 
et al., 2002), localisation within the cell (Metzen et al., 2003), protein stability and HIF-α target 
specificity (Appelhoff et al., 2004; Berra et al., 2003; Huang et al., 2002). PHD2 and PHD3 
expression is upregulated during hypoxia, representing a negative feedback-loop allowing for 
rapid HIF-α destabilisation upon reoxygenation (Berra et al., 2003; Marxsen et al., 2004; 
Minamishima et al., 2009; Pescador et al., 2005). PHD2 has been described to be the main PHD 
controlling HIF-1α stability and levels in normoxia (Berra et al., 2003).  
  
4 Introduction 
Table 1.1: Comparison of the members of the prolyl hydroxylase family 
 PHD1 PHD2 PHD3 reference 
alternative 
names 
HPH3 
EGLN2 
HPH2 
EGLN1 
HPH1 
EGLN3 
SM-20 
(Bruick and McKnight, 2001) 
(Epstein et al., 2001) 
(Wax et al., 1994) 
localisation nucleus cytoplasm 
nucleus, 
cytoplasm 
(Metzen et al., 2003) 
predominant 
form in 
testis - heart, liver (Lieb et al., 2002) 
inducible by 
hypoxia 
no + ++ 
(Aprelikova et al., 2004; Berra et al., 
2003; Marxsen et al., 2004; 
Minamishima et al., 2009; Pescador et 
al., 2005) 
1.1.5  Hypoxia signalling and cancer 
Hypoxia signalling is an important physiological process to allow the survival of cells during 
oxygen deprivation, as it might occur during embryonic development, wound healing and at 
high altitudes (Semenza, 2012a). However, the adaptive processes that are initiated through the 
hypoxia signalling have transforming potential (Semenza, 2012b). For instance, the resistance 
to cell death, angiogenesis and the glycolytic switch are all hallmarks of cancer (Figure 1.3). 
Accordingly, HIF-1α and HIF-2α have been shown to be overexpressed in many human cancers 
(Talks et al., 2000) and can serve as negative prognostic marker in different cancers (Rankin 
and Giaccia, 2008). HIF-α overexpression does however not always correlate with the present 
oxygen levels (Mayer et al., 2008). In this context, Otto Warburg found already almost 100 
years ago that cancer cells were highly glycolytic even in the presence of oxygen (Warburg et 
al., 1927) and hypothesised that the metabolic reprogramming was sufficient to cause cellular 
transformation (Warburg, 1956).  
In the case of clear cell renal cell carcinoma (ccRCC) the loss-of-function of the ubiquitin E3 
ligase pVHL is responsible for stabilised HIF-α and sustained hypoxia signalling (Maxwell et 
al., 1999). However in most other cancer types, it remains unexplained how the HIF-α 
expression is inappropriately upregulated. The gain or loss of post-translational modifications 
(PTMs) of HIF-α and other proteins of the hypoxia signalling pathway have the potential to 
modulate the canonical signalling pathway and could cause the deregulation. 
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Figure 1.3: Hallmarks of cancer. Properties of cancer cells that are required for malign 
transformation and cancer progression. From (Hanahan and Weinberg, 2011). 
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1.2 PTMs and deubiquitinases 
Post-translational modifications (PTMs) of proteins are the covalent and in most cases 
reversible attachment of a small functional group to a target protein. A PTM can alter the 
protein’s enzymatic activity, localisation, stability, and/or interaction with other proteins. 
Therefore, these non-genetically encoded modifications that are mainly carried out by enzymes, 
add to the complexity of the proteome as they can ascribe different functionalities to the same 
gene product. Common PTMs include among others phosphorylation, acetylation and alkylation 
as well as the covalent linkage of fatty acids, saccharides or small proteins such as ubiquitin and 
SUMO (small ubiquitin related modifier) to the target protein (Ribet and Cossart).  
1.2.1 PTMs in hypoxia signalling 
Most proteins of the hypoxia signalling pathway are known to be subjected to post-translational 
modifications that modulate their function. Apart from being poly-ubiquitinated by the 
canonical regulator pVHL after PHD-mediated prolyl-hydroxylation, HIF-1α and HIF-2α are 
also ubiquitinated by other ubiquitin E3 ligases (see 1.3.1 and 1.3.2). Furthermore, the covalent 
attachment of SUMO to HIF-1α and HIF-2α has been reported to inhibit their transcriptional 
activity, the underlying mechanisms however are not fully understood (Bae et al., 2004; Berta et 
al., 2007; van Hagen et al., 2010). Interestingly, also HIF-1β and CBP/p300 have been shown to 
be modified by SUMO and SUMOylation decreased the transactivation activity of the HIF 
complex (Huang et al., 2009; Tojo et al., 2002). SUMOylation also affects the upstream 
regulator of HIF - pVHL. pVHL SUMOylation by PIASy in hypoxia has been reported to 
increase its stability and to inhibit its ability to target HIF-α for degradation (Cai and Robertson, 
2010; Cai et al., 2010). HIF-α is also subjected to phosphorylation by various different kinases 
in response to various stimuli and with different functional outcomes ranging from 
destabilisation to enhanced transcriptional activity (Dimova et al., 2009). For example, the 
phosphorylation of HIF-1α by GSK-3β targets HIF-1α for pVHL-independent proteasomal 
degradation (Flugel et al., 2007). In contrast, phosphorylation by CDK1 stabilises HIF-1α 
(Warfel et al., 2013). Protein kinase CK2-mediated phosphorylation of HIF-1α does not affect 
HIF-1α protein stability but impairs its binding to HIF-1β and hence results in decreased HIF 
signalling (Kalousi et al., 2010). PKA has recently shown to activate HIF-1 signalling through 
direct phosphorylation by protecting HIF-1α from proteasomal degradation and by stimulating 
its interaction with the co-activator CBP/p300 (Bullen et al., 2016).  
Taken together, it becomes clear that apart from the oxygen-dependent canonical regulation of 
HIF signalling, there are many more mechanisms to regulate and fine-tune the pathway to 
adjust the response to the cell’s needs. 
  
 Introduction 7 
1.2.2 Ubiquitination 
Ubiquitin is a small protein that is ubiquitously expressed in all cell types. Two of the four 
ubiquitin coding genes Ubb, Ubc, RpL40 and RpS27, encode poly-ubiquitin which is cleaved by 
enzymes with deubiquitinating activity into ubiquitin monomers (Redman and Rechsteiner, 
1989). Monomeric ubiquitin gets covalently attached via its C-terminal glycine-glycine motif to 
the active site cysteine of an E1 ubiquitin-activating enzyme in an ATP-dependent manner. 
From the E1 enzyme it is transferred to a cysteine of an E2 ubiquitin-conjugating enzyme and 
ultimately with the help of a E3 ubiquitin-ligase the ubiquitin molecule is attached to a lysine 
residue of the target protein (see Figure 1.4A) (Pickart, 2001). The E3 ligase is determinant for 
the choice of the target protein as it establishes the specific contact between the target protein 
and the ubiquitin-loaded E2 enzyme. While RING-type E3 ligases bind E2 and target proteins 
via two different domains and hence mediate their direct interaction, HECT-type E3 ligases first 
accept the ubiquitin from the E2 enzyme and further transfer it onto the substrate protein. 
Ubiquitin contains seven internal lysine residues (K6, K11, K27, K29, K33, K48, K63) that can 
act as ubiquitin-acceptors themselves and therefore poly-ubiquitin chains can be built up. 
Moreover, poly-ubiquitin can be assembled by linking ubiquitin moieties to the N-terminus of 
the preceding molecule in a head-to-tail manner, creating linear poly-ubiquitin chains (Kirisako 
et al., 2006). While mono-ubiquitination is thought to be implicated in processes other than 
protein degradation, poly-ubiquitination was long understood to be the key signal for protein 
degradation by the proteasome. More closely examined, it is the type of poly-ubiquitin chain 
that determines the target protein’s fate (see Figure 1.4B). While K48- and K11-linked poly-
ubiquitination are thought to be the main signals for protein degradation (Chau et al., 1989; 
Matsumoto et al., 2010), K63 chains are known to be mainly implicated in lysosomal targeting 
as well as DNA damage and NF-κB signalling (Clague et al., 2012; Deng et al., 2000; Spence et 
al., 1995). The latter is additionally regulated by linear ubiquitin chains (Haas et al., 2009). The 
role of the other types of chains and of mixed chains (Figure 1.4B bottom) is much less 
understood, yet in several specific protein contexts some specific functions have been ascribed 
to some types. Whether they represent the general behaviour of the given ubiquitin modification 
or whether there it depends on each individual target protein and its interactors remains to be 
investigated (Yau and Rape, 2016). 
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Figure 1.4: Protein ubiquitination. (A) Ubiquitin (Ub) is activated by the ATP-dependent 
covalent attachment to an E1 activating enzyme. Ubiquitin is then transferred to an E2 enzyme 
from where the ubiquitin is directly or indirectly transferred to a substrate protein (S) with the 
help of an E3 ligase. (Poly-) ubiquitinated substrate can either be degraded by the proteasome or 
the ubiquitination can be removed by a deubiquitinating enzyme (DUB). (B) Types of ubiquitin 
(U) conjugations to the substrate protein (S) and their functional implications (Yau and Rape, 
2016). 
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1.2.3 Deubiquitination 
Ubiquitination is a reversible process and mono- and poly-ubiquitin chains are removed from 
target proteins by a class of enzymes that exhibit ubiquitin-specific protease activity that allows 
for proteolytic cleavage of the isopeptide bonds between two ubiquitin moieties or between the 
target protein and the first ubiquitin molecule linked to it. The DeUBiquitinases (DUBs) are 
divided into families based on the sequence and fold of their catalytic site (Komander et al., 
2009). The JAB1/MPN domain-associated metallopeptidases (JAMMs) is the only family using 
a metalloprotease active site, and JAMMs are associated with the proteasome where they are 
responsible for the de-ubiquitination of target proteins prior to their degradation (Verma et al., 
2002). All other families use a cysteine protease active site with a catalytic triad consisting of a 
cysteine, a histidine and an asparagine/aspartate residue. Among them, the biggest family are 
the ubiquitin specific proteases (USPs), currently having 56 members (Coyne and Wing, 2016). 
Further families are the ubiquitin COOH-terminal hydrolases (UCHs), the ovarian tumor 
proteases (OTUs), Machado–Joseph disease protein domain proteases (Josephins) and the most 
recent MINDYs (motif interacting with Ub-containing novel DUB family) (Abdul Rehman et 
al., 2016; Fraile et al., 2012; Komander et al., 2009). DUBs bind to their target proteins via 
ubiquitin binding domains such as ubiquitin-interacting motifs (UIM) and ubiquitin associated 
(UBA) domains. DUBs can trim poly-ubiquitin chains and remove them completely from the 
target protein by cleaving them one by one from the end (exo-cleavage) or by cleaving peptide 
bonds anywhere within the polyubiquitin chain (endo-cleavage). Furthermore, some DUBs 
display cleavage selectivity towards polyubiquitin chains of a certain linkage type (Komander et 
al., 2009).  
1.2.4 USP29 (Ubiquitin-specific protease 29) 
1.2.4.1 Discovery of the Usp29 gene 
The murine Usp29 gene was discovered in 2000 by Kim et al. while looking for new genes 
lying in a conserved imprinted region around the Peg3 gene (Kim et al., 2000). Peg3 (paternally 
expressed gene 3) is maternally imprinted and encodes a zinc finger protein (Kuroiwa et al., 
1996), which is expressed in murine brain tissue and has been shown to be required for 
appropriate maternal behaviour (Li et al., 1999). In 1999 the Zim1 gene (imprinted zinc finger 
gene 1) was found adjacent to the murine Peg3 gene. Zim1 is a maternally imprinted gene and it 
also encodes a zinc finger protein (Kim et al., 1999). Subsequently, a third murine gene within 
the same region was identified and was named ubiquitin-specific processing protease 29 
(Usp29) due to its homology with a putative yeast ubiquitin hydroxylase (Kim et al., 2000). The 
murine gene contains 5 exons, with the entire ORF being located in exon 5 and coding for a 869 
amino acid long protein. The expression of the gene from the paternal allele was mainly 
detectable in adult brain, but also in testis. The human PEG3 gene is located on chromosome 
19q13.4 and is mainly expressed in the ovary and placenta (Kim et al., 1997). As in mice, the 
human homologue of Usp29 was found adjacent to the human PEG3 gene and USP29 mRNA 
was only detectable in adult testis, indicating a different expression pattern compared to mouse 
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(Kim et al., 2000). The human USP29 gene encodes a 922 amino acid long protein that shares 
42.5% amino acid sequence identity with the murine homologue. However, mouse and human 
USP29 share the well conserved protease catalytic domain required for supposed DUB activity. 
This domain is split into two parts (Clague et al., 2013) with the catalytic cysteine C294 being 
located in the first part and the catalytic histidine 840 and asparagine 857 in the second part (Ye 
et al., 2009), indicating that the C-terminus needs to fold in to build up the functional catalytic 
site (Figure 1.5). USP29 further contains a pleckstrin homology (PH) domain as well as two 
ubiquitin interacting motifs (Clague et al., 2013). Interestingly bovine USP29 RNA, even 
though having lost its protein coding capability due to missense mutations is still expressed in 
adult brain, possibly having some functions as a non-coding RNA (Kim et al., 2007). 
 
Figure 1.5: USP29 domain structure. The N-terminal PH domain is displayed in blue. The 
catalytic domain (green) with its active site residues cysteine, histidine and asparagine is split 
into two parts with two ubiquitin interacting motifs (red) being located in between. 
1.2.4.2 Imprinting and transcription of the Peg3 domain and the Usp29 gene 
The Peg3 domain contains seven genes, Peg3, APeg3, Usp29, Zim1, Zim2, Zim3, and Zfp264 
(Figure 1.6). These genes are controlled by five promoters of which three are differentially 
methylated on maternal and paternal alleles (DMR). Peg3 and Usp29 genes are subjected to the 
control of a common imprinting control region (ICR), a 5 kb long region located around the 
first exons of the Peg3 and the Usp29 genes. The DMRs are established either during oogenesis 
(bi-directional Peg3/Usp29 promoter) or after fertilisation (Huang and Kim, 2009; Lucifero et 
al., 2004). The establishment of the methylation of the Peg3/Usp29 DMR during oogenesis has 
been shown to be dependent on the transcription factor Ying Yang 1 (YY1) (Kim et al., 2009). 
The 7 genes are clustered on the two sides of the Peg3 domain around a large 250 kb intergenic 
region, that while not containing any obvious ORF, contains 20 evolutionary conserved regions 
(ECRs) (Thiaville et al., 2013). One of these ECRs, ECR18 has been shown to interact with the 
bi-directional promoter of Peg3/Usp29 and the Zim2 promoter in testis and brain and to act as 
an enhancer. Additionally to its function in setting DNA methylation of the DMR, YY1 also 
seems to function as a direct transcription factor. Within the Peg3 domain, YY1 binds to two 
conserved sequence elements, CSE1 and CSE2. Binding of YY1 to CSE1 seems to repress 
expression of both murine Peg3 and Usp29. On the other hand, expression of Peg3 but not 
Usp29 is enhanced after binding of YY1 to CSE2 (Thiaville et al., 2013). Another group 
reported that the expression of USP29 was controlled by an enhancer element very similar to c-
myc’s FUSE (Far Upstream Cis Element), which they therefore called uFUSE. FUSE binding 
protein 1 (FBP1) was shown to bind to the uFUSE and to activate expression of the Usp29 gene 
upon its interaction with AIMP2 (p38/JTV1). Furthermore, they claim that AIMP2 translocates 
into the nucleus in response to oxidative stress and transactivates Usp29 (Liu et al., 2011). 
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Figure 1.6: Organisation of the human Peg3 domain. The Peg3 domain contains 7 genes of 
which 3 are maternally (red) and 4 paternally (blue) expressed. Three differentially methylated 
regions (DMR) are responsible for the imprinting of the gene on either the paternal or the 
maternal allele. 20 evolutionarily conserved regions (ECR) spread over the central non-coding 
region of the Peg3 domain control its imprinting and transcription. (He and Kim, 2014) 
1.2.4.3 USP29 biological functions 
The first evidence of USP29’s deubiquitinating activity and biological function was published 
in 2011 by Liu et al. They demonstrate that USP29 interacts with and stabilises the tumour 
suppressor p53 by de-ubiquitinating it in response to oxidative stress (Liu et al., 2011). USP29 
was also shown to localise to double strand breaks in the DNA and to reverse the Rnf8-
dependent “priming” mono-ubiquitination of local H2A histones. USP29 thereby prevents the 
recruitment and action of a second ubiquitin E3-ligase, RNF168, which is necessary for bulk 
histone ubiquitination, and hence focus formation and initiation of adequate DNA repair 
(Mosbech et al., 2013).  
The checkpoint adapter protein claspin is the most recent protein that has been claimed to be 
regulated by USP29. Claspin is regulated by ubiquitin-dependent proteasomal degradation 
throughout the cell cycle and upon DNA damage and is required for checkpoint recovery. 
Martín et al. present data pointing to a role of USP29 in protecting claspin from destabilisation 
and show that USP29 is required for adequate S-phase progression (Martin et al., 2015). 
1.3 Hypoxia signalling and the ubiquitin proteasome 
system 
In the past decade it has been shown that apart from HIF-α many other members of the hypoxia 
signalling pathway are also regulated by the ubiquitin proteasome system (UPS). Furthermore, 
ubiquitin E3 ligases other than pVHL have been described to poly-ubiquitinate HIF-α. 
Deubiquitinases have been shown to also interfere with the hypoxia signalling pathway by 
reversing canonical and non-canonical ubiquitinations. 
In the course of my PhD we published the Mini-Review article “DUBs, new members in the 
hypoxia signalling club” in Frontiers in Oncology’s Research Topic “Tumor hypoxia: Impact in 
tumorigenesis, diagnosis, prognosis and therapeutics”. The article summarises the current 
understanding, at that time, of how members of the hypoxia signalling pathway are regulated by 
ubiquitin ligases and deubiquitinases. Furthermore it highlights how DUBs are affected by 
hypoxia and where hypoxia-related DUBs have been implicated in diseases.  
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I drafted, wrote and revised the manuscript and answered to the reviewers in conjunction with 
Edurne Berra at CIC bioGUNE.  
The following paragraphs 1.3.1-1.3.5 are excerpts from the article which is included in this 
thesis as Appendix 1. 
1.3.1 DUBs in canonical hypoxia signalling 
In the context of the canonical HIF signalling pathway, so far there are relatively few DUBs 
reported in the literature, and reports are mostly focused on the impact on HIF-1α. USP20 (also 
called pVHL interacting deubiquitinating enzyme 2, VDU2) was the first DUB to be described 
to reverse pVHL-mediated HIF-1α ubiquitination (Li et al., 2005). In turn, USP20 is a pVHL 
target (Li et al., 2002). MCPIP1 also deubiquitinates HIF-1α to promote angiogenesis (Roy et 
al., 2013). In the context of ciliogenesis, USP8 has been found to bind to HIF-1α’s PAS domain 
and to partially protect HIF-1α from degradation (Troilo et al., 2014). More recently, UCHL1 
has been shown to be a positive regulator of HIF-1α protein stability acting on HIF-1α’s ODDD 
(Goto et al., 2015).  
Hicks et al. showed in a recent paper that Sprouty2 is a negative regulator of HIF-α, acting on 
the canonical hypoxia signalling pathway. Sprouty2 is associated with pVHL and destabilises 
HIF-α in hypoxia, presumably by mediating pVHL-dependent ubiquitination (Hicks and Patel, 
2016). The same group had shown previously that Sprouty2 itself is regulated via PHD-
dependent proline hydroxylation and subsequent pVHL-dependent ubiquitination and 
degradation (Anderson et al., 2011).   
1.3.2 DUBs in non-canonical HIF signalling 
Not surprisingly because of HIF’s crucial role in cell fate, many more proteins have been 
described to be involved in the control of its stability. The heat-shock protein 90 (HSP90) that 
interacts with the PAS domain of HIF-α regulates its degradation in an O2/PHD/pVHL-
independent manner (Isaacs et al., 2002). HSP90 competes with RACK1 for binding to HIF-α 
and prevents the recruitment of the Elongin C/B Ub E3 ligase complex (Liu et al., 2007). A 
similar mechanism has been proposed for HIF-α activation by ErbB4 (Paatero et al., 2012). As 
for other HSP90 client proteins, Cullin5 also regulates HIF-α degradation independently of 
Elongin C/B function (Ehrlich et al., 2009). The tumor suppressors p53, TAp73 and pTEN 
promote the ubiquitin-mediated degradation of HIF-1α via recruitment of the Ub E3 ligase 
Mdm2 (Amelio et al., 2015; Joshi et al., 2014; Ravi et al., 2000). Furthermore, Fbw7 
ubiquitinates and induces HIF-1α degradation following phosphorylation by GSK3β 
(Cassavaugh et al., 2011; Flugel et al., 2012). Interestingly, this degradation can be antagonized 
by the ubiquitin-specific protease (USP28) (Flugel et al., 2012). Until now, this is the only non-
canonical Ub E3-ligase-DUB pair identified for proteasomal degradation of HIF-α. HAF, the 
Hypoxia-Associated Factor, seems to play a dual role in the control of HIF-α stability and/or 
activity. While HAF acts as an Ub E3 ligase targeting HIF-1α for degradation independently of 
oxygen availability, hypoxia-induced SUMOylated HAF promotes HIF-2α transactivation 
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without affecting its stability (Koh et al., 2008; Koh et al., 2015). Furthermore, RNF4 controls 
the levels of SUMOylated HIF-2α (van Hagen et al., 2010). USP19 seems to be required for the 
hypoxic accumulation of HIF-1α, though the effect is not dependent on its deubiquitinase 
activity (Altun et al., 2012). USP19 is further substrate of Siah-1 and Siah-2 Ub E3 ligases, 
which also control the stability of PHD1, PHD3 (Fukuba et al., 2007; Nakayama et al., 2004; 
Velasco et al., 2013). Thus, further studies are necessary to clarify the direct impact of USP19 
in HIF-1α ubiquitination. 
The chaperone-dependent Ub ligase CHIP targets HIF-1α but not HIF-2α for degradation either 
by the proteasome or by the autophagic machinery, the second big protein degradation and 
recycling pathway that has been implicated in elimination of ubiquitinated HIF-α (Bento et al., 
2010; Ferreira et al., 2013; Hubbi et al., 2013; Luo et al., 2010). In this regard, Cezanne 
(OTUD7B), a deubiquitinase targeting K11 Ub chains (Bremm et al., 2010), has been reported 
to protect HIF-1α from lysosomal degradation. While this process is independent of HIF-1α 
prolyl hydroxylation, it depends on the presence of pVHL (Bremm et al., 2014).  
Calpain and the activation of the forkhead transcription factor FOXO4 destabilize HIF-α 
although the underlying molecular mechanisms are unknown (Tang and Lasky, 2003; Zhou et 
al., 2006). Further studies are also needed to characterize the role of Parkin in the regulation of 
HIF-α, based on its identification within the Parkin-dependent ubiquitinome by a proteomic 
approach (Sarraf et al., 2013). In contrast with all the previous reports, it is worth mentioning 
the role played by the Ub E3 ligase TRAF6. TRAF6 increases HIF-1α, but not HIF-2α, polyK-
63 ubiquitination and protects the protein from proteasomal degradation (Sun et al., 2013). 
The SUMO E3 ligase PIAS3 interacts with and stabilises HIF-1α and HIF-1α DM(PP/AA) by 
protecting it from degradation (Nakagawa et al., 2015). However, while PIAS3 seems to 
SUMOylate HIF-1α, the authors found that a catalytically inactive PIAS3 mutant was also able 
to increase HIF-1 dependent gene transcription, giving rise to the question of whether the 
SUMOylation of HIF-1α was in fact responsible for the stabilising effect. 
In addition to HIF-α stability, mRNA expression and activity of the transcriptional complex 
fine-tune HIF regulation. In this regard, USP52 is required for protection of HIF-1α (but not 
HIF-2α) mRNA from premature degradation and therefore allows the normal hypoxic induction 
of HIF-1α (Bett et al., 2013). The case of USP52 is somewhat special as this protein although 
structurally related to the family of USPs, lacks the catalytic cysteine (Quesada et al., 2004). 
Besides protecting HIF-1α protein from its degradation, Cezanne’s catalytical activity is also 
required for maintaining basal levels of the E2F1 transcription factor. Moniz et al. demonstrated 
that E2F1 controls the expression of HIF-2α mRNA and therefore, established an indirect role 
of the DUB Cezanne in HIF-2α expression (Moniz et al., 2015).  
Finally, a number of DUBs have been shown to regulate transcription factors and signaling 
pathways that cross-talk with HIFs likely contributing to the complexity and specificity of the 
cellular hypoxic response, even though they go beyond the scope of this review (Kim et al., 
2015; Scortegagna et al., 2011; Zheng et al., 2014).  
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1.3.3 Regulation of DUBs by hypoxia 
As for other enzymes, there are several possible layers of regulation of DUB activity. Next to 
the transcriptional regulation, the stability and translation of the mRNA can be regulated by 
mRNA-processing enzymes. The turnover and therefore, the availability of the mature protein 
can be set by a variety of post-translational modifications. PTMs can also interfere with the 
binding of the DUB to their target proteins or other interactors, as well as modulate reversibly 
and irreversibly the (auto) catalytical activity of the DUB. Hypoxia, being an extreme cellular 
stress condition, should be able to regulate deubiquitinating activity on all the possible different 
layers in order to adapt DUB functions to the cell’s needs. However, the literature about the 
regulation of specific DUBs by hypoxia (1% O2 if not specified differently) is still scarce and 
almost exclusively restricted to transcriptional regulation. For instance, the expression of 
USP13 is reduced upon treatment with as little as 6 h of 2% O2 in melanoma cell lines 
(Scortegagna et al., 2011). The reduction of the mRNA translates also to the protein level and 
causes the loss of Siah2 stabilization. Similarly, in colon cancer cells hypoxia reduces USP46 
mRNA and protein levels and therefore, diminishes USP46’s stabilizing effect on the tumor 
suppressors PHLPP1 and PHLPP2, conferring to the colon cancer cells an increased paclitaxel 
resistance (Li et al., 2013; Wen et al., 2013). Guo et al. provide more detailed information about 
the hypoxia-mediated transcriptional regulation of the UCH CYLD. They suggest that the in 
glioblastoma cells seen decrease of CYLD mRNA and protein is due to the hypoxia-induced 
increase of the transcriptional repressors Snail and Hes1 (Guo et al., 2014b).In contrast, hypoxia 
has been shown to increase Cezanne via p38MAPK (Luong le et al., 2013).  
An et al. claimed that CYLD is targeted for proteasomal degradation after interaction with the 
HPV E6 protein in hypoxia (An et al., 2008). This is to date the only report of a post-
translational regulation of DUB activity by hypoxia. However, Lee et al. present evidence that 
the activity of many, if not most, DUBs depends on the redox state of the cell. They show that 
the catalytically active cysteine residue can be oxidized for instance by intracellular hydrogen 
peroxide, leading to the abolishment of the deubiquitinating activity. The inactivating oxidation 
can be reversed in the presence of reducing agents such as DTT or prevented by anti-oxidants 
(Lee et al., 2013). As hypoxia and mitochondrial ROS production are intrinsically linked it 
might not be too far-fetched to propose that hypoxia directly modulates DUB activity via ROS.  
More recently, Scholz et al. have added a new DUB to the small collection of deubiquitinating 
enzymes that are regulated by hypoxia. OTUB1 is N-hydroxylated by FIH in an O2-dependent 
manner. While the OTUB1-hydroxylation does not affect its stability or activity, it affects its 
interaction with other proteins and activates AMPK signalling and therefore metabolic changes 
(Scholz et al., 2016). 
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1.3.4 Dysregulation of hypoxia-related DUBs in cancer (excerpt) 
Given the importance of Ub-mediated changes in protein function and homeostasis, it is not by 
chance that the entire process is highly regulated. Disruption of the ubiquitination cycle by 
mutations or altered expression of specific components within the cascade has been associated 
with several disorders. In particular, more than 30 DUBs have been associated with cancer 
directly or indirectly. Both, the loss of a specific DUB activity or its hyperactivity are non-
desired events if the targets are tumor suppressors or oncogenes, respectively. Recurrent 
mutations of DUBs are rare in cancer with only few exceptions. Gene fusions with RUNX are 
reported for USP42 and USP16 in hematologic diseases such as chronic myelomonocytic 
leukemia and acute myeloid leukemia. However, dysregulated mRNA levels of DUBs are 
implicated in many malignancies. Here, we will focus only on a few examples of hypoxia-
related DUBs, for a more extensive overview please refer to the very comprehensive review by 
(D'Arcy et al., 2015). 
Germline mutations of the tumor-suppressor gene CYLD are prevalent in familial 
cylindromatosis, a genetic condition that leads to predisposition for developing multiple skin 
tumors (Bignell et al., 2000; Takahashi et al., 2000). In addition, CYLD deubiquitinating 
activity has been seen to be abolished in different cancers on the protein level by inactivating 
phosphorylations or destabilizing polyubiquitination (Massoumi, 2011). More recently, it has 
been reported that USP8 is frequently mutated in adenomas causing Cushing's disease (Reincke 
et al., 2015).  
USP28 is a DUB whose overexpression has been reported in breast and colon cancer, and 
glioblastoma (Popov et al., 2007; Wang et al., 2015b). A recent publication has proposed 
USP28 to be a potential predictive marker in bladder cancer, as they found correlation of 
USP28 with tumor histological grade, clinical stage, recurrence and survival (Guo et al., 2014a). 
Similar to USP28, UCHL1 has also been proposed to be a useful biomarker, being 
overexpressed in gastric cancer (Gu et al., 2015) and in myeloma (Hussain et al., 2015), and 
epigenetically down-regulated in colorectal cancer (Abdelmaksoud-Dammak et al., 2015). As 
mentioned above, downregulation of USP46 may serve as a biomarker of resistance to 
chemotherapy in colon cancer (Wen et al., 2013). Finally, despite being inconsistent to its role 
in the regulation of HIF-1α and HIF-2α, decreased Cezanne expression is associated with the 
progression and poor prognosis in hepatocellular carcinoma (Wang et al., 2015a). 
1.3.5 DUBs as druggable targets for therapy  
Modulators of individual UPS components are emerging as a novel class of anti-cancer drugs. 
The initial research focus had been directed towards targeting the proteasome, with activity 
described for many compounds with proteasome inhibitory activity including bortezomib. 
Because Ub E3 ligases provide substrate specificity, their direct targeting may avoid the 
deleterious side effects associated with the global inhibition of the proteasome, making them 
interesting candidates as drug targets. Nutlin-3 and JNJ-26854165 are classic examples directed 
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against the Ub E3 ligase MDM2 and are currently undergoing clinical evaluation as anticancer 
therapy.  
Newly arising, DUBs may serve as equally or more useful targets. Indeed, DUBs are highly 
specialized and evolutionary linked to proteases, a typified pharmaceutical target class for drug 
discovery thanks to their well-characterized catalytical domain. Several partial and specific 
inhibitors against a small number of DUBs have been developed, have proved active in 
preclinical studies as reviewed recently by (D'Arcy and Linder, 2014) and provide feasibility 
for targeting these enzymes for anticancer purposes. Among them, HBX 41,108 is a partially-
selective USP inhibitor because it inhibits USP5, USP7, USP8, UCHL3 in addition to caspase 3 
(Colombo et al., 2010). This is to our knowledge the only DUB inhibitor so far described as 
targeting one of the DUBs linked to the HIF signaling pathway. Interestingly, inhibition of 
USP8 suppresses growth of gefitinib-resistant non-small cell lung cancer cells, though no link 
to the potential impact on HIF-1α is reported (Jeong, 2015). It is tempting to speculate about 
new drugs directed against hypoxia-related DUBs that succeed to fight intratumoral hypoxia-
signaling in the coming years.  
1.4 How to investigate signalling pathways 
The discovery of how signalling pathways work, that is how a stimulus is sensed by a receptor, 
how the message is transduced to an effector molecule and how the effector molecule executes 
its function, is key to understanding how alterations of a particular pathway can cause diseases 
and how to potentially treat them. Hence, various different techniques are used to identify the 
proteins involved, and unravel the mechanisms of the individual steps of the signal 
transduction.  
Classical biochemical approaches are the standard and often the starting-point of the 
investigations. Western Blotting, immunoprecipitation, qPCR and reporter gene assays allow us 
to measure how protein levels and their modifications are affected by different stimuli, whether 
proteins are associated with each other in the cell, whether gene transcription is altered and to 
what extend the signal is transduced, respectively. Those assays give us very valuable data, 
however the collected data represents averaged results as they come from a bulk of cells, which 
might display significant heterogeneity in the individual response to the stimulus.  
New single-cell techniques are already available and are being further developed in order to 
address this problem. The transcriptome of a single cell can now be examined by RNA 
sequencing (Wu et al., 2014) and while technically more challenging, the development of single 
cell proteomics methods are also on the rise (Lombard-Banek et al., 2016).  
Bioinformatics have also become an important part of the analysis of signalling pathways. They 
are not only needed for the analysis of omics data for example, but can also simulate and predict 
signalling processes based on acquired data or on publicly available data sets or a combination 
of both.  
Fluorescence-based single cell techniques require the labelling of the object of interest with a 
fluorescent label. For example, Fluorescence-Activated Cell Sorting (FACS) allows for 
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separation of living single cells depending on the presence of a fluorescence-labelled marker. 
Fluorescence imaging methods allow us to follow labelled proteins (or other structures) in 
single living cells over time and to study their spatial and temporal dynamics non-invasively in 
a way that no other technique is able to. Furthermore, the measurement of fluorescence is 
practically harmless to cells and can be easily quantified by intensity measurements. Apart from 
localising fluorescence-labelled proteins and determining their abundance, fluorescence 
imaging techniques allow us to measure their diffusion dynamics and their interaction. 
1.4.1 Fluorescence and fluorescence lifetime 
Fluorescence is the property of a molecule to absorb light of a certain wavelength and to emit a 
photon of a longer wavelength (Stokes, 1852). Both, the optimal absorption and emission 
wavelength, are determined by the atomic configuration of the fluorophore. If the incident 
photon carries the appropriate energy ΔE (ΔE = h ν, with ν being the frequency of the incoming 
wave), it can cause an electron to move from its energetic ground state S0 to its first excited 
state S1 (Figure 1.7A). From the excited state, the electron has several possibilities to relax back 
to the ground state, with the rates k of each possibility being intrinsically linked to the 
fluorophore’s electronic configuration. Either the electron relaxes back by emitting a photon 
(fluorescence) (Figure 1.7A) or it changes into a “dark” excited triplet state via intersystem 
crossing (ISC) from where it can later relax back to the ground level emitting a phosphorescent 
photon. The rates of the different relaxation processes determine for how long a molecule stays 
in its electronically excited state. This time - the fluorescence lifetime - is characteristic of a 
given fluorophore and is independent of excitation wavelength, excitation rate and fluorophore 
concentration. Importantly, the fluorescence lifetime can be quantitatively measured 
experimentally. Two different methods, time domain and frequency domain measurements that 
require different instrumentation and analyses, are available to measure fluorescence lifetimes. 
In the time-domain method (Figure 1.7B), a pulsed laser with optimally infinitely short laser 
pulses is used to excite the fluorophore. Excited fluorophores emit photons whose arrival times 
(typically in the range of a few nanoseconds) are recorded by time-correlated single photon 
counting (TCSPC) and plotted in a histogram. The fluorescence lifetime τ is then extracted by 
fitting the decay curve to a mono- (or multi) exponential decay function I(t) = I0 𝑒−𝑡/𝜏, with I(t) 
being the number of photons with the same arrival time t, and I0 being an exponential prefactor.  
The frequency-domain method relies on a continuous but intensity-modulated excitation source 
(Figure 1.7C). The fluorescence emission is equally modulated, but phase-shifted because of the 
delay between fluorophore excitation and photon emission - the fluorescence lifetime. The 
fluorescence lifetime of a given fluorophore can be altered by environmental conditions such as 
pH or viscosity of the medium, as well as by the presence of fluorescent and non-fluorescent 
quenchers (Lakowicz, 2006). 
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Figure 1.7: Fluorescence and fluorescence lifetime measurements. (A) Jablonski diagram: 
Absorption of light of a suitable wavelength (and energy) lifts the absorbing molecule into an 
electronically excited state (blue). The molecule relaxes back to the ground state by emitting a 
photon (fluorescence) (green). Grey arrows indicate non-radiative vibrational relaxation. (B): 
Time-domain method to measure fluorescence lifetime. After a short excitation pulse (green), 
emitted fluorescent photons (red) are recorded and fluorescence lifetime τ is extracted from the 
decay curve. C: Frequency-domain method to measure fluorescence lifetime. Excitation 
intensity (green) and accordingly the fluorescence emission (red) are modulated. The phase 
shift ΔΦ between the two curves allows for extraction of the fluorescence lifetime τ. B and C 
adapted from http://www.olympusmicro.com/primer/techniques/fluorescence/fret/fretintro.html. 
1.4.2 Förster resonance energy transfer (FRET)  
In 1948, Theodor Förster explained the decrease of fluorescence in a concentrated fluorophore 
solution by the non-radiative energy migration from an excited fluorophore to another identical 
fluorophore in close proximity, which subsequently emits a fluorescent photon (Förster, 1948). 
The efficiency of the energy transfer is strictly dependent on the distance between donor and 
acceptor molecule as it decreases with the factor r0
-6
, with r0 being the Förster radius that is 
specific to the donor-acceptor pair. This energy transfer is possible not only between identical 
fluorophores (homo-FRET), but also between two different fluorophores with distinct spectral 
properties (hetero-FRET or just FRET) (Figure 1.8A). The electronically excited molecule 
couples via dipole and spin moments with the acceptor molecule and transfers its energy non-
radiatively, thereby relaxing back to the electronic ground state. For the energy transfer to be 
possible, the emission spectrum of the donor fluorophore must have significant overlap with the 
absorption spectrum of the acceptor. In case that sufficient overlap exists and both fluorophores 
are in close spatial vicinity (around r0), FRET can occur and excitation of the donor results in 
fluorescence emission of the acceptor (Figure 1.8B). Therefore, FRET measurements can 
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provide information about optically not resolvable distances between a given donor-acceptor 
(or: FRET-) pair in the low nm range. In molecular biology, two proteins within these distances 
are typically directly interacting with each other, hence biologists have come up with different 
techniques to measure FRET between two fluorescence-labelled proteins in cells. 
Classically, FRET efficiencies were calculated based on the fluorescence intensities of donor 
and acceptor fluorescence after excitation of the donor molecule: FRET efficiency E =  
𝐼𝐴𝑐𝑐𝑒𝑝𝑡𝑜𝑟
𝐼𝐷𝑜𝑛𝑜𝑟
. 
Fluorescence intensities measured by this method were highly dependent on concentrations of 
both, donor and acceptor molecules. Additionally, the necessary overlap of donor absorption 
and acceptor emission spectra can cause direct excitation of the acceptor fluorophore by the 
donor excitation. This phenomenon, called spectral bleed-through, leads to the overestimation 
of the effective FRET efficiency. Therefore, in recent years the measurement of the 
fluorescence lifetime of the donor fluorophore has proved to allow more accurate determination 
of the FRET rate. Additionally, the choice of the FRET acceptor is less restricted as even a 
“dark” molecule, a quencher, can be used if it has the appropriate spectral properties in order to 
accept the energy transfer from the donor molecule.  
Apart from determining intermolecular distances and hence binding, FRET measurements are 
also used for sensing intracellular molecules, such as calcium and ATP for example. FRET-
based biosensors consist of the donor and the acceptor fluorophore, which are separated by a 
domain that can bind the molecule to be sensed (Hochreiter et al., 2015). Upon binding of the 
target molecule, this domain undergoes conformational rearrangements, which result in a 
change of distance between donor and acceptor and therefore in a change of donor fluorescence 
lifetime. 
 
Figure 1.8: Förster Resonance Energy Transfer (FRET). (A) FRET can occur only when 
donor (D) and acceptor (A) fluorophore are within the distance of the Förster radius r0 (grey). 
Homo-FRET occurs between two identical (top) and hetero-FRET between two different 
molecules with appropriate spectral overlap (bottom). (B) Jablonski diagram of FRET. After 
absorption of a photon (blue), instead of emitting a fluorescent photon (green), the excitation 
can be transferred non-radiatively via FRET (black) to an appropriate nearby acceptor molecule 
which consequently emits a fluorescent photon (red). 
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1.5 Aims of the project 
In many diseases, including cancer, the hypoxia signalling pathway has been found deregulated 
and signalling switched on permanently (Rankin and Giaccia, 2008; Semenza, 2012b). While in 
the specific case of renal cell carcinoma the loss of pVHL is responsible for the sustained HIF 
signalling, in most cases the underlying molecular mechanisms remain poorly understood 
(Mayer et al., 2008). However, as many of the members of the pathway are known to be 
regulated by PTMs, it is tempting to speculate that alterations in the PTM profiles may cause 
the excessive signalling, either by up-or down-regulating the physiological modifications or by 
adding new modifications.  
Hence, we hypothesised that cellular transformation might cause alterations of the PTMs of 
proteins of the hypoxia signalling pathway that result in abnormal signalling behaviour. The 
identification and characterisation of such aberrant modifications and the responsible regulators 
could help find new therapeutic approaches to modulate nonphysiological signalling. 
The project plan was to first identify novel regulators of hypoxia signalling  and to characterise 
the effect of the potential regulators on their respective target proteins on a molecular level. 
Next, we wanted to generate mutants that were either resistant to or would mimic the 
regulation. Further, the properties and down-stream effects of those mutants were to be 
characterised. A combination of biochemical assays in Edurne Berra’s lab at CIC bioGUNE 
(Spain) and advanced fluorescence microscopy techniques in Violaine Sée’s lab at the Centre 
for Cell Imaging (UoL) was used for this purpose. 
First of all, we needed to generate fluorescent versions of the proteins of interest and validate 
them for live cell imaging purposes and advanced imaging techniques for later use were to be 
set up (described in chapter 3). An siRNA-based screen that had been performed in Edurne 
Berra’s lab prior to my start had highlighted the deubiquitinase USP29 as a potential HIF 
regulator. We initially tested this hypothesis and established the role of USP29 as a novel non-
canonical activator of HIF-α and characterised the molecular basis of the regulation (chapter 4, 
including a submitted manuscript). We then further characterised the USP29 protein itself, by 
investigating its own post-translational regulations and its interactome (Chapter 5, including a 
manuscript in preparation).  
  
 Materials and Methods 21 
Chapter 2: Materials and Methods 
2.1 Materials 
All tissue culture media were purchased from Gibco. Chemicals were purchased from Sigma-
Aldrich unless stated otherwise. Custom oligo primers were purchased from Invitrogen and 
Sigma-Aldrich, siRNAs were bought from Sigma-Aldrich. 
2.2 Methods 
2.2.1 Molecular Biology 
2.2.1.1 Polymerase chain reaction (PCR) 
Polymerase chain reaction is used to exponentially amplify double-stranded DNA from a 
single- or double stranded DNA template. The introduction of point mutations, restriction 
enzyme sites and flanking sequences is possible by adequate modification of the primers used 
for the amplification. Primers anneal to complimentary target DNA and allow the DNA 
polymerase for elongation thereby copying the target sequence.  
DNA was amplified via PCR using KOD Hot Start DNA Polymerase (EMD Millipore). After 
an initial denaturation step for 5 minutes at 95°C, 30 cycles using the following scheme were 
performed: 1. denaturation: 95°C for 20 seconds, 2. annealing: primer-dependent temperature 
Tm for 15 seconds, 3. Elongation: 70°C for 30-90 seconds (depending on length of the DNA). 
2.2.1.2 Mutagenesis 
Stratagene’s QuikChange® II XL Site-Directed Mutagenesis Kit (Agilent Technologies) was 
used to introduce single or multiple point mutations. The mutations were introduced by 
amplification of 100 ng of template DNA with 0.25 μM forward and reverse primers (Table 
2.1), in the presence of 1x reaction buffer, 6% (v/v) Quick solution®, 0.1 mM dNTPs with 1.25 
units PfuUltra HF DNA Polymerase. After cycling (1 min 95ºC, 18x (50 seconds 95ºC, 50 
seconds 60ºC, 7 minutes 68ºC), 7 min 68ºC) template DNA was digested with 5 units of Dpn1 
for 1h at 37ºC and subsequently one sixth of the reaction was transformed into competent 
XL10-Gold (Agilent Technologies) cells. 
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Table 2.1: Primers used for site-directed mutagenesis 
mutation Primer sequence (5’) 
USP29 C294S 
F: ccccaatttgggaaacaccagttacatgaatgcagttttac 
R: gtaaaactgcattcatgtaactggtgtttcccaaattgggg  
USP29 siResistant 
F: gaaagcaggaatatgctcaaagagattgacaaaacttcattttacgc 
R: gcgtaaaatgaagttttgtcaatctctttgagcatattcctgctttc 
USP29 K127R 
F: gaaagcaggaatatgctgagggaaattgacaaaacttc 
R: gaagttttgtcaatttccctcagcatattcctgctttc 
USP29 K599R 
F: cgttgaaccagacaggaatgccgacctac 
R: gtaggtcggcattcctgtctggttcaacg 
USP29 K668R 
F: gtatgaagatggagggaggctgatcagcagc 
R: gctgctgatcagcctccctccatcttcatac 
HIF-1α K752/755/758R  
F: catcactttcttggagacgtgtaagaggatgtagatctagtgaacag 
R: ctgttcactagatctacatcctcttacacgtctccaagaaagtgatg 
2.2.1.3  Restriction digestion 
Restriction enzymes can be isolated from bacteria and cut DNA at specific 4-8 bp long 
palindromic sequences, creating either blunt ends or ends with overhangs. DNA was incubated 
with the restriction enzyme(s) of choice (1 µl / 1 µg of DNA) in appropriate buffer for at least 1 
hour at 37°C and DNA fragments were separated by size on 1% agarose gels containing 
SYBR® Safe DNA Gel Stain that allows for visualisation of the bands under UV exposure. 
2.2.1.4 Gateway® Cloning 
At the beginning we used the two-step Gateway® system (Invitrogen™) to readily generate 
fluorescent fusion proteins with the fluorescent protein being fused either to the N- or the C-
terminus of the protein to be tagged. As the first step, the coding sequence of the protein was 
amplified by PCR including specific attB flanking sequences. The λ-phage derived enzyme BP-
Clonase™ II then inserted the PCR product into the entry vector pG-DONR/Zeo through a 
recombination process via the attB sites in the PCR product and the attP sites in the entry 
vector. The entry clone was transformed and the purified plasmid DNA served as the donor for 
the second recombination reaction. LR Clonase™ II catalysed the recombination between the 
newly generated attL sites of the entry clone and the attR sites of any destination vector that 
contained the coding sequence of a fluorescent protein 5’ or 3’ of the attR sites. Thus, an 
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expression vector containing the coding sequence for a chimeric fluorescent protein was 
generated. All unwanted by-products of the BP and the LR reaction were dismissed during the 
transformation procedure as they contained the ccdB gene that is toxic for the used E. coli strain 
(DH5α). BP and LR reactions were performed following the supplier’s protocol. For BP and 
LR reactions 150 ng of entry vector or destination vector and equimolar amounts of PCR 
product or entry clone, respectively were used and the reaction was incubated at 25°C 
overnight. Proteinase K was then added and incubated at 37°C for 10 min prior to 
transformation of a total amount of 2-5 ng DNA into chemically competent DH5α. 
2.2.1.5 In-Fusion® HD Cloning 
In-Fusion® HD Cloning (Clontech) was used to quickly transfer a fluorescent label into 
expression vectors or inserting ORFs behind or in front of a fluorescent label. As it is a one-step 
reaction and practically all vectors and inserts can be used, this method is quicker and more 
convenient than the Gateway® Cloning. The destination vector was linearised by single or 
double digestion or by PCR and the insert was amplified by PCR using specific primers 
creating overhangs that were complimentary to the vector backbone at the site of insertion. 
Next, linearised vector and PCR product were gel-purified with a gel purification kit 
(Macherey-Nagel) and the In-Fusion® reaction was set up with an insert:vector-ratio of 2:1. Of 
the 1:10-diluted In-Fusion reaction 2.5 μl were transformed into 50 μl competent Stellar™ cells. 
2.2.1.6 Plasmid propagation 
Amplification of circular plasmid DNA was carried out by transforming the DNA into 
chemically competent E. coli DH5α (InvitrogenTM), XL10-Gold (Agilent Technologies) or 
Stellar™ (Clontech) cells. Therefore the plasmid needed to contain a bacterial origin of 
replication and an antibiotic resistance for selection purposes. 2-5 ng of plasmid DNA were 
incubated with 50 µl of competent bacteria for 30 min on ice. Bacteria were then heat-shocked 
in a 42°C waterbath for 45 seconds and after 2 minutes on ice, 450 µl of SOC-medium was 
added. Bacteria were allowed to grow for 1 hour at 37°C in a shaker (225 rpm) before plating 
50 and 300 µl onto LB plates containing the selection antibiotic (50 µg/ml kanamycin or 100 
µg/ml ampicillin). Plates were incubated overnight at 37°C and single colonies were picked and 
inoculated into 5 and 200 ml of antibiotic containing LB-medium for minicultures and 
maxicultures respectively and allowed to grow for 16 hours. The GeneJET Plasmid Miniprep 
Kit (Thermo Fisher Scientific) and the PureLink® HiPure Plasmid Maxiprep Kit (Invitrogen
TM
) 
or the QIAGEN Plasmid Maxi Kit were used for plasmid purification from mini- and 
maxicultures, respectively. 
All sequences were verified by sequencing with appropriate primers either by STABvida or by 
GATC Biotech.  
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2.2.2 Cell Culture and transfections 
HEK293T cells were cultured in DMEM + GlutaMAX™ supplemented with 5 % FBS at 37°C 
and 5 % CO2. Sub-confluent plates were trypsinised and cells for experiments were plated at a 
density of 27 000 cells/cm
2
.  
HeLa and PC3 cells were cultured in DMEM + GlutaMAX™ supplemented with 10 % FBS 
and SK-N-AS cells with additionally 1 % non-essential amino acids. A2780 and LNCaP were 
cultured in RPMI + GlutaMAX™ supplemented with 10 % FBS and MDA-MB-231 and SH-
SY5Y cells were cultured in DMEM:F12(1:1) + GlutaMax supplemented with 10% FBS. For 
experiments all cell lines were trypsinised and plated at 30 000 cells/cm
2
.  
The next day, cells were transfected using Lipofectamine® 2000 (Thermo-Fisher Scientific) at 
a Lipofectamine:DNA ratio of 2:1 using Opti-MEM medium. With the exception of the 
HEK293T cells, the medium was changed 6 hours after transfection. Lysis was done 24 hours 
post-transfection and cells lysates were further processed for Western Blot or pull-downs. 
For cell imaging experiments, HeLa cells were plated at 10 000 cells/cm
2
 and transfected the 
following day using FuGENE® 6 (Promega) at a ratio FuGENE:DNA of 2:1. Cells were 
imaged 24h post-transfection. 
2.2.3 RNAi 
In order to silence the expression of endogenous or overexpressed proteins, cells were silenced 
with 20 nM siRNAs (Table 2.2). The first transfection of the siRNAs with Lipofectamine® 
2000 (3 μl Lipofectamine® 2000 per 3.5 cm dish) was made in suspension at the moment of 
plating, 24 h later the cells were transfected again with the siRNAs (and eventually with the 
corresponding DNA) after a medium change. Cells were analysed 48h after the first 
transfection.  
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Table 2.2: sequences of siRNA 
siRNA siRNA sequence 
siControl  5’- CCUACAUCCCGAUCGAUGAUGdTdT 
siDDB1 5’- UAACAUGAGAACUCUUGUCdTdT             (Li et al., 2006) 
siFbw7 5’- CGGGTGAATTTATTCGAAAdTdT           (Zhao et al., 2010) 
siHIF1α 5’- AAAGGACAAGUCACCACAGGAdTdT 
siHUWE1 5’- GAGUUUGGAGUUUGUGAAGdTdT         (Hall et al., 2007) 
siMDM2 5’- GACAAAGAAGAGAGUGUGGdTdT   (Wu and Leng, 2015) 
siPARK2 5’- AGUGCCGUAUUUGAAGCCUCAdT      (Gong et al., 2014) 
siPHD2 5’- CUUCAGAUUCGGUCGGUAAAGdTdT 
sipVHL 5’- GGAGCGCAUUGCACAUCAACGdTdT 
siRLIM 5’- GUGAGAACCUAUGUCAGUAdT     (Her and Chung, 2009) 
siSKP1 5’- GCAAACUACUUAGACAUCAdTdT        (Chan et al., 2012) 
siSTUB1/CHIP 
5’- UUCGCGAUUCGAAGAGCGCUGdTdT 
 (Maruyama et al., 2010) 
siTRAF6 
5’- CUGUGCUGCAUCAAUGGCAdTdT  
(Zhong and Kyriakis, 2004) 
siTRIM28 5’-GAUGAUCCCUACUCAAGUGdTdT    (Sripathy et al., 2006) 
siUSP29 #1 5’- GGAAUAUGCUGAAGGAAAUdTdT     (Martin et al., 2015) 
siUSP29 #2 5’- GGUCACUUUCAAAUCUGGAdTdT 
2.2.4 RNA extraction and quantitative PCR (qPCR) 
RNA was extracted from cells using Qiagen’s RNeasy Mini Kit as described in the 
manufacturer’s protocol. 1 μg RNA was used as template for reverse transcription with 
qScript™ cDNA SuperMix (Quanta Biosciences). 1/100th of the reaction was subsequently used 
for qPCR using specific primer sets and 0.1 μl TaqMan® probe (Roche) per sample (Table 2.3). 
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Table 2.3: Primer and TaqMan® probes used for quantitative qPCR 
Gene Primers TaqMan® probe 
PARK2 
F: AAAACCACCAAGCCCTGTC 
R: TGCGGACACTTCATGTGC 
#75 
TRAF6  
F: TCCTCTACCAGCGCCTTG 
R: TGGGTCCCTTCAGAAGTTCAT 
#79 
MDM2 
F: GACTCCAAGCGCGAAAAC 
R:GGTGGTTACAGCACCATCAGT 
#68 
STUB1/CHIP 
F: AGGCCAAGCACGACAAGTA 
R: AAAGCTGATCTTGCCACACA 
#35 
DDB1 
F: CCCCTCAATTCAGATGGCTA 
R: GGTGAGGGTGCTATTGTTGG 
#64 
Skp1 
F: CTGAGGAGATTCGCAAGACC 
R: ACCACTGGTTCTCTTTGCGTA 
#69 
TRIM28 
F: TGGTCAATGATGCCCAGA 
R: CTTGGTCATGGTCCAGTGC 
#1 
HUWE1 
F: TGAATGCTCTGGCTGCATAC 
R: AACCCCAGGTTTAGGATCAGA 
#6 
RLIM 
F: CCGCAAAACTCAGATGAAAAT 
R: CCAGTTTGTCTGACAGAGTTAAGC 
#63 
Fbw7 
F: CCTCCAGGAATGGCTAAAAA 
R: AATGAGTTCATCTAAAGCAAGCAA 
#78 
HIF-1α 
F: TCAAGCAGTAGGAATTGGA  
R: CGATCATGCAGCTACTACATCAC 
#66 
USP29 
F: GGATCTCAAGGAATGGCTGA 
R: TTCATCTATGATGCTCTCCTCAAT 
#28 
Rplp0 
F: TCTACAACCCTGAAGTGCTTGAT 
R: CAATCTGCAGACAGACACTGG 
#6 
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2.2.5 Immunofluorescence 
Hela cells were seeded on glass coverslips and when necessary transfected 24h prior to fixation. 
Then, cells were washed with PBS and fixed with 4% paraformaldehyde for 10 min at room 
temperature. After three washes with PBS, cells were incubated for 20 min at room temperature 
with 50 mM NH4Cl to reduce autofluorescence. Next, cells were incubated with blocking buffer 
(1% BSA, 0.1% Triton X-100, 0.4% Tween 20 in PBS) for 20 min in order to reduce unspecific 
binding of the antibody. Subsequently, the coverslips were incubated with the primary antibody 
diluted in blocking buffer overnight at 4°C. The next day, coverslips were washed three times 
with PBS and incubated with the secondary antibody diluted in blocking buffer. After thorough 
washing the coverslips were mounted on glass slides using Fluorescence Mounting Medium 
(Dako).  
2.2.6 MitoTracker staining 
HeLa cells were seeded on glass coverslips and transfected with a plasmid of interest if desired. 
24 h post-transfection cells were incubated for 30 min with 100 nM MitoTracker® Red CM-
H2XRos (Thermo-Fisher Scientific) in growth medium, washed with PBS and fixed with 4% 
paraformaldehyde for 15 min at room temperature. Coverslips were mounted using 
Fluorescence Mounting Medium (Dako) and images were taken with a fluorescence LSM 
(Zeiss 780) with a 100x oil immersion objective. 
2.2.7 Western Blot 
Cells were lysed in 1.5x Laemmli (50 mM Tris-HCl pH 6.8, 1.25% SDS, 15% glycerol), lysates 
were frozen, boiled at 95°C for 15 min and sonicated. Protein quantification was performed 
with the DC™ Protein Assay (BioRad). Between 10 and 40 μg of protein were loaded on a self-
cast SDS polyacrylamide (Bio-Rad) gel (7.5 %, 10 % or 12 %) or a 4-15 % gradient gel (Bio-
Rad) and migrated at 160 V for 90 min. Then, proteins were transferred in a tank blot system 
onto a PVDF-membrane (EMD Millipore) with 100 V for 1h at 4°C. Membranes were stained 
with amidoblack, air-dried, rehydrated by washing with ethanol, 2 washes with TNT (50 mM  
Tris-HCl pH 7.4, 150 mM NaCl, 0.1 % Triton X-100) and 1 wash with TN (50 mM  Tris-HCl 
pH 7.4, 150 mM NaCl). The membrane was then blocked for 1 hour with 5 % milk in TN and 
incubated with the primary antibody (diluted in 5 % milk in TN) at 4°C overnight. After 3 
washes with TNT, 1 wash with TN and a short blocking step (5 % milk in TN), membranes 
were incubated with the HRP-conjugated secondary antibody for 1 h. After further washing 
steps, home-made ECL (solution A: 100 mM Tris-HCl pH 8.5, 0.4 mM coumaric acid, 2.5 mM 
luminol; solution B: 100 mM Tris-HCl, 2% H2O2; solution A:solution B = 1:1) was incubated 
on the membranes for 1 min and signal was detected with Amersham Hyperfilm ECL (GE 
Healthcare Life Sciences).  
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2.2.8 Antibodies 
Table 2.3: Primary and secondary antibodies and the used dilutions 
Antibody Reference Dilution 2
ndary 
antibody 
β-actin Sigma A5441 1 : 50 000 mouse 1 : 20000 
CAIX clone MN75, Bayer 1 : 1 000 mouse 1 : 5000 
FLAG M2-HRP Sigma A8592 1 : 1 000 - 
GFP Roche 11 814 460 001 1 : 1 000 mouse 1 : 5000 
HA Covance 16B12 1 : 10 000 mouse 1 : 10000 
HIF-1α 2087 Home-made (Richard et al., 1999) 1 : 5 000 rabbit 1 : 5000 
HIF-1α P564OH Cell Signaling ab8980 1 : 1 000 rabbit 1 : 5000 
His Novagen 70796-3 1 : 1 000 mouse 1 : 10000 
LC-3 Cell Signaling 2775s 1 : 1 000 rabbit 1 : 5000 
Myc Cell Signaling 9B11 1 : 1 000 mouse 1 : 5000 
PCNA Chromotek 16D10 1 : 2 000 rat 1 : 5000 
PHD2  Home-made (Berra et al., 2003) 1 : 1 000 rabbit 1 : 5000 
Ubiquitin (P4D1) Santa Cruz (P4D1) 1 : 1 000 mouse 1 : 5000 
USP29  Abcam ab57545 1 : 5 000 mouse 1 : 5000 
2
ndary 
antibodies Reference   
anti-mouse-HRP Promega W4021   
anti-rabbit-HRP Promega W4011   
anti-Rat-HRP Jackson ImmunoResearch   
2.2.9 Ubiquitination assay with Ni-NTA purification 
Cells transfected with (His)6-Ubiquitin and myc-HIF-1α DM were treated with 10 μM MG132 
for 4 h prior to lysis to accumulate ubiquitinated proteins. Cells in 10 cm dishes were lysed with 
5 ml lysis buffer (6 M guanidinium-HCl, 0.1 M Na2HPO4/NaH2PO4, 0.01 M Tris-HCl pH 8), 
sonicated to decrease viscosity and centrifuged for 15 min at 3500 rpm. Supernatant was 
incubated in the presence of 10 mM β-Mercaptoethanol with blocked Nickel-NTA agarose 
beads for 2-3 h (blocking of the beads with 0.05 % BSA in PBS overnight followed by washes 
with PBS). Beads were washed with lysis buffer, 3x washing buffer 1 (8 M urea, 0.1 M 
Na2HPO4/NaH2PO4, 0.01 M Tris-HCl pH 8, 10 mM β-Mercaptoethanol, 5 mM Imidazol), 3x 
washing buffer 2 (8 M urea, 0.1 M Na2HPO4/NaH2PO4, 0.01 M Tris-HCl pH 6.3, 10 mM β-
Mercaptoethanol, 5 mM Imidazol) and incubated with disruption buffer (150 mM Tris pH 6.8, 
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6% SDS, 30% glycerol, 10% β-Mercaptoethanol, 0.2% bromphenolblue) for 1 h at 37°C. Beads 
were boiled for 5 min and eluted proteins were subjected to SDS-PAGE for subsequent probing 
with anti-myc and anti-(His)6 antibody. 
2.2.10 Ubiquitination assay with GFP-trap® pulldown 
The assay has been published previously (Lee et al., 2014). Here, HEK293T cells co-transfected 
with FLAG-Ubiquitin and GFP-USP29 or myc-Clover-HIF-1α DM were treated 24h post-
transfection with 10 μM MG132 for 2-4h prior to lysis to accumulate ubiquitinated proteins. 
Lysis was performed on ice from 3.5 cm dishes with 300 μl lysis buffer (50 mM Tris-HCl pH 
7.5, 150 mM NaCl, 1 mM EDTA, 0.5% Triton X-100, 40 mM β-Glycerolphosphate, 1 μg/ml 
Leupeptin, 1 μg/ml Aprotinin, 1 μg/ml Pepstatin A, 7 mg/ml N-ethylmaleimide (NEM)). 
Lysates were centrifuged for 15 min at 13000 g at 4ºC and the supernatant was diluted with 
dilution buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 1 mM EDTA, 40 mM β-
Glycerolphosphate, 1 μg/ml Leupeptin, 1 μg/ml Aprotinin, 1 μg/ml Pepstatin A, 7 mg/ml N-
ethylmaleimide (NEM)) to reduce detergent concentration to 0.2%. The diluted lysate was 
incubated for 2.5h at RT with 15 μl pre-washed GFP-traps® (Chromotek). Then, beads were 
washed with 500 μl dilution buffer and subjected to 3 stringent washes in denaturing conditions 
with 8 M urea in 1% SDS in PBS, followed by one wash in 1% SDS in PBS. GFP-fusion 
proteins were then eluted from the beads by boiling 10 min in elution buffer (250 mM Tris-HCl 
pH 7.5, 40% glycerol, 4% SDS, 0.2% bromophenol blue, 5% β-mercaptoethanol). The eluate 
was migrated two times on pre-cast 4-15% Tris-glycine gradient gels and membranes were 
probed with anti-GFP and anti-FLAG M2-HRP antibody. 
2.2.11 Co-immunoprecipitation using GFP-traps® 
HEK293T cells were transfected with the GFP-tagged protein of interest and 24h post-
transfection cells were lysed on ice with lysis buffer (50 mM Tris-HCl (pH 8), 120 mM NaCl, 1 
mM EDTA, 1 % IGEPAL CA-630, 40 mM β-Glycerolphosphate, 1 μg/ml Leupeptin, 1 μg/ml 
Aprotinin, 1 μg/ml Pepstatin A). Lysates were centrifuged for 15 min at 13000 g at 4ºC and the 
supernatant was diluted with Co-IP buffer buffer (50 mM Tris-HCl (pH 8), 120 mM NaCl, 1 
mM  EDTA, 40 mM β-Glycerolphosphate, 1 μg/ml Leupeptin, 1 μg/ml Aprotinin, 1 μg/ml 
Pepstatin A) to reduce detergent concentration to 0.2%. The diluted lysate was incubated for 1h 
at 4ºC with 15 μl pre-washed bab-20 (Chromotek) beads for pre-clearing. The lysate was then 
incubated with 15 μl pre-washed GFP-traps® overnight at 4ºC. The beads were subjected to 3 
washes with dilution buffer and 1 washing with PBS, before the bound protein was eluted from 
the beads by boiling them for 10 min in elution buffer (250 mM Tris-HCl pH 7.5, 40% glycerol, 
4% SDS, 0.2% bromophenol blue, 5% β-mercaptoethanol). The eluate was analysed by 
Western Blot.  
 
30 Materials and Methods 
 
Figure 2.1: Scheme of GFP-trap® ubiquitination assay. HEK293T cells were transfected 
with FLAG-ubiquitin and a green-fluorescent protein-fused protein of interest (here HIF-1α). 
Cells were treated with MG132 and lysed in the presence of a DUB inhibitor. The lysate was 
incubated with GFP-traps®. The traps were then subjected to stringent washes in order to 
discard proteins that bind unspecifically to the beads or are associated with the GFP-fused 
protein (purple). Next, the captured protein was eluted from the beads and migrated twice for 
detection of ubiquitinated- and non-modified protein of interest by WB with an anti-FLAG or 
anti-GFP antibody, respectively. 
2.2.12 Size exclusion chromatography 
Cells overexpressing HA-USP29 were lysed on ice with lysis buffer (50 mM Tris-HCl (pH 8), 
120 mM NaCl, 1 mM EDTA, 1 % (v/v) IGEPAL CA-630, 40 mM β-Glycerolphosphate, 1 
μg/ml Leupeptin, 1 μg/ml Aprotinin, 1 μg/ml Pepstatin A). The lysate was centrifuged for 15 
min at 13000 g at 4ºC for preclearing and the pellet was discarded. The sample was then loaded 
onto a previously equilibrated Superdex™ 200 10/300 GL (GE Healthcare Europe GmbH) with 
flow buffer (50 mM Tris-HCl (pH 8), 120 mM NaCl, 1 mM EDTA) and proteins were 
separated via size exclusion chromatography with the biggest proteins and aggregates of such 
eluting first and small proteins eluting later. The eluates were collected in 24 fractions of 0.5 ml 
and 5% of the fractions of interest were run on SDS-PAGE and/or a in a native gel for 
subsequent detection of HA-USP29 by immunoblotting. A BSA solution was run on the column 
before and after the sample and allowed for estimation of the molecular weight in the fractions 
as BSA eluted in two fractions, representing dimeric and monomeric BSA. 
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2.2.13 Sequence alignment 
Sequence alignments were performed using the website expasy.org 
2.2.14 Mass spectrometry (MS) analysis 
For MS analysis sample was prepared as described in 2.2.11 but scaling up to three 10cm-
dishes per condition (approximately 12 mg protein) and analysed in CIC bioGUNE's 
Proteomics Facility. Samples were processed following both a gel-based and a gel-free strategy. 
On the one hand, the sample was separated by SDS-PAGE and specific bands were cut out and 
digested individually with trypsin. In addition to the gel-based strategy, the whole crude sample 
was submitted to in-solution tryptic digestion. Triplicates of each experiment were carried out. 
Peptides were loaded onto a nanoAcquity UPLC (Waters) coupled to an LTQ Orbitrap XL ETD 
(Thermo Fisher Scientific) and identified using Mascot search engine (www.matrixscience.com, 
Matrix Science, London, UK) with Proteome Discoverer v.1.2. software (Thermo Electron, 
Bremen, Germany). Proteins with a spectral-count ratio of at least 3 (including exclusive 
binding partners) when compared to a GFP-only control sample in at least 2 out of 3 replicates 
were considered to be specifically binding to the bait. STRING 10 (Search Tool for the 
Retrieval of Interacting Genes/Proteins) software (http://string-db.org/) was used to display 
proteins that were detected in all three replicates as functional clusters. 
2.2.15 Fluorescence Imaging 
2.2.15.1 Acquisition of confocal fluorescence images 
Confocal fluorescence images were acquired in the Centre for Cell Imaging on the Zeiss LSM 
510, 710 and 780 with the available argon and diode lasers and inbuilt detectors (Table 2.4). For 
optical sectioning a pinhole of one airy unit (1 AU) was chosen. The laser power was kept as 
low as possible to avoid photobleaching and saturation of the signal.  
 
Table 2.4: Settings for the acquisition of fluorescence images 
Fluorophore Excitation wavelength Emission filter 
ECFP 458 nm (argon laser) 500 – 580 nm 
GFP, Clover, Alexa Fluor 488 488 nm (argon laser) 500 – 540 nm 
EYFP 514 nm (argon laser) 500 – 580 nm 
dsRedXP, mRuby2, mCherry 561 nm (DPSS laser) 588 - 650 nm 
2.2.15.2 RICS measurements and data analysis 
For Raster Image Correlation Spectroscopy (RICS), HeLa cells were transfected with the 
expression vector of interest at least 24 hours before measurements and medium was replaced 
32 Materials and Methods 
by phenol-red free medium. RICS measurements were performed on a ZEISS LSM 710 at 37°C 
and 5% CO2 with a 63x water immersion objective. Red-labelled proteins were excited with a 
DPSS 561-10 laser and green fluorescent proteins with the 488nm-line of an Argon laser at 0.5 
– 2% excitation power. A frame of 256x256 pixels with a pixel size of 0.04 µm was recorded 
by scanning the sample monodirectionally with a pixel dwell time of 6.3 µs. A time series of 70 
images was acquired. For RICS analysis SimFCS Software was used. A moving average of 10 
frames was subtracted and the auto-correlation function was fitted on the basis of all 70 frames.  
2.2.15.3 FRAP measurements 
Series of images were acquired of cells transfected with a red fluorescent labelled protein prior 
to photobleaching with the Zeiss LSM780. Then, the fluorescence in a defined region of interest 
(ROI) was irreversibly destroyed by subjecting the ROI to 30 iterations of bleaching with the 
561 laser line at 100% output power. Subsequently, a series of images was taken to record the 
red fluorescence recovery after photobleaching (FRAP) in the ROI caused by the dynamic 
relocation of non-bleached protein from places outside of the ROI.  
2.2.15.4 FLIM-FRET measurements 
Fluorescence Lifetime Imaging (FLIM) was used to measure Förster Resonance Energy 
Transfer (FRET). First, regular fluorescence images were taken with the Zeiss LSM780. For 
excitation of green fluorophores the 488nm line of the Argon laser and for red fluorophores the 
561nm diode laser was used. Next, a fluorescence lifetime image of the GFP or Clover donor 
fluorophore in absence of any possible FRET acceptor fluorophore was acquired with the 
PicoQuant FLIM upgrade kit (Figure 2.2A top). After that, FLIM images of the donor 
fluorophore in the presence of the red-fluorescent acceptor fluorophore were acquired (Figure 
2.2B top). FLIM image acquisition was carried out by scanning the sample with the LSM780 
(Zeiss) scan head unidirectionally and without averaging, recording frames of 256 x 255 pixel 
with a pixel dwell time of 25.21 μs. Excitation of the green-fluorescent donor fluorophore was 
controlled by the PDL 828 "Sepia II" unit (PicoQuant) operating a 485 nm pulsed diode laser 
(PicoQuant) with a repetition rate of 40 MHz. The fluorescence emission was collected by the 
C-Apochromat 40x/1.2 W Corr M27 (Zeiss) and diverted through a 520/535 nm bandpass filter 
onto a Hybrid Detector PMA 40 (PicoQuant). The laser power was adjusted to obtain maximal 
count rate of 2000 kcounts per second (corresponding to 5% of the repetition rate) and a total of 
10
5
 peak photons were collected over a time of about 3-5 min. The exact time between the 
excitation pulse and the arrival of a photon on the detector was recorded by the TimeHarp260 
(PicoQuant) time-correlated single photon counting (TCSPC) device. In the SymPhoTime 64 
Software (PicoQuant) each detected photon was plotted according to its arrival time, thereby 
building up a fluorescence decay curve (Figure 2.2 A and B, bottom). Together with every 
dataset an instrument response function (IRF) was recorded for analysis purposes (Figure 2.2C). 
To that end, the fluorescence lifetime of erythrosine B was quenched with a saturated potassium 
iodide solution to as little as 24 ps and the lifetime was measured with the same settings as the 
dataset (Szabelski et al., 2009). With 24 ps the quenched lifetime is shorter than the length of 
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the excitation pulse and therefore the measured decay represents internal properties of the 
instrumentation, such as the rise and length of the excitation pulse and the reaction times of the 
detector and the counting device. SymPhoTime 64 software (PicoQuant) controlled all 
PicoQuant hardware devices. At least 5 cells of each condition were measured, and experiments 
were repeated at least 2 times. 
2.2.15.5 FLIM-FRET analysis 
The SymPhoTime 64 software package (PicoQuant) was used for analysis of the FLIM data. A 
pseudo-coloured FastFLIM image was depicted based on the average arrival time of all photons 
per pixel, with red pixels representing long average lifetimes and blue pixels representing short 
average lifetime (Figure 2.3A). For lifetime fitting each FLIM was analysed individually. Only 
photons within regions of interest (ROI) were included (e.g. the nucleus) (Figure 2.3A). The 
decay curve was reconvoluted with the corresponding IRF to correct for instrumental resolution 
and fitted to a decay function (Figure 2.3B). The simplest decay is a mono-exponential decay, 
however as can be seen in Figure 2.3C, fluorophores do not always decay mono-exponentially, 
resulting in a bad fit which is represented by an oscillating residuals curve. A bi-exponential fit 
results in a better fit with the residuals around noise level (Figure 2.3D). The fitting equation is 
𝐼(𝑡) =  𝐴1 ×  𝑒
−𝑡
 𝜏1 + 𝐴2 × 𝑒
−𝑡
 𝜏2 , with τ1 and τ2 being two components of the lifetime decay. The 
intensity based average lifetime τAv Int was extracted (Figure 2.3E) and average lifetimes for 
each experimental condition were calculated. When FRET occurred, there was a significant 
decrease of average τAv Int values in cells that contained both donor and acceptor fluorophores as 
compared to cells that contained donor fluorophores only.  
2.2.16 Statistical tests 
All experiments were performed at least three times. Origin Pro 2015 was used to calculate 
averages and standard deviations and to do hypothesis testing. Two different conditions were 
subjected to Student’s T-Test and only results where their means had a 95% probability of 
being different were considered statistically significant (p < 0.05). 
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Figure 2.2: FLIM-FRET measurements. (A) Fluorescence and fluorescence lifetime images 
(FLIM) of a GFP-fused protein (top) and the corresponding time-correlated single photon 
counting (TCSPC) curve, representing a histogram of the arrival times of all collected photons 
(bottom). (B) same as A, but the GFP-fused protein interacts with the red-fluorescence-tagged 
protein. (C) The TCSPC curve of erythrosine B (in KI) represents the instruments response 
function (IRF). 
 Materials and Methods 35 
 
 
Figure 2.3: FLIM analysis. An ROI (white contour line) is defined in the fluorescence lifetime 
image (FLIM) (A). The setup of the fitting parameters in the SymPhoTime 64 software is 
shown in B. The TCSPC curve of the ROI (green) is reconvoluted with the measured IRF (red) 
and fitted to a mono- (C) or bi-exponential (D) decay curve. The fitted curve is shown in black 
and the quality of the fitting is displayed below the TCSPC curves in the residuals diagram in 
green. The average intensity-based lifetime τAv Int (arrow) is extracted from the fitting results 
window (arrow) (E). 
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Chapter 3: Generation and characterisation of 
tools for live cell imaging 
3.1 Introduction 
The thesis’ objective was to find and characterise new regulators of hypoxia signalling. We 
planned to use, amongst others, fluorescence imaging techniques to explore the properties of 
such regulators and the molecular basis of the regulation at single cell level in living cells. To 
this aim, key proteins needed to be available as a fusion with a fluorescent tag. Fluorescent tags 
can be small organic dyes or fluorescent proteins. While organic dyes need to be taken up by 
the cell and then react specifically with the target protein, fluorescent proteins can be 
synthesized by the cell itself. Fluorescent proteins naturally occur in marine species such as 
jellyfish and corals and are nowadays available in all different colours. Tagging of a fluorescent 
protein with a protein of interest can be achieved by fusing the DNA sequences of the open 
reading frames (ORF) of both proteins. This construct can then be transfected into and 
expressed by the cells. Because fluorescent proteins are considerably bigger than organic dyes 
(up to 35 kDa compared to up to 1 kDa), they are more prone to interfere with the protein’s 
functions and properties and therefore careful choice of the fluorescent protein and 
characterisation of the fusion protein are required. 
As a starting point, work from Edurne Berra’s lab was used. They had shown that PHD1 and 
PHD3 are SUMOylated and while SUMOylation increased the cytoplasmic population of 
PHD1, in the case of PHD3 it caused a decreased HIF1-dependent target gene expression. We 
wanted to investigate whether PHD1-SUMOylation was required for nuclear import and 
whether PHD3-SUMOylation altered its ability to directly bind to HIF-1α. 
This chapter summarises the efforts made to create fluorescent versions of the required proteins 
and to characterise and validate them. They were then used in several advanced imaging 
techniques, which were chosen and set-up to answer the different biological questions (3.2, 3.3). 
Chapter 3.4 is dedicated to the testing of the newly installed fluorescence-based FRET system, 
used to measure protein-protein interactions. 
Furthermore, a fluorescent version of USP29, the central protein of chapters 4 and 5, was 
generated and validated (3.5).  
3.2 Effect of PHD3-SUMOylation on HIF-1α binding 
Work by Edurne Berra’s PhD student Analía Nuñez-O'Mara had shown that PHD3 was post-
translationally conjugated to the small ubiquitin-like modifier (SUMO) protein, both in a cell-
free in vitro SUMOylation system and in cellulo. They had found that the SUMOylation of 
PHD3 inhibited the transcriptional activity of HIF-1 in a prolyl hydroxylation- and degradation-
independent way. However, they had been unsuccessful at clarifying whether PHD3-
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SUMOylation impacted directly on its interaction with HIF-1α. Based on this, we set out to 
measure this interaction depending on PHD3’s SUMOylation status by Förster resonance 
energy transfer (FRET). Therefore, appropriate fluorescent fusion proteins of the interacting 
proteins were required. At the time we only had intensity-based FRET techniques at hand, 
which required a cyan FRET-donor and a yellow FRET acceptor, were available. For future 
more modern and robust FLIM-based FRET experiments a green FRET-donor and a red FRET 
acceptor were also necessary, Therefore, I generated in parallel both pairs for initial tests, 
choosing fluorescent proteins that were available in the lab. 
3.2.1 Generation of fluorescent PHD3 and HIF-α DM proteins  
PHD3 has been reported to localise to the cytoplasm as well as in the nucleus (Metzen et al., 
2003). Moreover, two different groups have reported that PHD3 “homo-multimerises” or 
“aggregates” and that these complexes have biological importance as they confine PHD3 
catalytic activity (Nakayama et al., 2007; Rantanen et al., 2008; Rantanen et al., 2013). 
In order to see whether the orientation of the fluorescent label affected PHD3’s localisation or 
altered its aggregation properties, dsRedXP and ECFP were N-terminally as well as C-
terminally fused to PHD3 using the Gateway® system (Figure 3.1A). dsRedXP- and ECFP-
fused PHD3 localised to the cytoplasm as well as to the nucleus, regardless on whether the 
fluorescent protein was fused to PHD3’s N- or C-terminus. Small aggregates could also be 
found in most cells.  
The Gateway® system was also used to generate N-terminal green (Clover) and C-terminal 
yellow (EYFP) fluorescent HIF-α DM fusion proteins. In these HIF-α double mutant (DM) 
proteins the two proline residues within the oxygen dependent degradation domain have been 
replaced by alanines (P402A and P564A), making the proteins resistant to PHD-dependent 
hydroxylation and subsequent degradation (Berra et al., 2003). As expected, HIF-1α DM and 
HIF-2α DM displayed nuclear localisation (Figure 3.1B), but while HIF-1α DM was distributed 
homogenously throughout the nucleus, HIF-2α DM formed very defined speckles, as has been 
recently described (Taylor et al., 2016). 
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Figure 3.1: Generation of fluorescent PHD3 and HIF-α proteins. All plasmids were 
generated using Gateway® or In-Fusion® cloning, transfected into HeLa cells and imaged 24 h 
post-transfection. (A) N- and C-terminal fusions of dsRedXP and ECFP to PHD3. (B) N-
terminal and C-terminal fusions of Clover and EYFP, respectively, to HIF-1α DM and HIF-2α 
DM. The scale bar is 20 μm.  
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3.2.2 Validation of the differentially tagged PHD3 and HIF-α 
constructs in preliminary FRET experiments  
The distance between FRET-donor and FRET-acceptor and their orientation to each other 
determines whether and with which efficiency FRET can occur. As the orientation of PHD3 and 
HIF-α in the binding complex is not known, we performed preliminary intensity based FRET 
acceptor photobleaching experiments to determine if N- or C-terminal PHD3 fusions were more 
suitable FRET donors for the EYFP-fused HIF α DM. 
For that purpose the fluorescence emission of the donor fluorophore was recorded in the 
presence of the acceptor. Next, the acceptor fluorophore was irreversibly destroyed by intensive 
excitation with high laser power and was hence unable to serve as a FRET acceptor. Therefore, 
after acceptor photobleaching the donor emission increased. This rise of donor fluorescence 
could be detected for instance by performing λ-scans, which record the emission spectrum over 
a range of wavelengths. 
Here, we used this method to investigate whether ECFP-PHD3 or PHD3-ECFP were more 
suitable to act as a FRET donor for HIF-1/2α DM-EYFP. HeLa cells were co-transfected with 
ECFP-PHD3 or PHD3-ECFP and HIF-1α DM-EYFP or HIF-2α DM-EYFP. Figure 3.2 shows 
representative λ-scans of individual representative cells of each condition. The peak at 510 nm 
represents the ECFP (donor) emission and the peak at 540 nm represents the acceptor emission. 
The spectrum before bleaching is displayed in red and the post-bleach spectrum in black. 
Successful photobleaching of the acceptor can be seen as the intensity decrease in the acceptor 
emission peak. As a sign of FRET, the donor emission peak rose slightly after photobleaching. 
This was true in all tested combinations, indicating that ECFP-PHD3 and PHD3-ECFP were 
both able to serve as FRET-donors, when using HIF-1/2α DM-EYFP as the FRET acceptor.  
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Figure 3.2: FRET acceptor photobleaching measurements. HeLa cells were co-transfected 
with ECFP-tagged PHD3 and EYFP-tagged HIF-α and FRET experiments were performed 24 
hours post-transfection. A λ-scan of the ECFP emission (red) was recorded before 
photobleaching the EYFP fluorescence by subjecting a defined region to 30 iterations of 
bleaching at 514 nm with 100% laser power. Then a λ-scan of the ECFP emission was recorded 
again (black). The donor emission (ED) peaks around 510 nm and the acceptor emission (EA) 
peaks around 540 nm.  
 
Taking the localisation and FRET results together, we did not find any major differences in 
PHD3 localisation when fused C- or N-terminally to dsRedXP or ECFP, and with both 
orientations it was be possible to measure some FRET between ECFP-tagged PHD3 and HIF-
1/2α DM-EYFP. Therefore, we were ready to start to investigate how PHD3 SUMOylation 
affected its interaction with HIF-1/2α DM. 
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3.2.3 Fluorescence tagging of the PHD3 SUMO mutants  
In order to understand how the SUMOylation of PHD3 affected HIF signalling, Edurne Berra’s 
lab had generated a panel of PHD3 SUMO-mutants. The mutation of three lysine residues 
within PHD3 abolished its capability to be SUMOylated, and therefore this SUMOylation dead 
mutant was called PHD3ΔSUMO. In order to mimic the SUMOylated version, either SUMO1 
or SUMO3 were fused to PHD3’s C-terminus, generating chimeric PHD3-SUMO1 and PHD3-
SUMO3 proteins. Thus, we decided to fuse the red fluorescent protein to PHD3’s N-terminus, 
hoping to allow the C-terminally fused SUMO moiety to behave as naturally as possible. In the 
anticipation of the FLIM system to be installed, we generated dsRedXP-PHD3ΔSUMO, 
dsRedXP-PHD3-SUMO1, and dsRedXP-PHD3-SUMO2/3 using the Gateway® system (Figure 
3.3). Strikingly, we found that all mutants seemed to be excluded from the nucleus as opposed 
to a more homogenous distribution throughout the cell that we had found previously.  
 
Figure 3.3: Expression vectors encoding PHD3 SUMO mutants N-terminally fused to 
dsRedXP. Plasmids were generated using Gateway® cloning and transfected into HeLa cells 24 
hours prior to imaging. The scale bar is 20 μm. 
Therefore, we wanted to scrutinise the localisation of all the constructs, including the dsRedXP- 
and ECFP-tagged PHD3 wildtype and SUMO mutants. In order to compare them with the non-
fluorescent parental HA- tagged construct, we fixed all samples and stained with an anti-PHD3 
antibody. Interestingly, we found that the HA-tagged constructs showed stronger nuclear 
localisation than the correspondent dsRedXP-tagged versions (Figure 3.4A). Fluorescence 
intensities in unsaturated cells were measured in equally shaped and sized regions of interest 
(ROIs) in representative areas of nucleus and cytoplasm using ImageJ and the fluorescence 
intensity ratios nucleus:cytoplasm are shown in Figure 3.4 B. dsRedXP-tagged PHD3 proteins 
clearly displayed a statistically significant reduction of nuclear localisation as compared to the 
ECFP- and HA-tagged PHD3 fusion proteins.  
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Figure 3.4: Localisation of HA- and dsRedXP-tagged PHD3 WT and PHD3ΔSUMO. HeLa 
cells were transfected 36 hours before PFA fixation, stained with PHD3 antibody and Alexa 
Fluor 488 secondary antibody. (A) Pictures were taken with a 40x oil objective. The scale bars 
are 20 μm. (B) Fluorescence intensities of Alexa Fluor 488 were measured in ROIs in nucleus 
and cytoplasm using ImageJ. (*) indicates that there was a statistically significant difference in 
the two-sided Student’s T-Test. 
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Having found that the dsRedXP-label induced a change in protein localisation, the question 
emerged to what extent the occurrence of aggregates was influenced by the label. To assess 
that, the fixed and PHD3 antibody stained cells were classified into groups according to the 
amount of visible aggregates (Figure 3.5). While less than 35% of cells expressing HA-tagged 
wildtype PHD3 protein exhibited visible aggregation, more than 70% and 45% of cells 
expressing N- or C-terminally dsRedXP-tagged PHD3 showed aggregates. The percentage of 
cells that contained aggregates was also increased from less than 35% in the HA-tagged 
PHD3ΔSUMO mutant to more than 75% and 60 % for the N- and C-terminally dsRedXP-
tagged PHD3ΔSUMO, respectively, suggesting that labelling with dsRedXP did indeed boost 
PHD3 aggregation.  
Hence, we concluded that as dsRedXP itself forms a tetramer (Baird et al., 2000) it might 
reinforce PHD3’s intrinsic property to aggregate (Nakayama et al., 2007; Rantanen et al., 2008; 
Rantanen et al., 2013), resulting in an artifactual aggregation. This aggregation might be 
directly responsible for the reduction in the nuclear accumulation through PHD3 sequestration 
in the cytoplasm and exclusion of PHD3 aggregates from the nucleus.  
Figure 3.5: Influence of the fluorescent label on PHD3 aggregation. HeLa cells were 
transfected with the HA- and dsRedXP-tagged proteins, fixed, immunostained with anti-PHD3 
antibody and pictures were taken (see Figure 3.4A). Cells were classified into groups according 
to the amount of visible aggregates. 
dsRedXP was therefore not a suitable label for tagging PHD3 and an alternative fluorescent 
protein needed to be found in order to be able to perform the planned FLIM-based FRET 
experiments. To solve the problem of label-mediated aberrant localisation and aggregation, we 
decided to test the new fluorescent protein mRuby2 for tagging of PHD3 and to test its 
performance. mRuby2 is a monomeric red fluorescent protein that has improved brightness and 
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photostability compared to its parent mRuby and has been engineered and described by Lam et 
al. as an efficient FRET acceptor for the green fluorescent protein Clover (Lam et al., 2012). 
3.2.4 Performance of the mRuby2 label 
The coding sequence of mRuby2 was N-terminally inserted into the expression vectors 
encoding PHD3 WT and PHD3ΔSUMO using In-Fusion® HD Cloning. Localisation and 
aggregation properties of the mRuby2-labelled PHD3 proteins were assessed after transfection 
into HeLa cells and anti-PHD3 antibody staining as previously. mRuby2-tagged PHD3 WT and 
PHD3ΔSUMO displayed similarly strong nuclear localisation as the HA-tagged proteins 
(Figure 3.6A and B) and mRuby2 did not significantly alter PHD3-aggregate formation (Figure 
3.6C).  
 
Figure 3.6: Performance of mRuby2 as a fluorescent label for PHD3. Localisation and 
aggregation of mRuby2-labelled PHD3 WT and PHD3ΔSUMO were evaluated after 
transfection of the expression vectors into HeLa cells, fixation and permeabilisation of the cells 
and staining with PHD3 antibody. Immunofluorescence images (A) were used to assess 
localisation (B) and aggregation (C) of the tagged PHD3 proteins. The scale bar is 20 μm. 
Taking these data together, mRuby2 seemed to be a suitable label for PHD3 and mRuby2-
PHD3 WT and mRuby2-PHD3ΔSUMO could be used for further experiments. As the FLIM 
system was not available yet at that point, we initially sought to test whether the measurement 
of the diffusion coefficients of the proteins could give us information about their interaction. 
This is for example possible with fluorescence cross-correlation spectroscopy (FCCS), but we 
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used a less known method called Raster Image Correlation Spectroscopy (RICS) that had just 
been implemented on one of the CCI’s systems by the Master’s student Julien Dumont. 
3.2.5 Measurement of diffusion coefficients and interaction 
Raster Image Correlation Spectroscopy (RICS) is a technique to measure diffusion coefficients 
of fluorescent molecules in solution or in cells. It makes use of the information inherent to an 
image or a series of images that have been taken with a laser scanning microscope. As the 
microscope scans a sample, the laser beam dwells for a specific time on a pixel of a defined 
size, detecting a signal if a fluorophore is present in the scanned pixel before moving on to the 
next pixel (Figure 3.7). Mobile molecules within the sample can therefore be detected in 
consecutive pixels creating a trace of their motion on the image. Software can be used to 
calculate an autocorrelation function based on the temporal and spatial information inherent to 
the image or the series of images, from which a diffusion coefficient can be extracted. Diffusion 
coefficients as a measure of the mobility of proteins within a cell can indicate whether proteins 
diffuse freely or whether they do interact with other cellular components. Two interacting 
proteins will essentially have the same diffusion coefficient, however the same diffusion 
coefficient is not sufficient to state interaction of two proteins. RICS had been recently used to 
measure the binding of the transcription factor p53 to DNA or interacting proteins upon DNA 
damage (Hong et al., 2010), as well as to measure the movement of DNA lipoplexes through 
the cytoplasm (Mieruszynski et al., 2015). 
 
Figure 3.7: Raster Image Correlation Spectroscopy (RICS). The laser beam (green) scans 
the sample (left) pixel by pixel and a signal is recorded in the image (right) if a fluorophore (red 
circle) is present in the pixel. As the fluorophore moves (red dotted line) throughout the sample, 
it can be detected in consecutive pixels. Several images are used for the calculation of the 
autocorrelation function and subsequent fitting (bottom right) to extract the diffusion 
coefficient. 
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As a reference of our system, the diffusion coefficient of EGFP in HeLa cells was measured 
(Figure 3.8A). The values of 21 μm2/s in the nucleus and 13 μm2/s in the cytoplasm are in the 
same range as diffusion coefficients reported in the literature (Figure 3.8C). 
We next measured the diffusion coefficient of HIF-1α DM-Clover in the nucleus and found it to 
be with 5 μm2/s considerably lower than EGFP’s, indicating that in contrast to EGFP, HIF-1α 
DM-Clover was not diffusing as freely as EGFP (Figure 3.8D). This is in accordance with the 
fact that as a dimeric transcription factor HIF-1α binds to other proteins (HIF-1β and its 
coactivator CBP/p300) and to DNA. Interestingly, the nuclear diffusion coefficients of the 
mRuby2-fused PHD3 proteins were with 5-6 μm2/s very similar to HIF-1α DM-Clover’s 
(Figure 3.8E). This might already indicate that PHD3 and HIF-1α DM might be part of the 
same multiprotein complex. On the basis of this assumption, it would be impossible to measure 
increased or decreased interaction of PHD3ΔSUMO with HIF-1α DM based on their diffusion 
coefficients. Accordingly, Figure 3.8D shows that we measured no change in the diffusion 
coefficient of HIF-1α DM-Clover in the presence of neither mRuby2-PHD3 WT nor mRuby2-
PHD3ΔSUMO. Reciprocally, when measuring the diffusion coefficient of mRuby2-PHD3 WT 
or mRuby2-PHD3ΔSUMO alone or in the presence of HIF-1α DM-Clover, no differences were 
detectable (Figure 3.8E). 
 
Figure 3.8: RICS measurements in HeLa cells. Diffusion coefficients of EGFP (A) and 
mRuby2 (B) were measured in nucleus and cytoplasm. (C) Reference values for EGFP 
diffusion from the literature. (D) Diffusion coefficient of HIF-1α DM-Clover alone and in the 
presence of mRuby2-PHD3 WT and mRuby2-PHD3ΔSUMO. (E) Diffusion coefficient of 
mRuby2-PHD3 WT and mRuby2-PHD3ΔSUMO alone and in the presence of HIF-1α DM-
Clover. 
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Taken together, RICS measurements could not provide answers to the question whether the 
SUMOylation of PHD3 had a direct impact on binding of PHD3 to HIF-1α DM. Therefore, 
techniques that are able to measure the binding of two proteins to each other more directly, are 
indispensable. The method of choice was FLIM-based FRET, however I was unable to obtain 
conclusive results either, possibly due to the low fluorescence signal of the FRET acceptor. 
Hence, the data about the effect of PHD3 SUMOylation on HIF-1 transactivation were 
published without the additional information of how their binding to each other was affected 
(Nunez-O'Mara et al., 2015). 
3.3 Exploration of PHD1 nuclear shuttling by FRAP 
Work by Almudena Gerpe-Pita in Edurne Berra’s lab showed that not only PHD3, but also 
PHD1 is SUMOylated. She had identified that PHD1’s lysine residues K118 and K120 were 
subjected to SUMOylation. The mutation of both residues to arginines (K118/120R), did not 
only reduce PHD1 SUMOylation, but increased also the cytoplasmic fraction of PHD1. 
Interestingly, K118 and K120 are located within PHD1’s nuclear localisation signal (NLS). 
Upon inhibition of nuclear export with Leptomycin B however, the increased cytoplasmic 
localisation was reversed. This suggested that PHD1-SUMOylation might be required for 
retention of PHD1 in the nucleus (Gerpe-Pita et al., in preparation). In order to test this 
hypothesis, I performed fluorescence recovery after photobleaching (FRAP) experiments. 
3.3.1 Fluorescence tagging of PHD1 WT and K118/120R mutant 
As the mRuby2 fluorescent label had proved to be a suitable N-terminal tag for the PHD3 
protein, the mRuby2 coding sequence was fused to PHD1’s and PHD1 K118/120R’s N-termini 
by In-Fusion cloning. Reassuringly, the mRuby2-fusion proteins displayed the same 
localisation as the respective HA-tagged constructs, with PHD1 being exclusively localised to 
the nucleus and PHD1 K118/120R also populating the cytoplasm (Figure 3.9). 
48 Generation and characterisation of tools for live cell imaging 
 
Figure 3.9: HA- and mRuby2-PHD1 constructs. HeLa cells were transfected with HA- (top) 
and mRuby2- (bottom) tagged PHD1 and PHD1 K118/120R and imaged 24h post-transfection. 
HA- images were taken by Almudena Gerpe-Pita. The scale bar is 20 μm. 
3.3.2 FRAP experiments 
Qualitative Fluorescence Recovery After Photobleaching (FRAP) experiments were performed 
in order to understand the dynamics of nuclear import of PHD1 and PHD1 K118/120R. For that 
purpose, HeLa cells were transfected with the newly generated constructs and consecutive 
images were acquired for approximately 30 min. Then the entire nuclear population of 
mRuby2-tagged PHD1 was irreversibly photobleached (Figure 3.10, dotted white line) and the 
fluorescence recovery in the nucleus was recorded over the following 30 min. Both, PHD1 WT 
and the K118/120R mutant recovered nuclear fluorescence over time (Figure 3.10). These 
results confirmed that the K118/120R mutation did not prevent the nuclear import of PHD1. In 
the case of mRuby2-PHD1 nuclear fluorescence recovery was very slow and incomplete as can 
be seen by a very gentle linear recovery curve (Figure 3.10 top). This is likely to be due to the 
small pool of cytoplasmic mRuby2-PHD1, which largely restricts the speed of nuclear recovery 
to the rate of de novo synthesis of the protein. In contrast, in the case of PHD1 K118/120R 
nuclear recovery was much faster and more pronounced, as seen by an initial steep linear curve 
that reaches a high plateau after about 10 min (Figure 3.10 bottom). This quick and strong 
nuclear fluorescence recovery can be explained by the mobilisation of the cytoplasmic fraction 
of mRuby2-PHD1 K118/120R to the nucleus. The FRAP data are therefore in line with 
Almudena’s biochemical data and point towards an important role of PHD1-SUMOylation in 
the nuclear retention of PHD1 and will be included in the respective manuscript, which is 
currently been prepared. It has been suggested already more than a decade ago, that some 
proteins were SUMOylated within their NLS upon entering the nucleus (Seeler and Dejean, 
2003). SUMOylation might be required for instance to allow the tethering of PHD1 to nuclear 
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structures or to prevent PHD1’s interaction with its nuclear export receptor. In line with this, 
other reports show that SUMOylation is required for nuclear retention of other proteins, such as 
the transcriptional repressor DREAM and the ubiquitin E3 ligase TRAIP (Palczewska et al., 
2011; Park et al., 2016).  
 
Figure 3.10: Nuclear fluorescence recovery after photobleaching (FRAP) for PHD1 and 
PHD1 K118/120R. HeLa cells were transfected with mRuby2-PHD1 (A) or mRuby2-PHD1 
K118/120R (B) and 24 h post-transfection cells were imaged for 30 min. Subsequently, the 
entire nucleus was bleached (t=0) and the fluorescence recovery in the bleached region (dotted 
white lines) was recorded for 30 min. Scale bars are 10 μm.  
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3.4 Proof of principle – FLIM-FRET experiment 
FLIM-based FRET measurements to measure protein-protein interactions are very sensitive and 
highly reproducible, but the proper setup of the instrumentation and the analysis pipeline are 
crucial for acquisition of reliable results. After the installation of the new FLIM system, we 
sought to measure the interaction of a relevant and well-defined pair of proteins to test the new 
system. The two subunits of HIF-1, HIF-1α and HIF-1β, form a tight dimer that binds to HRE 
sequences present within hypoxia-responsive genes and recruits coactivators to stimulate gene 
expression (Jiang et al., 1996).  
Clover-HIF-1α DM was used as FRET donor and dsRedXP-HIF-1β was used as FRET 
acceptor. HeLa cells were transfected with Clover-HIF-1α DM alone or co-transfected together 
with dsRedXP-HIF-1β. First, conventional high-resolution fluorescence images were taken 
(Figure 3.11A, first two columns). Next, fluorescence lifetime images (FLIM) of Clover-HIF-
1α DM in both conditions were acquired (Figure 3.11A, last column). In the FLIM each pixel is 
pseudo-coloured according to the average arrival time of all photons within the pixel. Long 
average arrival times are displayed in red and short mean arrival times are displayed in blue. In 
the absence of a FRET acceptor, the fluorescence lifetime image of Clover-HIF-1α DM showed 
long lifetimes in the red spectrum. However, when the FRET acceptor dsRedXP-HIF-1β was 
present, Clover-HIF-1α DM lifetime images was yellow and green, reflecting shorter lifetimes. 
This decrease in lifetime is due to FRET and therefore indicates that within the cell HIF-1α DM 
and HIF-1β are in very close proximity to each other, as expected. Importantly, when the 
dsRedXP was photobleached and therefore unable to accept the energy transfer from the donor, 
Clover-HIF-1α DM’s lifetime increased again (Figure 3.11B). This confirmed that the measured 
fluorescence lifetime reduction was indeed due to the close interaction with and FRET to 
dsRedXP-HIF-1β.  
For the quantification the fluorescence lifetimes, intensity-based average fluorescence lifetimes 
in the nucleus were extracted from the FLIM measurements as described in the Methods 
section. In the case of Clover-HIF-1α DM alone we measured an average lifetime of 2.9 ± 0.024 
ns from 17 cells from 3 independent experiments (Figure 3.11C). In the presence of dsRedXP-
HIF-β the fluorescence lifetime of Clover-HIF-1α DM is significantly decreased to 2.7 ± 0.069 
ns, indicating FRET (17 cells from 3 independent experiments) and confirming their close 
spatial proximity. 
Hence, we have a functioning FLIM-FRET system at hand that will allow us to measure the 
interaction of two proteins with each other. 
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Figure 3.11: FLIM-FRET measurements of the HIF-1α/β pair. HeLa cells were transfected 
with Clover-HIF-1α DM alone or co-transfected with dsRedXP-HIF-1β. (A) Representative 
conventional fluorescence and pseudo-coloured fluorescence life time images (FLIM) of both 
conditions. The scale bars are 10 μm long. (B) The fluorescence of the acceptor was bleached 
by high intensity laser irradiation (dotted line) and a FLIM image was acquired after successful 
bleaching. (C) The nuclear average intensity-based lifetime was extracted from FLIM images of 
three independent experiments (total n=17 per condition) and displayed in a box plot. p = 
4.71*10
-10
.  
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3.5 Fluorescence tagging of USP29 
On the search for new regulators of hypoxia signalling, other preliminary work in Edurne 
Berra’s lab had pointed towards a possible implication of the deubiquitinase USP29. The rest of 
this thesis is dedicated to the thorough investigation of USP29’s role in HIF signalling (chapter 
4) and to the characterisation of the USP29 protein itself (chapter 5). The experiments that are 
presented in those chapters, were to a large part performed with HA- as well as GFP-tagged 
USP29 constructs from (Liu et al., 2011). Both constructs displayed the same exclusively 
nuclear localisation as had been described previously (Urbe et al., 2012) (Figure 3.12).  
 
Figure 3.12: USP29 localises to the nucleus. HeLa cells were transfected with HA-USP29 or 
GFP-USP29 and after 24 h either fixed and stained with anti-HA antibody or imaged directly, 
respectively. The scale bar is 20 μm. 
For FLIM- based FRET experiments, we needed a red fluorescent version of USP29. Therefore, 
the GFP coding sequence was replaced by the red fluorescent protein mRuby2 as it had proved 
to be a suitable label even for PHD1 and the aggregation prone PHD3 (3.2.4). Surprisingly, 
mRuby2-9aa-USP29 did not show any fluorescence when transfected into cells, even though in 
western blots we were able to detect a band corresponding to full-length and in-frame expressed 
mRuby2-9aa-USP29 with anti-USP29 antibody (Figure 3.13A). However, the antibody also 
detected a second band of a lower molecular weight, which could be the result of a post-
translational cleavage of mRuby2-9aa-USP29. Additionally, the overexpressed mRuby2-9aa-
USP29 was not able to induce the accumulation of its target HIF-1α (see chapter 4.3). This 
suggested that the construct was not functional. To decrease potential interference of the 
mRuby2 with USP29 and vice versa, we extended the linker sequence from 9 to 15 and 21 aa. 
Indeed, these constructs displayed faint fluorescence, however the localisation was dispersed 
(Figure 3.13B). We hypothesised that for unknown reasons mRuby2 disturbed USP29 function 
and/or USP29 impeded appropriate mRuby2 fluorophore maturation. We replaced mRuby2 
with mCherry, another monomeric red fluorescent protein, and the new construct mCherry-
15aa-USP29 was localised exclusively in the nucleus, reproducing the localisation pattern we 
had seen for HA-USP29 and GFP-USP29 and displayed very bright fluorescence (Figure 
3.13B). Importantly, mCherry-15aa-USP29 was able to accumulate HIF-1α DM(PP/AA), 
indicating that the mCherry-tag did not interfere with USP29’s catalytic activity (Figure 3.13C). 
Therefore, this construct was chosen for use in experiments that are presented in the following 
two chapters. 
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Figure 3.13: Generation of a red fluorescent USP29. (A) HEK293T cells were transfected 
with mRuby2-9aa-USP29 and the lysate was probed for USP29 and HIF-1α by WB. (B) 
mRuby2-15aa-USP29, mRuby2-21aa-USP29 or mCherry-15aa-USP29 were transfected into 
HeLa cells and pictures were taken 24h post-transfection with the same acquisition settings. 
Scale bars are 20 μm. (C) mCherry, mCherry-15aa-USP29 and mCherry-15aa-USP29C/S were 
co-transfected together with myc-Clover-HIF-1α DM(PP/AA) into HEK293T cells. Red 
fluorescent protein and HIF-1α were detected by immunoblotting.  
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3.6 Discussion 
3.6.1 Choice of the fluorescent tag  
Fluorescence imaging gives us insights into what happens inside living cells on a molecular 
level. It allows us to study how molecules move in real time and how they dynamically interact 
with one another. However, to be able to visualise and follow the molecules of interest they 
need to be labelled with a fluorescent dye. Modern monomeric fluorescent proteins that are 
used as tags for the protein of interest, fold independently and have short maturation times, are 
photostable and bright, and therefore allow for imaging with low laser power and hence reduce 
the amount of photodamage. However, with their size of approximately 35 kDa they can 
interfere with the correct folding and/or functioning of the tagged protein.  
We found that the tetrameric fluorescent protein dsRedXP boosted the aggregation of PHD3 
and resulted in an incorrect intracellular localisation. This is not an unprecedented case. Han et 
al. found that the fusion of a fluorescent protein such as GFP or mCherry to Caveolin-1 induced 
its mislocalisation and altered its oligomerisation status (Han et al., 2015). Similarly, Landgraf 
et al. found that tagging bacterial Clp protease with a panel of monomeric fluorescent proteins 
such as sfGFP, Venus and mCherry caused the protease to concentrate in a single focus 
(Landgraf et al., 2012). Immediately after cell division the focus was only present in one of the 
two daughter cells resulting in a substantial difference in protease activity between them. The 
introduction of a mutation into the GFP (GFPmut3) or the usage of Dendra2 or Dronpa could 
restore the correct homogenous localisation and distribution of Clp between the daughter cells. 
Furthermore, they showed that other bacterial proteins that had previously been described to 
form foci did not do so when fused to GFPmut3. Likewise, when we fused the monomeric 
protein mRuby2 to PHD3, the native localisation and aggregation pattern was reproduced. 
Moreover, mRuby2 also proved to be a suitable tag for PHD1.  
However, when we fused mRuby2 to USP29, the chimeric protein displayed very faint 
fluorescence, seemed to be retained in the cytoplasm and to have lost its ability to stabilise its 
target protein HIF-1α. While the fluorescence intensity was slightly improved when increasing 
the linker between mRuby2 and USP29 from 9 amino acids (aa) to 15 aa, a further increase to 
21 aa did not further enhance the weak signal, and the localisation remained aberrant. The 
problem was solved by fusing USP29 to an alternative monomeric fluorescent tag, mCherry. 
The mCherry-USP29 displayed bright, nuclear fluorescence and was able to accumulate HIF-
1α, attesting its functionality. 
Taken together, it becomes clear that there is not such a thing as a universal fluorescent protein 
tag that readily labels any given protein with the guarantee of not affecting its function. 
3.6.2 Measuring protein-protein interactions in live cells 
Most, if not all, signal transduction mechanisms depend on the interaction of two or more 
proteins with each other (Pawson and Nash, 2000). To understand the signalling dynamics, it is 
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therefore crucial to be able to reliably measure protein-protein interactions in living cells. 
Several live cell imaging methods are available for that purpose. Diffusion-based techniques 
such as RICS and FCS allow us to determine quantitatively the diffusion coefficient of one 
labelled protein at a time. The RICS approach has recently been used successfully to measure 
the recruitment of p53 to DNA upon DNA damage (Hong et al., 2010) and to measure the 
homo-dimerisation of the EGFR upon stimulation with EGFR (Kluba et al., 2015). In both 
cases this was possible because of a dramatic change of their diffusion coefficient following the 
respective stimulation. Generally however, while two (or more) proteins that are associated do 
have the same diffusion behaviour, same diffusion coefficients are not sufficient to state their 
interaction. In particular, if two proteins are part of a big multiprotein complex and/or tethered 
to high molecular structures such as the DNA, their diffusion behaviour will be identical 
independently of whether within the complex the two are directly bound to each other or not.  
In order to more directly and quantitatively measure the interaction of two proteins with each 
other, the (FLIM-)FRET and FCCS technique can be used. The most direct proof of interaction 
is delivered by FRET experiments as FRET can only occur when donor and acceptor 
fluorophore are within a few nanometres’ distance. FLIM-based FRET measurements are 
especially useful as the fluorescence lifetime is a very robust property, resulting in low cell-to-
cell- and experiment-to-experiment variability (Becker, 2012). Apart from their distance, the 
orientation of donor and acceptor fluorophore are important for FRET to occur and depending 
on the proteins to be measured, FRET measurements might not be successful. In this case the 
diffusion-based FCCS method might help to find an answer to the questions. By being able to 
measure the diffusion coefficients of two differentially labelled proteins within the small focus 
volume, FCCS adds spatial information to the diffusion measurements (Bacia et al., 2006). Two 
interacting proteins therefore not only exhibit the same diffusion parameters, but also appear in 
the focal volume together. 
Taken together, fluorescent live cell imaging is a powerful tool, but correct selection and 
validation of the fluorescent label and the adequate technique for each and every particular 
protein and research question is crucial for obtaining meaningful results. There is not one 
fluorescent protein tag, which can warrant that the tagged protein behaves as its endogenous 
counterpart. Instead, the careful assessment of localisation and activity of the fusion protein is 
required, preferably by comparing it with the properties of the endogenous protein, or if this is 
not possible by comparing it to the protein when fused to a small peptide-tag. 
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Chapter 4: USP29 is a new regulator of HIF-α 
4.1 Introduction 
The canonical hypoxia signalling pathway that senses low oxygen concentrations and triggers 
processes involved in cell survival and adaptation was discovered more than 20 years ago 
(Semenza and Wang, 1992). In the last 2 decades the understanding of the pathway has 
expanded and more and more proteins are now known to modulate HIF signalling. At the same 
time it became clear that the hypoxia signalling pathway was deregulated in many cancers. 
Sustained expression of HIF target genes confers resistance to induced cell death and makes 
cells highly glycolytic, as well as induces angiogenesis (Semenza, 2012b). However, despite the 
amount of information available nowadays, the mechanisms that cause the inappropriate HIF 
signalling remain not fully understood.  
The hypoxia signalling pathway is heavily regulated by the ubiquitin proteasome system. In 
particular, the stability of the α-subunit of the central transcription factor HIF is regulated 
through ubiquitination. But also other important members of the pathway, such as PHD1 and 
PHD3 are subjected to ubiquitination and subsequent degradation (Fukuba et al., 2007; 
Nakayama et al., 2004; Velasco et al., 2013). Hence, enzymes that de-conjugate ubiquitin could 
have the potential to modify the hypoxic response significantly. Indeed, several of such 
deubiquitinases (DUBs) had already been shown to impact hypoxia signalling (see 1.3.1 and 
1.3.2). Based on the fact that DUBs are potentially druggable enzymes, Edurne Berra’s lab 
decided to perform a DUB screen in order to identify potential new regulators of the hypoxia 
signalling pathway. Such a new regulator could help to expand the understanding of how and 
why hypoxia signalling is deregulated in disease and might in the future serve as a biomarker or 
even a drug target. 
This chapter presents the work done to establish USP29 as a novel non-canonical regulator of 
HIF-α. Using a combination of standard biochemical methods in Edurne Berra’s lab, as well as 
advanced live cell imaging in Violaine Sée’s lab, we found that USP29 activated hypoxia 
signalling by directly acting on HIF-α. Parts of this chapter are part of a manuscript, which is 
being tried to publish. My contribution to the work is stated in italics in each figure legend.  
4.2 First experiments performed in Edurne Berra’s lab 
Encarni Perez-Andrés transfected a library of pools of shRNAs targeting more than 60 DUBs 
into HeLa cells together with an HRE-luciferase reporter gene (Figure 4.1A). The cells were 
exposed to either normoxia or hypoxia and HIF transcriptional activity was read out using the 
luciferase assay. The experiment was carried out three times in triplicates, and several DUBs 
were shown to have an effect on HIF activity. Among them, the ubiquitin-specific protease 29 
(USP29) was one of the top hits. Validation experiments performed by Sara Pozo and Onintza 
Carlevaris confirmed that the knock-down of endogenous USP29 with the pool of shRNAs did 
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significantly and reproducibly decrease HRE-luciferase activity as well as the expression of 
HIF-target genes in normoxia and hypoxia. Furthermore, not only the pool, but also all three 
independent shRNAs targeting USP29 did reproduce the inhibitory effect on HIF-driven 
transcriptional activity (Figure 4.1B).  
 
Figure 4.1: Identification and validation of USP29 as an activator of HIF signalling. (A) 
HeLa cells were silenced with pools of 3 individual shRNAs targeting DUBs and transfected 
with a HRE-luciferase reporter plasmid. Cells were exposed to normoxia and hypoxia and 
luciferase activity was determined. (B) HeLa cells were silenced for HIF-1α and USP29 with 
three different shRNAs and transfected with HRE-luciferase. The luciferase activity was 
measured after incubation in normoxia or hypoxia (24h). These Experiments were performed by 
members of Edurne Berra’s lab.  
4.3 USP29 is a positive regulator of HIF-1α 
Apart from significantly reducing the hypoxia-driven HRE-luciferase expression (Figure 4.2A), 
the silencing of endogenous USP29 with a pool of 3 independent shRNAs in HeLa cells also 
abrogated the hypoxic induction of the HIF target gene CA9 (Figure 4.2B). The pool of 
shUSP29s efficiently silenced GFP-USP29 at mRNA and protein levels (Figure 4.3A). 
Interestingly, in cells silenced for endogenous USP29 the accumulation of HIF-1α protein in 
hypoxia was significantly decreased and the induction of CAIX and PHD2 was impaired to a 
similar extent as when silencing HIF1A (Figure 4.2C). Anyhow, HIF1A mRNA was not 
affected by the silencing of USP29 (Figure 4.3B). More importantly, similar to the pan-
hydroxylase inhibitor DMOG, the ectopic expression of USP29 led to the accumulation of 
endogenous HIF-1α, CAIX and PHD2 even in normoxia (Figure 4.2D). Nonetheless, HIF1A 
mRNA expression was not affected by the USP29 overexpression (Figure 4.3C), pointing to 
USP29 as a novel upstream post-translational activator of HIF-1α.  
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Figure 4.2: USP29 is a positive regulator of HIF-1α. (A) HeLa cells were silenced with 
scrambled or shRNAs targeting HIF1A and USP29 and transfected with a reporter vector (pRE-
Δtk-Luc) containing three copies of the HRE from the erythropoietin gene and CMV-β-gal to 
normalize for transfection efficiency. Cells were incubated for 16 h in normoxia (21% O2) or 
hypoxia (1% O2) and luciferase and β-galactosidase activities were measured. (B) HeLa cells 
were treated as in A and total RNA was extracted, reverse-transcribed and expression of CA9 
was determined by qPCR. (C) Whole cell extracts (WCE) from HeLa cells treated as in A were 
subjected to SDS-PAGE followed by immunoblotting with the indicated antibodies. (D) 
HEK293T cells were transfected with empty vector or HA-USP29 and left untreated or treated 
with DMOG for 4 hours prior to lysis. WCE were subjected to SDS-PAGE and immunoblotting 
was performed using the indicated antibodies. All experiments were performed by the EB lab. 
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Figure 4.3: USP29 is a positive regulator of HIF-1α (supplement). (A) HeLa cells were 
silenced with scrambled or shRNAs targeting USP29 and transfected with GFP-USP29. RNA 
and protein were extracted and subjected to qPCR and immunoblotting, respectively. (B) HeLa 
cells were silenced with scrambled shRNAs or shRNAs targeting HIF1A and USP29 and 
incubated for 16 h in normoxia (21% O2) or hypoxia (1% O2). Total RNA was extracted, 
reverse-transcribed and expression of HIF1A was determined by qPCR. (C) HEK293T cells 
were transfected with empty vector or HA-USP29, RNA was extracted and expression of 
USP29 as well as HIF1A was determined by qPCR. All experiments were performed by the EB 
lab. 
4.4 USP29 upregulates HIF-1α in a non-canonical way  
Surprisingly, the HIF-1α that accumulated in the presence of USP29 in normoxic conditions 
induced PHD2 and CAIX (Figure 4.2D), albeit being prolyl-hydroxylated (Figure 4.4A). 
Furthermore, the ectopic expression of USP29 also accumulated HIF-1α DM(PP/AA), a HIF-1α 
mutant whose two oxygen-sensitive proline residues have been replaced by alanines 
(P402/564A), suggesting that USP29 regulates HIF-1α in a non-canonical way (Figure 4.4B). 
Consistently, silencing of endogenous USP29 with 2 different siRNA sequences decreased 
both, HIF-1α WT and HIF-1α DM(PP/AA) protein levels (Figure 4.4C and Figure 4.5A). As 
expected, the silencing of the canonical negative regulators, PHD2/EGLN1 and pVHL, only 
affected HIF-1α WT but not HIF-1α DM(PP/AA) (Figure 4.4C). Similarly, the overexpression of 
the Ub E3-ligase pVHL did only affect HIF-1α WT, but not the DM protein (Figure 4.5B). 
Taken together, these results indicate that USP29 acts on HIF-1α through a non-canonical 
mechanism.  
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Figure 4.4: USP29 regulates HIF-1α in a non-canonical way. (A) HEK293T cells were 
transfected with empty vector or HA-USP29 and treated with the hypoxia mimetic DMOG (1 
mM), the proteasome inhibitor MG132 (10 μM) or hypoxia (1% O2) for 4 hours. WCE were 
prepared and analysed by immunoblotting with the indicated antibodies. (B) HEK293T cells 
were co-transfected with myc-HIF-1α or myc-HIF-1α DM(PP/AA) and empty vector or GFP-
USP29. Levels of myc- and GFP-tagged proteins in WCE were determined by immunoblotting 
in WCE. (C) HEK293T cells were silenced with control or siRNAs (20 nM) targeting 
endogenous USP29, PHD2/EGLN1 or pVHL mRNA and transfected with myc-HIF-1α or myc-
HIF-1α DM(PP/AA). Total cell extracts were subjected to SDS-PAGE followed by 
immunoblotting with the indicated antibodies. B and C were performed by me. 
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Figure 4.5: USP29 regulates HIF-1α in a non-canonical way (supplement). (A) HEK293T 
cells were silenced with scrambled siRNA or two independent siRNA sequences (20nM) 
targeting USP29 and transfected with myc-HIF-1α DM(PP/AA) or HA-USP29. WCE were 
analysed by WB for the expression levels of myc-HIF-1α DM(PP/AA) or HA-USP29, 
respectively. (B) HEK293T cells were co-transfected with myc-HIF-1α or myc-HIF-1α 
DM
(PP/AA)
 and HA-pVHL. Total cell extracts were subjected SDS-PAGE followed by 
immunoblotting with the indicated antibodies. All experiments were performed by me. 
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4.5 Universality of USP29’s effect on HIF-α  
The effect of USP29 on HIF-1α was observed in a variety of cell lines of different origins, 
including A2780 (ovarian cancer), PC3 and LnCaP (prostate cancer), SH-SY5Y and SK-N-AS 
(neuroblastoma) and MDA-MB-231 (breast cancer). In all tested cell lines the overexpression 
of USP29 led to an increase in HIF-1α DM(PP/AA) levels (Figure 4.6A), indicating that this 
regulation might be a wide phenomenon. Moreover, both, the wild type and the oxygen-
insensitive DM
(PP/AA)
 forms of HIF-2α/EPAS also accumulated upon overexpression of USP29 
(Figure 4.6B). 
 
Figure 4.6: Wide impact of USP29 on HIF-α. (A) Cancer cell lines of different origins were 
co-transfected with myc-HIF-1α DM(PP/AA) and empty vector or HA-USP29 and left untreated or 
treated with the proteasome inhibitor MG132 (10 μM) for 4 hours. WCE were subjected to 
SDS-PAGE followed by immunoblotting with the indicated antibodies. (B) HEK293T cells 
were co-transfected with myc-HIF-2α or myc-HIF-2α DM(PP/AA) and empty vector or GFP-
USP29 and total cell extracts were analysed by immunoblotting. A was performed by me. 
4.6 USP29 stabilises HIF-α by protecting it from 
proteasomal degradation  
In order to determine the molecular mechanism of HIF-α DM(PP/AA) accumulation by USP29, we 
treated HEK293T cells with the proteasome inhibitor MG132 for 4 hours in the absence or 
presence of ectopic USP29 (Figure 4.7A). Both, the USP29 overexpression and the proteasome 
inhibition induced HIF-1α DM(PP/AA) accumulation, but the lack of additivity indicated that they 
both acted on the same pathway. Furthermore, as USP29 accumulated HIF-1α DM(PP/AA) more 
efficiently than MG132, we tested whether HIF-1α DM(PP/AA) was also degraded via the 
lysosomal pathway. Yet, the inhibition of this pathway by treatment with chloroquine failed to 
prevent HIF-1α DM(PP/AA) degradation (Figure 4.8A), confirming that it requires the proteasome 
activity and suggesting that the difference between MG132- and USP29-induced HIF-1α 
DM
(PP/AA)
 accumulation was due to incomplete proteasome inhibition. Cycloheximide 
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experiments showed that USP29 increased HIF-1α DM(PP/AA)’s half-life from ≅ 1 to ≅3 hours 
(Figure 4.8B). More importantly, USP29 stabilised endogenous HIF-1α upon reoxygenation 
(Figure 4.7B). Although USP29 did not avoid the initial HIF-1α degradation within the first 10 
minutes of reoxygenation, thereafter HIF-1α levels remained stable during at least one hour in 
the presence of USP29, while the protein was not longer detectable 30 minutes after 
reoxygenation in the absence of USP29. To gain further insight into how USP29 stabilised HIF-
α, we generated a catalytically inactive USP29 mutant by replacing its active site cysteine 
residue C294 with a serine (USP29
C/S
). This mutation completely abrogated USP29’s ability to 
accumulate HIF-1α DM(PP/AA) (Figure 4.7C), pointing towards a crucial role of USP29’s 
ubiquitin specific peptidase activity in HIF-α DM(PP/AA) stabilisation. 
 
Figure 4.7: USP29 stabilises HIF-1α by protecting it from proteasome-mediated 
degradation. (A) HEK293T cells were co-transfected with myc-HIF-1α DM(PP/AA) and empty 
vector or GFP-USP29 and left untreated or treated with the proteasome inhibitor MG132 (10 
μM) for 4 hours. Total cell extracts were subjected to SDS-PAGE followed by immunoblotting 
with the indicated antibodies. (B) HEK293T cells were transfected with empty vector or GFP-
USP29 and incubated in hypoxia (1% O2) for 4 hours. Then cells were treated with 
cycloheximide (20 μg/ml) to inhibit protein synthesis, reoxygenated and cell extracts were 
prepared at the indicated time points. HIF-1α protein levels were determined by Western 
Blotting. (C) HEK293T cells were co-transfected with myc-HIF-1α DM(PP/AA) and empty vector, 
GFP-USP29 or GFP-USP29
C/S
. Cell extracts were subjected to immunoblotting with the 
indicated antibodies. A and C were performed by me.  
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Figure 4.8: USP29 stabilises HIF-1α by protecting from proteasome-mediated degradation 
(supplement). (A) HEK293T cells were transfected with myc-HIF-1α DM(PP/AA) and left 
untreated or treated with either the proteasome inhibitor MG132 (10 μM), the autophagy 
inhibitor chloroquine (30 μg/mL) or both inhibitors together for 6 hours. Protein levels were 
determined by immunoblotting of the whole cell extracts with the indicated antibodies. (B) 
HEK293T cells were co-transfected with myc-HIF-1α DM(PP/AA) and empty vector or GFP-
USP29 and treated with cycloheximide (CHX) (20 μg/ml) to inhibit protein synthesis. Cell 
extracts were collected at the indicated times after CHX addition and subjected to 
immunoblotting with the indicated antibodies. A was performed by me. 
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4.7 USP29 interacts with and deubiquitinates HIF-α 
DM(PP/AA) 
As the catalytical activity of USPs is responsible for removal of (poly)ubiquitin chains from 
their target proteins, we next tested whether USP29 was able to function as a deubiquitinase for 
HIF-α. To analyse the ubiquitination pattern of HIF-1α DM(PP/AA) we used Nickel-NTA-beads 
for specific purification of all the proteins conjugated to (His)6-tagged ubiquitin in cellulo. 
However, the first experiments showed that myc-tagged HIF-1α DM(PP/AA) bound unspecifically 
to the Nickel-beads even in the absence of (His)6-ubiquitin (Figure 4.9A). Therefore, this 
classical approach was not suitable for our purpose. At that time, an ubiquitination assay based 
on GFP-traps® had just been established and proved effective by Ugo Mayor’s group (Lee et 
al., 2014). GFP-traps®’s single-chain camelid antibody has a very high affinity to various 
variants of green fluorescent proteins that permits very stringent washes without losing the 
targeted protein. We therefore inserted the Clover sequence into the myc-Clover-HIF-1α 
DM
(PP/AA)
 construct and found that Clover did not interfere with HIF-1α DM(PP/AA) behaviour in 
response to different treatments. Myc-Clover-HIF-1α DM(PP/AA) accumulated upon treatment 
with MG132 and in the presence of USP29 but was not induced by DMOG or the catalytically 
inactive USP29
C/S 
(Figure 4.9B). According to these results, we successfully set-up the GFP-
traps® based ubiquitination assay with myc-Clover-HIF-1α DM(PP/AA). 
 
Figure 4.9: Setup of an HIF-α ubiquitination assay. (A) HEK293T cells were transfected 
with (His)6-ubiquitin, myc-HIF-1α DM
(PP/AA)
 or both together. Nickel-NTA-beads were used to 
pull down proteins that were conjugated to (His)6-ubiquitin in denaturing conditions. (B) 
HEK293T cells were transfected with myc-Clover-HIF-1α DM and treated with DMOG or 
MG132 or co-transfected with catalytically active or inactive HA-USP29. All experiments were 
performed by me. 
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First, we analysed the interaction between USP29 and HIF-α using fluorescence lifetime based 
FRET measurements. The fluorescence lifetime of the FRET donor, Clover-HIF-1α DM(PP/AA), 
was significantly decreased from 2.86 ± 0.02 ns to 2.7 ± 0.09 ns in the presence of the FRET 
acceptor mCherry-USP29 (Figure 4.10A). As FRET only occurs when both fluorophores are in 
very close proximity (around 6 nm), these data clearly show that USP29 is directly bound to 
HIF-1α DM(PP/AA). Similar results were obtained when we analysed the interaction between 
USP29 and HIF-2α DM(PP/AA) (Figure 4.11A). HIF-2α DM(PP/AA)-GFP’s lifetime was 
significantly reduced from 2.39 ± 0.01 ns to 2.28 ± 0.06 ns in the presence of the FRET 
acceptor mCherry-USP29. Furthermore, when GFP-tagged HIF-1α DM(PP/AA) or GFP alone 
were immunoprecipitated from HEK293T cells, we found HA-USP29 to interact with GFP-
tagged HIF-1α DM(PP/AA), but not with GFP alone (Figure 4.11B). Next, we cotransfected GFP-
tagged HIF-1α DM(PP/AA) together with FLAG-ubiquitin either in the absence or the presence of 
HA-USP29 or HA-USP29
C/S
. After the enrichment of the ubiquitinated proteome by MG132-
treatment, GFP-HIF-1α DM(PP/AA) was pulled-down under highly denaturing conditions and 
anti-FLAG-antibody was used to detect ubiquitinated GFP-HIF-1α DM(PP/AA). We found that 
USP29 wild type, but not the catalytically inactive USP29
C/S
,
 
considerably decreased the basal 
ubiquitination of HIF-1α DM(PP/AA) and increased the non-modified population of HIF-1α 
DM
(PP/AA)
 (Figure 4.10B). Accordingly, when silencing endogenous USP29, we observed 
increased poly-ubiquitination of HIF-1α DM(PP/AA) (Figure 4.10C), pointing towards a basal 
deubiquitinating activity of endogenous USP29. Expression of a siRNA-resistant USP29 
restored the basal HIF-1α DM(PP/AA) ubiquitination pattern (Figure 4.10C right lane). 
Furthermore and in concordance with Figure 3B, USP29 also exerted deubiquitination activity 
towards HIF-2α DM(PP/AA) (Figure 4.11B). Taken together, our results indicate that endogenous 
and ectopic USP29 is an efficient deubiquitinase for HIF-α DM(PP/AA) thereby increasing HIF-α 
stabilisation and subsequent HIF activation. 
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Figure 4.10: USP29 deubiquitinates HIF-α DM(PP/AA). (A) HeLa cells were transfected with 
the FRET donor Clover- HIF-1α DM(PP/AA) alone or together with the FRET acceptor mCherry-
USP29. Fluorescence images for donor (green) and acceptor (red) channel were acquired (left 
and central panel). The lifetime of the donor was measured and pseudo-colour coded 
fluorescence life time images (FLIM) were generated. From 3 independent experiments average 
lifetimes of the donor in the absence (n = 34) and the presence (n = 25) of the FRET acceptor 
were calculated. Scale bars are 10 μm long, (*) p = 1.32*10-8. (B) HEK293T cells were co-
transfected with GFP-HIF-1α DM(PP/AA), FLAG-ubiquitin and either HA-USP29 or HA-
USP29
C/S
. Cells were treated with the proteasome inhibitor MG132 (10 μM) for 2 hours and 
lysed in the presence of the DUB inhibitor NEM. GFP-HIF-1α DM(PP/AA) was pulled down with 
GFP-traps® and subjected to stringent washes (8 M urea, 1% SDS). Ubiquitinated and non-
ubiquitinated GFP-HIF-1α DM(PP/AA) protein in the eluate was analysed by immunoblotting with 
anti-FLAG and anti-GFP antibodies, respectively. (C) HEK293T cells were silenced with a 
control or a siRNA targeting USP29 (20 nM) and co-transfected with GFP-HIF-1α DM(PP/AA), 
FLAG-ubiquitin and either empty vector or siRNA-resistant HA-USP29. Treatment of cells, 
pull-down with GFP-traps® and subsequent analysis of the ubiquitinated and non-ubiquitinated 
GFP-HIF-1α DM(PP/AA) protein in the eluate were performed as in (B). All experiments were 
performed by me. 
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Figure 4.11: USP29 deubiquitinates HIF-α DM(PP/AA) (supplement). (A) HeLa cells were 
transfected with the FRET donor HIF-2α DM(PP/AA)-GFP alone or together with the FRET 
acceptor mCherry-USP29. Fluorescence images for donor (green) and acceptor (red) channel 
were acquired (left and central panel). The lifetime of the donor was measured and pseudo-
colour coded fluorescence life time images (FLIM) were generated. Average lifetimes of the 
donor in the absence (n = 25) and the presence (n = 29) of the FRET acceptor were calculated 
from 3 independent experiments. Scale bars are 10 μm long, (*) p = 2.36*10-11. (B) HEK293T 
cells were co-transfected with HA-USP29 and either GFP alone or GFP-HIF-1α DM(PP/AA). 
Cells were lysed in native conditions and GFP-tagged protein was immunoprecipitated with 
GFP-traps®. Immuno-complexes were analysed for the presence of HA-USP29 by 
immunoblotting. (C) HEK293T cells were co-transfected with GFP-HIF-2α DM(PP/AA), FLAG-
ubiquitin and either HA-USP29 or empty vector. Cells were treated with the proteasome 
inhibitor MG132 (10 μM) for 2 hours and lysed in the presence of the DUB inhibitor NEM. 
GFP-HIF-2α DM(PP/AA) was pulled down with GFP-traps® and subjected to stringent washes (8 
M urea, 1% SDS). Ubiquitinated and non-ubiquitinated GFP-HIF-2α DM(PP/AA) protein in the 
eluate was analysed by immunoblotting with anti-FLAG and anti-GFP antibodies, respectively. 
A and B were performed by me. 
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4.8 HIF-1α is specifically targeted by USP29 
We have shown that overexpressed USP29 efficiently deubiquitinated and hence accumulated 
HIF-1α and HIF-1α DM(PP/AA) in normoxic cells. To exclude that the deubiquitination was an 
unspecific event as a result of the overexpression of USP29, we tested whether the 
overexpression of another nuclear deubiquitinase would also accumulate HIF-1α. While GFP-
USP29 efficiently accumulated both, HIF-1α and HIF-1α DM(PP/AA), the presence of 
overexpressed deubiquitinase activity in form of another nuclear DUB - USP11 - was not 
sufficient to do the same (Figure 4.12). Together with the siUSP29 data, this indicated that 
USP29 was indeed targeting HIF-1α specifically.  
 
Figure 4.12: USP29 but not another nuclear DUB accumulates HIF-1α. HEK293T cells 
were co-transfected with myc-HIF-1α or myc-HIF-1α DM(PP/AA) and GFP-USP29 or GFP-
USP11. Whole cell lysates were subjected to SDS-PAGE followed by immunoblotting with the 
indicated antibodies. The experiment was performed by EB’s technician. Experiment was 
performed by me. 
 
 
4.9 USP29 targets the C-terminal part of HIF-α  
To identify the potential lysine residues targeted by USP29’s deubiquitinating activity, we 
tested several truncated forms of HIF-1α DM(PP/AA) for their susceptibility to USP29. The N-
terminal part, HIF1αDM1-657, was not affected by the presence of USP29 (and MG132, data not 
shown), while the C-terminal end (HIF-1α630-826) accumulated in the presence of USP29 
similarly to the full-length protein (Figure 4.13A). The USP29
C/S
 mutant that lacked catalytical 
activity was not able to accumulate HIF-1α630-826 (Figure 4.14A). Correspondingly, USP29 
acted also on the C-terminus of HIF-2α (Figure 4.14B). We used truncations of the C-terminus 
to further confine the USP29 target site within HIF-1α. HIF-1α630-713 and HIF-1α630-750 were 
resistant to USP29-mediated accumulation (Figure 4.14C) and pointed out the importance of the 
very C-terminal tail of HIF-1α for this regulation. This tail contains two evolutionary conserved 
lysines (K752 and K755), which are also shared by HIF-2α and a neighbouring lysine (K758) 
(Figure 4.14D). Mutation of all three lysines to arginines (HIF-1α DMKKK/RRR) conferred to this 
mutated protein a higher stability in cycloheximide experiments (Figure 4.13B). Importantly, 
the basal ubiquitination of HIF-1α DMKKK/RRR was significantly reduced as compared to HIF-1α 
DM (Figure 4.13C). 
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Figure 4.13: USP29 targets the C-terminal part of HIF-α. (A) HEK293T cells were co-
transfected with myc-HIF-1α DM1-826, myc-HIF-1α DM1-657 or myc-HIF-1α DM630-826 and either 
empty vector or GFP-USP29. Whole cell extracts were subjected to SDS-PAGE followed by 
immunoblotting with the indicated antibodies. (B) HEK293T cells were transfected with myc-
HIF-1α DM or myc-HIF-1α DMKKK/RRR and cells were treated with cycloheximide (CHX) (20 
μg/ml) to inhibit protein synthesis. Cell extracts were collected at the indicated times after CHX 
treatment and protein levels of the myc-tagged HIF-1α DM(PP/AA)  proteins were analysed by 
western blot. (C) HEK293T cells were co-transfected with GFP-HIF-1α DM or myc-HIF-1α 
DM
KKK/RRR
 and FLAG-ubiquitin. Cells were treated with the proteasome inhibitor MG132 (10 
μM) for 2 hours and lysed in the presence of the DUB inhibitor NEM. GFP-tagged protein was 
pulled down with GFP-traps® and subjected to stringent washes (8 M urea, 1% SDS). 
Ubiquitinated and non-ubiquitinated GFP-HIF-1α protein in the eluate was analysed by 
immunoblotting with anti-FLAG and anti-GFP antibodies, respectively. B and C were 
performed by me. 
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Figure 4.14: USP29 targets the C-terminal part of HIF-α (supplement). (A) HEK293T cells 
were co-transfected with myc-HIF-1α DM630-826 and either empty vector, GFP-USP29 or GFP-
USP29
C/S
. Whole cell extracts were prepared and submitted to immunoblotting with the 
indicated antibodies. (B, C) HEK293T cells were co-transfected with (B) myc-HIF-2α DM601-870 
or (C) myc-HIF-1α DM630-826, myc-HIF-1α DM630-713 or myc-HIF-1α DM630-750 and either empty 
vector or GFP-USP29. Whole cell extracts were prepared and submitted to immunoblotting 
with the indicated antibodies. (D) Alignment of the lysine-containing C-terminal sequence of 
HIF-1α and HIF-2α from human (H), mouse (M), rat (R), cow (T), xenopus (X) and zebrafish 
(Z). A and D were performed by me. 
 
4.10 MS analysis of HIF-1α DM’s PTMs 
We had located USP29’s target site within HIF-1α to three lysine residues at the very C-
terminus of the protein. Upon mutation of K752, K755 and K758 to arginines basal poly-
ubiquitination of HIF-1α DMKKK/RRR was clearly reduced as compared to HIF-1α DM (Figure 
4.13C). We sought to confirm this data by mass spectrometry. To that end, Clover-HIF-1α 
DM
(PP/AA)
 and FLAG-ubiquitin were co-transfected into HEK293T cells and these cells were 
treated with MG132 to accumulate ubiquitinated populations, lysed and incubated with GFP-
traps®. Stringent washes removed proteins that interacted non-covalently with Clover-HIF-1α 
DM or the beads and subsequently Clover-HIF-1α DM(PP/AA) was eluted from the beads. On a 
SDS gel the eluate showed two major bands, which supposedly corresponded to Clover-HIF-1α 
DM
(PP/AA)
 (Figure 4.15A, upper band) and to Clover (lower band). The upper band was cut out 
generously in order to include the high molecular weight poly-ubiquitinated populations of 
Clover-HIF-1α DM(PP/AA), and subsequently digested with trypsin. Fragments were loaded onto 
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the mass spectrometer and unique peptides were mapped to the HIF-1α sequence (Figure 4.15B, 
red). Only a coverage of 36% of the sequence was obtained. As trypsin cuts C-terminally of 
lysine and arginine residues if they are not followed by a proline, K752 (underlined) is the last 
residue of a 32 amino acid long fragment while K755 and K758 (underlined) are part of di- and 
tripeptides, respectively, after complete trypsin digestion (Figure 4.15C). While the former is 
too long to be resolved by MS, the latter two are too short, even if they were ubiquitinated 
which would add a di-glycine to the lysine residue. This might explain why none of the three 
lysine residues was detected by the analysis. However, K48-linked poly-ubiquitin was present 
in the analysed sample. This is evidence for Clover-HIF-1α DM(PP/AA) being indeed poly-
ubiquitinated with the classical signal for proteasomal degradation.  
 
Figure 4.15: MassSpec analysis of HIF-1α DM(PP/AA). (A) Clover-HIF-1α DM(PP/AA) was 
pulled down from HEK293T cells in denaturing conditions after MG132 treatment, run on a 
SDS gel and stained with SYPRO®. The band corresponding to Clover-HIF-1α DM(PP/AA) was 
digested with trypsin and analysed on the mass spectrometer. (B) Unique identified peptides 
(red) were mapped to the HIF-1α sequence. (C) Sequence context of the lysine residues of 
interest (K752, K755, K758, underlined). Scissors indicate tryptic cleavage sites. Samples were 
prepared by me and processed by the proteomics platform at CIC bioGUNE: 
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4.11 USP29 levels correlate with tumour progression and 
HIF target gene expression 
The fact that USP29 stabilises HIF-α and is able to maintain hypoxia signalling switched on in 
normoxic conditions, led us to inquire its potential function in tumour progression. We 
therefore assessed whether USP29 expression was altered in certain tumours. Data mining 
analysis of publicly available databases revealed that USP29 expression was significantly 
correlated with prostate cancer progression (Figure 4.16A). The expression levels of USP29 
mRNA increased from normal tissue over primary tumour to metastasis. Interestingly, USP29 
expression exhibited a significant association with the Gleason Score (GS), used in the clinics 
to stratify prostate cancer patients and predict their prognosis, as reflected by higher GS 
associated with higher USP29 expression levels (Figure 4.16B). Furthermore, in the prostate 
cancer samples the expression of USP29 also showed a significant positive correlation with the 
expression levels of the HIF target gene CA9 (Figure 4.16C).  
 
Figure 4.16: USP29 expression in prostate cancer. (A, B) Gene expression analysis of 
USP29 in a dataset of prostate cancer samples (Taylor et al, 2010). USP29 mRNA levels in 
prostate samples were compared on the basis of their tissue origin (A) or the Gleason score 
(GS) of the patient (B) (normal tissue (N): n = 29, primary tumours (PT): n = 131; metastatic 
tumours (Met): n = 19). (C) Correlation analysis between USP29 and CA9 mRNA levels in the 
aforementioned dataset of primary prostate cancer samples (Taylor, n = 131). Analysis was 
performed by Ana M Aransay at CIC bioGUNE. 
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4.12 USP29’s effect on HIF-1α in hypoxia 
USP29 removes non-canonical poly-ubiquitin chains from HIF-1α. In contrast to the canonical 
poly-ubiquitination by pVHL, HIF-1α could be modified by those chains in hypoxia as well. 
Yet, we found that in 1% O2, USP29 overexpression was not able to further enhance HIF-1α 
accumulation (Figure 4.17A). In 5% O2, however, USP29 was able to further accumulate HIF-
1α (Figure 4.17B). This indicated that in mild hypoxia HIF-1α might be still poly-ubiquitinated 
by pVHL as well as by the other ubiquitin E3 ligase whose action is counteracted by USP29. 
 
Figure 4.17: USP29 affects HIF-1α in mild hypoxia. HEK293T cells were transfected with 
HA-USP29 or with empty vector and incubated in normoxia, 1% O2 or 5% O2 for 4h prior to 
lysis and western blotting. Experiments were performed by EB lab members. 
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4.13 Further FLIM-FRET experiments: USP29 - HIF-α 
interaction 
Apart from the FLIM-based FRET measurements presented before we performed further 
experiments to explore how robust the FRET-measured interaction between USP29 and HIF-α 
was. For that purpose different fluorescent-fusion constructs that were available in the lab were 
used. As well as constructs with the fluorescent tag fused to the opposite end of the protein of 
interest, we were able to swap FRET donor and FRET acceptor in some conditions. Table 4.1 
resumes the possible combinations and the performed FLIM-FRET measurements.  
 
Table 4.1: Combinations of available FRET donor and FRET acceptor constructs and the 
measured fluorescence lifetimes of the donors in the absence and the presence of the 
acceptors. ND = not determined. 
FRET acceptor 
FRET donor 
mCherry-USP29 HIF-2α-dsRedXP 
HIF-1α DM-Clover 
(2.86 ± 0.017 ns) 
Figure 4.10A 
(2.70 ± 0.093 ns) 
ND 
Clover- HIF-1α DM 
(2.95 ± 0.027 ns) 
 Figure 4.18A 
(2.85 ± 0.078 ns) 
ND 
HIF-2α DM-GFP 
(2.39 ± 0.011 ns) 
Figure 4.11A 
(2.28 ± 0.057 ns) 
ND 
GFP-USP29 
(2.39 ± 0.016 ns) 
 Figure 5.7 
(2.36 ± 0.028 ns) 
Figure 4.18B 
(2.34 ± 0.040 ns) 
 
When having Clover attached to the N-terminus instead of to the C-terminus of HIF-1α DM, we 
were still able to measure FRET between HIF-1α DM and USP29. Clover-HIF-1α DM’s 
lifetime decreased significantly from 2.95 ± 0.027 ns to 2.85 ± 0.078 ns in the presence of 
mCherry-USP29 (p = 1.06 *10
-5
) and the lifetime recovered by photobleaching of the acceptor 
fluorophore mCherry (Figure 4.18A). 
Unsurprisingly, we also found that USP29 interacted with wildtype HIF-2α. GFP-USP29’s 
lifetime decreased from 2.39 ± 0.016 ns to 2.34 ± 0.040 ns in the presence of HIF-2α-dsRedXP 
(p = 1.16 *10
-5
) and acceptor photobleaching reversed this effect (Figure 4.18B). Besides, we 
also saw a clear redistribution of GFP-USP29 as it was moved from a homogenous nuclear 
localisation into the typical HIF-2α speckles (Taylor et al., 2016). 
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Figure 4.18: USP29 and HIF-α interact with each other. Hela cells were transfected with a 
green fluorescent FRET donor alone or together with a red fluorescent FRET acceptor. 
Representative fluorescence and pseudo-coloured fluorescence lifetime (FLIM) images are 
shown in the first two and the last column, respectively. The white dotted line shows the region 
of interest that was photobleached. Average fluorescence lifetimes of the nuclear FRET donor 
were extracted from the images and represented in the box pot (right panel). (A) 14 cells 
expressing Clover-HIF-1α DM(PP/AA) and 19 cells co-expressing Clover-HIF-1α DM(PP/AA) and 
mCherry-USP29 from 2 different experiments were analysed. (B) 25 cells expressing GFP-
USP29 and 20 cells co-expressing GFP-USP29 and HIF-2α-dsRedXP from 3 different 
experiments were analysed. Scale bars are 10 μm long. Experiments were performed by me. 
4.14 Searching for HIF-1α’s non-canonical ubiquitin E3 
ligase 
We have showed that USP29 stabilised HIF-1α without affecting prolyl-hydroxylation by PHDs 
or poly-ubiquitination by pVHL. Furthermore, upon depletion of endogenous USP29 hypoxic 
induction of HIF-1α accumulation was impaired and HIF-1α DM(PP/AA) poly-ubiquitination was 
increased (Figure 4.10). This pointed towards the existence of an ubiquitin E3-ligase that targets 
HIF-1α for proteasomal degradation independently of cellular oxygen tension and whose 
function is opposed by USP29. Several non-canonical HIF-1α ubiquitin E3 ligases have been 
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described previously (Table 4.2) and we checked whether they also down-regulated HIF-1α 
DM
(PP/AA)
. We further tested whether an additional set of components of E3 ligase complexes 
that we found to interact with USP29 (see 0) affected HIF-1α DM(PP/AA) levels.  
Table 4.2: Potential non-canonical ubiquitin E3 ligases for HIF-1α. Ubiquitin E3 ligases 
and components of such complexes described as modulators of HIF-1α or identified in 
USP29’s interactome (chapter 0) 
 HIF-1α modulators USP29’s interactome 
PARK2 (Sarraf et al., 2013) No 
STUB1/CHIP (Luo et al., 2010) yes (2/3) 
MDM2 (Ravi et al., 2000) No 
TRIM28 (Li et al., 2003) yes (3/3) 
Fbw7 (Cassavaugh et al., 2011) No 
TRAF6 (Sun et al., 2013) No 
DDB1 No yes (3/3) 
SKP1 No yes (3/3) 
HUWE1 No yes (2/3) 
RLIM No yes (2/3) 
Therefore, we monitored the protein level of HIF-1α DM(PP/AA) in HEK293T cells upon siRNA-
mediated depletion of each individual ubiquitin E3 ligase complex component (Figure 4.19). 
Silencing of most of the tested E3 ligases resulted either in no change or in a drop of HIF-1α 
DM
(PP/AA)
 levels. In particular, HIF-1α DM(PP/AA) levels were not increased in any condition, as 
it would be expected when silencing the negative regulator. This suggested that either a novel 
ubiquitin E3 ligase was responsible for targeting HIF-1α DM(PP/AA) for degradation or that, even 
though good silencing efficiencies were achieved (Figure 4.19), residual ubiquitination activity 
was sufficient to keep targeting HIF-1α DM(PP/AA) for degradation. 
 
Figure 4.19: HIF-1α DM(PP/AA) is not down-regulated by the selected potential ubiquitin 
E3-ligases. E3 ligases were depleted from HEK293T cells with siRNAs and the silencing 
efficiency was determined using qPCR (bottom). HIF-1α DM(PP/AA) was overexpressed in the 
silenced cells and HIF-1α DM(PP/AA) protein levels were determined by immunoblotting. 
Experiment was performed by me. 
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4.15 Discussion 
We sought to find new regulators of hypoxia signalling in the hope of improving the 
understanding of why HIF-α levels do not always correlate with oxygen levels present in the 
cells. This is particularly prevalent in cancer where HIF-α has even been described to be a 
negative prognostic factor (Trastour et al., 2007; Zhong et al., 1999). As HIF-α’s are tightly 
regulated through ubiquitination followed by proteasomal degradation, a protein that 
deconjugates ubiquitin – a deubiquitinase – would be a logical candidate for being a HIF-α 
stabiliser.  
A DUB screen performed in Edurne Berra’s lab revealed USP29 as a potential novel activator 
of the hypoxia signalling. The data presented in manuscript form in this chapter confirm 
USP29’s role as a HIF-α stabiliser. USP29 binds to both, HIF-1α and HIF-2α, in a hydroxy-
proline (and pVHL-) independent manner and deubiquitinates them very efficiently in cellulo, 
thereby protecting them from proteasomal degradation even in normoxic conditions. The 
mechanism through which USP29 acts on HIF-α is therefore fundamentally different from how 
the DUB Cezanne/OTUD7B affects HIF-1α. Cezanne has recently been shown to stabilise HIF-
1α through a mechanism that depends on pVHL and protects HIF-α from lysosomal 
degradation, presumably by deconjugating K11-linked poly-ubiquitin (Bremm et al., 2014).  
Further, USP29 is the only deubiquitinase known today that exhibits catalytical activity towards 
HIF-2α, and besides USP28 the second deubiquitinase that is known to rescue HIF-1α from 
PHD/pVHL-independent targeting to the proteasome (Flugel et al., 2012). However, while it 
has been shown that Fbw7 is the ubiquitin E3 ligase that is counteracted by USP28, no ubiquitin 
E3 ligase has been reported to act on the very C-terminus of HIF-α, which we found to be 
targeted by USP29. In this region we identified a cluster of three conserved lysine residues and 
their mutation to arginines considerably reduced basal ubiquitination of HIF-1α DM(PP/AA) that 
translated into higher stability of the protein. No function has been previously ascribed to these 
lysines and accordingly, when we knocked down known ubiquitin E3 ligases for HIF-α, in none 
of the conditions was HIF-α DM(PP/AA) stabilised. The same was true when we tested a panel of 
ubiquitin E3 ligase complexes that we found to be associated with USP29. Hence, the identity 
of HIF-α DM(PP/AA)’s negative regulator remains unknown, however our data propose that it 
assembles proteasome-targeting K48-linked poly-ubiquitin on HIF-α.  
Furthermore, the fact that the overexpression of USP29 protected both, endogenous wildtype 
HIF-α and oxygen-insensitive HIF-α DM(PP/AA), very efficiently from normoxic proteasomal 
degradation suggested that this unidentified HIF-α-E3 ligase was continuously active and 
limiting HIF-α availability in a similar way as does pVHL. Moreover, we found evidence for 
endogenous USP29 to be continuously stabilising HIF-1α, as siUSP29-mediated knock-down 
resulted in reduction of HIF-1α levels. The fact that USP29 levels were below detection limit 
with commercially available antibodies suggested that although being scarce, USP29 was 
catalytically highly active. Therefore, we propose that USP29 and the opposed ubiquitin E3 
ligase contribute to HIF-α steady-state levels in normoxia independently of oxygenation.  
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Their inactivation or hyperactivation either genetically or via post-translational regulations are 
therefore likely to have an important impact on HIF homeostasis and might be implicated in 
various diseases that are known to have deregulated hypoxia signalling. In particular, sustained 
HIF-1α levels and consequential active HIF signalling could be caused either by the inactivation 
of the ubiquitin E3 ligase or by the hyperactivation of USP29, respectively. The development of 
HIF inhibitors has yielded some promising results recently (Chen et al., 2016; Cho et al., 2016), 
but targeting the responsible deregulated upstream regulator might be a more promising and 
more specific alternative. The presence of conserved cysteine or metalloprotease active sites in 
DUBs makes them potentially more easily druggable than the ubiquitin E3 ligases which lack a 
canonical active site.  
Taken together, it is tempting to speculate about USP29’s potential use as a drug target in 
conditions where overexpressed and/or overactive USP29 is responsible for inappropriate HIF 
signalling. In physiological conditions USP29 expression is thought to be very tightly 
controlled on a transcriptional level. The USP29 gene is imprinted and hence we and others 
found endogenous USP29 mRNA and protein levels barely above background by qPCR and 
Western Blot, respectively, using commercially available antibodies for protein detection (Kim 
et al., 2000; Liu et al., 2011). The epigenetic mechanisms that control USP29 expression and 
how those mechanisms are disturbed in cancer remain to be determined. For instance, LOI (loss 
of imprinting)-mediated activation of the normally silent maternal allele might cause an USP29 
upregulation. Furthermore, Liu and co-workers suggested that USP29 expression was induced 
upon oxidative stress (Liu et al., 2011). In their experimental setup H2O2 treatment induced 
cooperative binding of FBP (FUSE binding protein) and AIMP2 (JTV1/p38) to USP29’s Far 
Upstream Sequence Element (FUSE), thereby triggering USP29 transcription. Notably, AIMP2-
DX2, an AIMP2 splice-variant, was particularly effective in inducing USP29 expression (Liu et 
al., 2011) and high AIMP2-DX2 expression has been correlated with lung cancer progression 
(Choi et al., 2011). Independently of the molecular mechanism underlying the transcriptional 
USP29 upregulation, the inactivation of USP29 activity could have the potential to reverse 
pathological hypoxia signalling efficiently. In particular, this would not interfere with the 
physiological signalling pathway that allows for adaptation to hypoxia. A specific and 
adequately dosed drug that targets USP29, despite being delivered to all cells of the body, 
would only affect cells with high amounts of USP29 where it could normalise HIF-α levels.  
Both, academic research, as well as pharmaceutical companies are currently trying to develop 
specific DUB inhibitors (Ndubaku and Tsui, 2015). However, to date no specific USP29 
inhibitor is available yet. The catalytic cysteine protease domain might be a druggable domain, 
but USP29 has also other domains with unknown functions that might be worth investigating. 
However, before the exploration of potential drugs targeting USP29 it is also crucial to 
understand how USP29 itself is regulated and which other signalling pathways would be 
potentially affected upon USP29 inhibition in order to anticipate possible detrimental side 
effects of treatment. 
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Chapter 5: Biochemical characterisation of 
USP29  
5.1 Introduction 
In the previous chapter we established the ubiquitin specific protease 29 (USP29) as a new non-
canonical positive regulator of HIF-α stability and hypoxia signalling. We further found a 
positive correlation between USP29 mRNA levels and prostate cancer progression and severity. 
Therefore, USP29 might become a possible therapeutic target in the future. However, while the 
discovery of the paternally expressed USP29 gene dates back to the year 2000, the USP29 
protein has hardly received any scientific attention (Kim et al., 2000). To date, only two reports 
about USP29’s function have been published (Liu et al., 2011; Martin et al., 2015). While they 
describe USP29’s implication in p53 and claspin stabilisation, no information about the USP29 
protein itself is available.  
To close this gap in the literature, our objective was to biochemically characterise the USP29 
protein. We wanted to find out whether apart from its strong transcriptional regulation by 
imprinting, USP29 was also regulated on a post-translational level. Furthermore, in order to 
better understand in which other biological processes USP29 might be implicated we performed 
pull-down experiments with ectopic USP29 to find proteins that were associated with USP29.  
In this chapter we therefore present novel insights into the properties of the so far poorly 
characterised USP29. We have here investigated how USP29 auto-regulates its own stability as 
well as present an interactome of USP29. 
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5.2 USP29 autoregulation  
5.2.1 USP29C294S is degraded by the proteasome 
In accordance with previously published data (Urbe et al., 2012), HA- and GFP-tagged USP29 
are localised in the nucleus, as well as the catalytically inactive mutant GFP-USP29
C294S
 (Figure 
5.1). 
 
Figure 5.1: Localisation of USP29. HeLa cells were transfected with HA-USP29, fixed, and 
stained with anti-HA-antibody. GFP-USP29 and GFP-USP29
C294S
 transfected cells were imaged 
live. Scale bars are 20 μm.  
In line with the weaker fluorescence of GFP-USP29
C294S
 (Figure 5.1), we found that its 
expression levels were greatly decreased compared to GFP-USP29 when transfecting the same 
amount of both plasmids (Figure 5.2A). To assess whether degradation of GFP-USP29
C294S
 by 
the proteasome was responsible for its low expression levels, we treated cells with the 
proteasome inhibitor MG132. Indeed, while GFP-USP29 levels remained unaffected by this 
inhibition, GFP-USP29
C294S
 levels were considerably increased (Figure 5.2B). To confirm that 
MG132 exerted its effect on USP29
C294S
 via the proteasome, we treated the cells with the more 
specific proteasome inhibitor epoxomicin. Epoxomicin also led to accumulation of GFP-
USP29
C294S
. In agreement with USP29
C294S’s proteasomal degradation, we found USP29C294S to 
be less stable than USP29 in cycloheximide experiments. While catalytically active USP29 was 
stable throughout 6 hours, the half-life of USP29
C294S
 was heavily reduced to less than 1 hour 
(Figure 5.2C). 
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Figure 5.2: USP29
C294S
 is less stable than USP29. HEK293T cells were transfected with GFP-
USP29 or GFP-USP29
C294S
. A: same amounts of plasmids were transfected. B: cells were left 
untreated or treated for 4 h in the presence of 10 μM MG132 or epoxomicin. C: 8-fold more 
GFP-USP29
C294S
 than GFP-USP29
 
was transfected, cells were treated with cycloheximide (0.05 
mg/ml) and cell extracts were prepared at the indicated times after treatment. 
5.2.2 USP29 auto-deubiquitinates itself 
To investigate whether catalytic activity of USP29 was sufficient to avoid the proteasomal 
degradation of the inactive mutant, HA-USP29 was co-transfected together with GFP-
USP29
C294S
. In the presence of catalytically active HA-USP29, USP29
C294S
 protein levels were 
increased and reached similar levels to GFP-USP29 (Figure 5.3A).  
Interestingly, USP29 catalytic activity did accumulate USP29
C294S
 more efficiently than the 
inhibition of the proteasome using MG132. Therefore, we tested whether USP29
C294S
 might also 
be degraded through the autophagic pathway, the second major protein destruction machinery. 
To this end, HEK293T cells transfected with GFP-USP29
C294S
 were treated either with the 
proteasome inhibitor MG132 or the autophagy inhibitor chloroquine or both together for 6h 
prior to lysis (Figure 5.3B). Autophagy was efficiently inhibited as seen by the appearance of 
the lower band of LC3, LC3-II. No significant accumulation of USP29
C294S 
upon inhibition of 
the autophagic pathway was seen, and inhibition of both pathways at the same time did not 
further increase USP29
C294S
 levels as compared to MG132-treatment alone. This suggested that 
the autophagic machinery was not implicated in USP29
C294S
 degradation and that the difference 
seen in USP29
C294S
 levels between MG132 treatment and overexpression of catalytically active 
USP29 might be due to incomplete inhibition of the proteasome. 
On the basis of these previous data, we hypothesised that USP29’s catalytic activity was 
required to auto-deubiquitinate itself, thereby preventing its degradation by the proteasome. To 
test this hypothesis, GFP-USP29 or GFP-USP29
C294S
 were co-transfected together with FLAG-
ubiquitin in the absence or presence of HA-USP29. Prior to lysis, cells were treated for 2h with 
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MG132 and GFP-tagged proteins were pulled down with GFP-traps® under denaturing 
conditions. Ubiquitinated forms were not detectable for GFP-USP29 (Figure 5.3C). In the case 
of GFP-USP29
C294S
 however, we detected very little non-modified GFP-USP29
C294S
 and a great 
amount of poly-ubiquitinated GFP-USP29
C294S
, which was visible as a high molecular weight 
smear. This poly-ubiquitination was completely removed in the presence of HA-USP29, 
showing that USP29 is able to intermolecularly deubiquitinate USP29. 
 
Figure 5.3: USP29 catalytic activity is sufficient to protect USP29
C294S
 from proteasomal 
degradation. A: HEK293T cells were transfected with same amounts of GFP-USP29 and GFP-
USP29
C294S
 plasmids in the absence or presence of catalytic active HA-USP29. Cells were left 
untreated or treated with MG132 (10 μM) for 4h. B: HEK293T cells were transfected with 
GFP-USP29
C294S
 and treated with 10 μM MG132 and/or 30 μg/ml chloroquine for 6h. C: 
HEK293T cells were co-transfected with FLAG-ubiquitin and GFP-USP29, GFP-USP29
C294S
 or 
GFP-USP29
C294S
 and HA-USP29. Cells were treated with MG132 for 2h and GFP-tagged 
USP29 was pulled-down under denaturing conditions with GFP-traps®. Eluted proteins were 
run on gradient gels and non-modified and ubiquitinated forms detected by WB.  
5.2.3 Identification of USP29’s ubiquitination target residues 
We sought to identify the lysine residue(s) subjected to ubiquitination that are thereby 
determining the stability of USP29. To this end, GFP-USP29
C/S
 eluted from GFP-trap® under 
denaturing conditions was migrated on a SDS gel and stained with SYPRO® (Figure 5.4A). A 
broad band covering high molecular weight and potentially ubiquitinated GFP-USP29
C/S
 was 
cut out, digested with trypsin and loaded on the mass spectrometer. The analysis achieved 51% 
of sequence coverage, and two lysine residues were identified to be modified by ubiquitination, 
K127 and K668 (Figure 5.4B). Furthermore, the canonical signal for proteasomal degradation - 
K48-linked polyubiquitin - was present in the sample. Additionally, in an experiment aimed at 
exploring proteins that interact with USP29 (see paragraph 5.3.1) we found USP29 to be 
modified by ubiquitination at K599. Interestingly, the same peptide was found to be 
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phosphorylated either at threonine 584 or serine 587 (Figure 5.4C), however ubiquitination and 
phosphorylation seemed to be mutually exclusive. With the exception of the rodent lineage, all 
three identified lysine residues were evolutionary conserved, which highlighted their potential 
functional importance (Figure 5.4D).  
 
Figure 5.4: MassSpec analysis of GFP-USP29
C/S
. GFP-USP29
C/S 
was co-transfected into 
HEK293T cells together with FLAG-ubiquitin, treated with MG132 for 4 h, lysed and 
incubated with GFP-traps®. Traps were washed with stringent buffers before GFP-USP29
C/S
 
got eluted. Eluate was migrated on a SDS gel and bands stained with SYPRO® (A). Indicated 
gel slice was digested with trypsin and analysed by MS. (B) Red sequences were identified in 
the MS, underlined K residues were found to be ubiquitinated. (C) Peptide that was found to be 
either ubiquitinated (K599) or phosphorylated (T584 or S587), on the red residues. (D) 
Sequence alignment of the lysine residues that were identified to be ubiquitinated. HU: human, 
PR: hyrax, LO: elephant, RA: rat, MO: mouse, MA: rhesus macaque, GO: gorilla NO: gibbon 
monkey, HO: horse, SH: sheep. 
Single mutation of lysine residues 127 and 668 to arginine (K127R and K668R) did not alter 
USP29
C/S’s expression levels and behaviour upon proteasome inhibition (Figure 5.5A). In order 
to exclude that there was some cooperative effect between the potential ubiquitination sites, 
USP29
C/S
 double mutants (K127/668R and K599/668R) as well as the triple mutant 
K127/599/668R were generated. None of these constructs displayed increased expression levels 
as compared to USP29
C/S
. Accordingly, all constructs continued to be regulated by the 
proteasome, indicating that the tested lysines were not directly and uniquely responsible for 
USP29
C/S’s degradation (Figure 5.5B). It is however possible that their ubiquitination might 
have degradation-independent regulatory functions. This is supported by the fact that we 
identified phosphorylation of two residues (T and S) in the very close proximity of K599, but 
only when K599 was not ubiquitinated. It has yet to be determined whether and how these 
phosphorylations affect USP29 behaviour. It is tempting to speculate that K599-ubiquitination 
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antagonises the phosphorylation of the neighbouring residues by preventing or mediating the 
binding of the responsible kinase or phosphatase, respectively. Vice versa, the phosphorylation 
status of the T and S residues might dictate further ubiquitination. 
 
Figure 5.5: K127, K599 and K668 are not sufficient to regulate the proteasomal 
degradation of USP29
C/S
. HEK293T cells were transfected with HA-USP29C/S and the single 
K/R-mutants HA-USP29
C/S
 K127R or HA-USP29
C/S
 K668R (A) and the multiple K/R mutants 
HA-USP29
C/S
 K127/668R, K599/668R and K127/599/668R (B). Cells were left untreated or 
were treated with MG132 for 4h before lysis.  
5.2.4 USP29 forms dimers 
The fact that USP29 was able to remove poly-ubiquitin from USP29
C294S
, suggested that USP29 
interacted with USP29
C294S
. USP29 does not only contain a split catalytic domain, but with its 
PH domain also a putative homodimerisation site (see Figure 1.5) and therefore, we 
investigated whether USP29 was able to form dimers. HEK293T cells were transiently 
transfected with HA-USP29 and lysed under native conditions. The lysate was separated by size 
exclusion chromatography and parts of the fractions were run on SDS-PAGE and probed for the 
presence of HA-USP29 (Figure 5.6A and B). USP29 was present not only in the peak 
corresponding to aggregates, but also in several other fractions (Figure 5.6B). These fractions 
were further run on a native gel in order to analyse whether USP29 ran as a monomer, a dimer 
or an oligomer. The WB of the native gel reveals one clear band corresponding to the 
approximately correct size of the monomeric HA-USP29 in the fractions B6-B1 (Figure 5.6C). 
Interestingly, in the higher molecular weight fractions B6 and B5 additional bands that could 
correspond to dimeric, trimeric and tetrameric HA-USP29 were also detected.  
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Figure 5.6: USP29 exists as monomer and oligomer. HEK293T cells were transfected with 
HA-USP29, lysed in native conditions and loaded onto a Superdex 200 10/300 GL column. 
Elution fractions (500 μl) were collected (A) and 1/50th of these fractions were migrated in a 
denaturing (B) or a native (C) gel and immunoblotted for HA-USP29. The arrowhead and 
asterisks correspond to the monomeric and oligomeric forms of HA-USP29, respectively. As an 
internal control, we identified dimeric BSA of 134 kDa size eluted in fraction B2.  
For a more direct proof of the interaction, we further used FLIM-based FRET measurements. 
The fluorescence excitation of a donor fluorophore can only be transferred to an appropriate 
acceptor fluorophore if both fluorophores are in very close proximity, typically within as little 
as 6 nm (Lam et al., 2012). Here, we used GFP-USP29 as the FRET donor and mCherry-USP29 
or mCherry-USP29
C/S
 as the FRET acceptor. We found GFP-USP29’s lifetime to be 
significantly decreased from 2.39 ± 0.013 ns to 2.36 ± 0.028 ns in the presence of mCherry-
USP29 (Figure 5.7A). Importantly, the lifetime decrease was readily reversed when mCherry 
was photobleached, confirming that this decrease was indeed due to FRET (Figure 5.7A, 
bottom images). Furthermore, GFP-USP29 also bound to mCherry-USP29
C/S
 as reflected by a 
lifetime decrease from 2.40 ± 0.008 ns in the absence to 2.37 ± 0.022 ns in the presence of 
mCherry-USP29
C/S
 (Figure 5.7B). These results clearly demonstrated that USP29 
homodimerisation did not require catalytic activity, and further support the deubiquitination of 
USP29
C/S
 by USP29.  
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Figure 5.7: USP29 homodimerises. Hela cells were transfected with GFP-USP29 alone or 
together with mCherry-USP29 (A)
 
or mCherry-USP29
C/S
 (B) and 24 h post-transfection, cells 
were imaged. Representative fluorescence and pseudo-coloured fluorescence lifetime (FLIM) 
images are shown in the first two and the last column, respectively. The white dotted line shows 
the region of interest that was photobleached. Average fluorescence lifetimes of nuclear GFP-
USP29 were extracted from the images and represented in the box pot (right panel). (A) 53 cells 
expressing GFP-USP29 and 38 cells co-expressing GFP-USP29 and mCherry-USP29 from 5 
different experiments were analysed (p = 5.4 * 10
-9
). (B) 18 cells expressing GFP-USP29 and 9 
cells co-expressing GFP-USP29 and mCherry-USP29
C/S
 from 2 different experiments were 
analysed (p = 0.002). Scale bars are 10 μm. 
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5.2.5 Ube3a is not USP29’s E3-ligase 
As USP29 is the first imprinted DUB described and there is only one known imprinted E3-
ligase (Ube3a), we tested whether they might be counterplayers. However, HA-Ube3a was 
neither able to decrease basal GFP-USP29
C/S
 levels nor HA-USP29-dependent accumulation of 
GFP-USP29
C/S
 (Figure 5.8). 
 
Figure 5.8: Ube3a does not regulate USP29
C/S
 protein levels. HEK293T cells were 
transfected with GFP-USP29
C/S 
alone or in combination with HA-USP29 and/or HA-Ube3a. 
5.3 USP29’s protein interaction landscape 
5.3.1 USP29’s interactome 
In order to identify proteins that might be implicated in the regulation of USP29 protein 
stability and catalytic activity as well as the downstream pathway triggered by USP29, a 
proteomic approach was applied. GFP-tagged USP29 or GFP alone was pulled down in native 
conditions from HEK293T cells and co-immunoprecipitated proteins were migrated on a SDS 
gel (Figure 5.9A). The gel was cut in slices, subjected to trypsin digestion and analysed by MS. 
Only proteins that were at least 3-fold enriched in the GFP-USP29 catch as compared to the 
GFP-bait were considered. The experiment was performed three times and remarkably, there 
was a set of 69 USP29-interacting proteins that was present in all the three independent 
replicates and another 222 proteins were detected in at least 2 samples (Figure 5.9B). Of the 69 
common proteins, 47 were interconnected and participate in a variety of biological processes 
(Figure 5.9C). USP29 interacted with mitochondrial and ribosomal proteins, proteins involved 
in the cytoskeletal organisation of the cell, and in concordance with its primarily nuclear 
localisation with proteins that bind to chromatin, DNA and mRNA. A complete list of these 291 
proteins can be found in Appendix Table 12. 
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Figure 5.9: MassSpec analysis of the USP29 interactome. In three independent experiments 
GFP-tagged USP29 was pulled down with GFP-traps® from HEK293T cells and the co-
immunoprecipitated proteins were migrated on a SDS gel (A: representative picture). The gel 
was cut in slices, subjected to trypsin digestion and analysed by mass spectrometry and 
compared with the catch of GFP alone. (B) Overlap of the USP29-specific proteins between the 
three replicates. (C) Functional clustering of the proteins that were identified in all three 
replicates (created with STRING).  
In their work “Defining the Human Deubiquitinating Enzyme Interaction Landscape” Sowa and 
co-workers identified interacting proteins of 75 DUBs by co-IPs followed by MS analysis 
(Sowa et al., 2009). An overlap of 108 proteins stands out when comparing their catch using 
USP29 as a bait with our own approach (Figure 5.10A). Globally 60% of the 69 proteins that 
90 Biochemical characterisation of USP29 
we identified in all three replicates and in particular our top 10 proteins were confirmed (Figure 
5.10B). Because of the high abundance of mitochondrial proteins among the interactors they 
postulated that USP29 was a mitochondrial protein.  
 
Figure 5.10: Comparison of our USP29 interactome with a previously published one. (A) 
Overlap of the USP29 interacting proteins that we identified in at least 2 out of 3 replicates 
(2/3) with the dataset from Sowa et al. (B) Each line represents a protein that is also present in 
Sowa’s dataset. 
However, based on a scoring system that incorporated for each detected protein the individual 
counts of its unique peptides in the MS analysis, as well as its natural abundance and the 
reproducibility in other replicates, Sowa et al. proposed that the only specific interactor was 
cathepsin B. As a consequence, they state that all other detected proteins were non-specifically 
interacting with the bait. In line with that, there is a very substantial overlap of our USP29 
interactome with the CRAPome (www.crapome.org). The CRAPome is a collection of data 
from negative controls of affinity purification experiments that allows identifying common 
contaminants in such experiments (Mellacheruvu et al., 2013). Among the most abundant 
CRAPome proteins are heat-shock proteins, tubulins, actins, elongation factors, 
ribonucleoproteins and ribosomal proteins, and the authors explain their unspecific enrichment 
by their high abundance in the cell. Indeed, these are groups of proteins that we found enriched 
in our USP29 interactome (Figure 5.9C). Of the 290 identified proteins, 282 are represented in 
the CRAPome and 50 of them are such common contaminants that they are found in more than 
half of all the 441 control experiments included in the repository. Furthermore, neither Sowa’s 
cathepsin B, nor the other previously described USP29 interactors, p53 (Liu et al., 2011) and 
claspin (Martin et al., 2015) or HIF-1α were present in our MS data. This very clearly 
questioned the usefulness of our approach, but nevertheless we tried to show some validity of 
our data by a co-immunoprecipitation followed by conventional WB. 
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5.3.2 PCNA is interacting with USP29 
Proliferating cell nuclear antigen (PCNA) was one of the top 20 interacting proteins of USP29 
in the proteomic approach (see Figure 5.9), both in terms of reproducibility and abundance. CIC 
bioGUNE’s Paco Blanco performed a bioinformatical analysis of the sequence of USP29 and 
found that USP29 contained the canonical PIP-box (PCNA interacting protein-box) sequence 
469
QxxLxxFF
477
, a motif commonly seen in proteins that bind to PCNA (Warbrick, 1998). 
Furthermore, Mosbech and co-workers mention in their paper from 2013 without displaying 
experimental evidence that “USP29 but not USP44 reversed ubiquitylation of several other 
factors, including proliferating cell nuclear antigen (PCNA)” (Mosbech et al., 2013). This 
encouraged us to test the potential interaction of the nuclear protein PCNA with USP29, despite 
the fact that PCNA is listed as a common contaminant according to the CRAPome (present in 
23% of all listed control experiments). Hence, USP29 was immunoprecipitated from cells using 
GFP-traps® and the eluate was probed for PCNA (Figure 5.11). And indeed, PCNA co-
immunoprecipitated with GFP-USP29, but not with GFP only, confirming their interaction seen 
by mass spectrometry. Furthermore, PCNA also co-immunoprecipitated with catalytically 
inactive GFP-USP29
C/S
. This indicated that the interaction was not dependent on USP29’s 
catalytic activity and supported the idea that USP29’s PIP-box may be responsible for PCNA 
binding.  
 
Figure 5.11: PCNA interacts with USP29 independently of its catalytic activity. HEK293T 
cells were transfected with GFP, GFP-USP29 or GFP-USP29
C/S
 and lysed 24h post-
transcription. GFP and GFP-fusion proteins were pulled down in native conditions with GFP-
traps® and eluates were subjected to SDS-PAGE followed by WB against endogenous PCNA 
protein. 
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5.3.3 Potential Ub E3 ligases for USP29 
The fact that we had found a PIP-box in USP29’s sequence and were able to co-
immunoprecipitate endogenous PCNA together with USP29, encouraged us to test other 
proteins of our interactome approach. Hence, we analysed the list of interactors by focusing on 
potential upstream regulators of USP29. Among the proteins detected in at least 2 replicates 
there were several candidate ubiquitin E3 ligases or components of ubiquitin E3 ligase 
complexes that could be responsible for the regulation of USP29 stability (Table 5.1). In order 
to study their potential role as regulators of USP29, we silenced them individually using 
siRNAs. As USP29 deubiquitinates not only itself but also HIF-1α, we hypothesised that both 
proteins might be targeted by the same Ub-E3 ligase and therefore included additional siRNAs 
targeting known HIF-1α Ub-E3 ligases.  
Table 5.1: Ub-E3 ligases or components of Ub-E3 ligase complexes that could be potential 
regulators of USP29
C/S
.  
 USP29 interactome HIF1 α modulator  
DDB1 yes (3/3) No 
SKP1 yes (3/3) No 
TRIM28 yes (3/3) (Li et al., 2003) 
HUWE1 yes (2/3) No 
STUB1/CHIP yes (2/3) (Luo et al., 2010) 
RLIM yes (2/3) No 
Fbw7 No (Cassavaugh et al., 2011) 
PARK2 No (Sarraf et al., 2013) 
TRAF6 No (Sun et al., 2013) 
MDM2 No (Ravi et al., 2000) 
pVHL No (Maxwell et al., 1999) 
 
All siRNA sequences efficiently silenced their target mRNA as determinded by quantitative 
real-time PCR (Figure 5.12 bottom). We analysed the effect of each silencing condition by 
monitoring the protein levels of the catalytic inactive USP29
C/S
. USP29
C/S
 levels remained 
unchanged or were reduced in most samples, however in the absence of HUWE1, USP29
C/S
 
protein levels increased substantially and to a comparable extent as upon proteasome inhibition 
(Figure 5.12). This suggested that HUWE1 might be responsible for the destabilisation of 
USP29
C/S
. 
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Figure 5.12: Potential Ub-E3 ligases for USP29. HEK293T cells were silenced with siRNAs 
against a panel of E3-ligases or components of E3-ligase complexes and transfected with GFP-
USP29
C/S
. As a positive control, control cells were treated with MG132 for 4h. The silencing 
efficiency was determined by TaqMan® qPCR of RNAs of cells simultaneously transfected and 
lysed. 
In order to confirm and further characterise the effect HUWE1 showed to have on USP29
C/S
, 
HUWE1-depleted cells were treated with the proteasome inhibitor MG132 and USP29
C/S
 
protein levels monitored. The depletion of HUWE1 with siRNA resulted in increased basal 
USP29
C/S
 protein levels comparable to those in control cells upon inhibition of proteasomal 
degradation (Figure 5.13). Furthermore, USP29
C/S
 levels were further increased when inhibiting 
the proteasomal degradation pathway alongside with the depletion of HUWE1.  
 
Figure 5.13: USP29
C/S
 accumulates upon knock-down of HUWE1. HEK293T cells were 
silenced with control and siRNA targeting HUWE1, transfected with GFP-USP29
C/S
 and left 
untreated or treated with MG132 for 4h. USP29
C/S
 levels in whole cell extracts were assessed 
by WB.  
This suggested that HUWE1 downregulated USP29
C/S
 by targeting it for proteasomal 
degradation. In the light of HUWE1 being an ubiquitin E3 ligase, we hypothesised that HUWE1 
poly-ubiquitinated USP29
C/S
. To test this, GFP-tagged USP29
C/S
 was co-expressed together 
with FLAG-ubiquitin and after treatment with MG132, USP29
C/S
 was pulled down under 
denaturing conditions using GFP-traps®. Unexpectedly, upon knock-down of endogenous 
HUWE1 protein with siRNA, USP29
C/S
 polyubiquitination was clearly increased, while the 
presence of HA-USP29 diminished USP29
C/S’s ubiquitination (Figure 5.14A). Moreover, when 
we subjected the samples to MS analysis, only K48-linked poly-ubiquitin was detected in the 
control condition and upon silencing of HUWE1 the sample contained additionally K6-, K11- 
and K63-linked polyubiquitin (Figure 5.14B). 
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Figure 5.14: Silencing of HUWE1 increases the poly-ubiquitination of USP29
C/S
. HEK293T 
silenced with either control siRNA or siHUWE1 were co-transfected with GFP-USP29
C/S 
and 
FLAG-ubiquitin and HA-USP29. Cells were treated with MG132 for 4h and GFP-tagged 
USP29
C/S 
was pulled-down under denaturing conditions with GFP-traps®. (A) Eluted proteins 
were run on gradient gels and non-modified and ubiquitinated forms detected by WB. (B) 
Eluted proteins were run on a SDS gel and stained with SYPRO®. The gel was cut above the 
main band of GFP-USP29
C/S
 to recover poly-ubiquitinated populations (brackets), subjected to 
trypsin digestion and analysed by MS. 
While a confirmation of these results with a second independent siHUWE1 is required, we 
hypothesize that HUWE1 might be binding to USP29
C/S
 in a way that prevents the binding of 
other ubiquitin ligases that are responsible for stabilising ubiquitination to USP29
C/S
. Another 
scenario is that HUWE1 might negatively regulate the stability of those ubiquitin E3 ligases 
which are therefore able to polyubiquitinate USP29
C/S
 only when HUWE1 is silenced. 
Strikingly, in their own approach Sowa and co-workers found HUWE1 to be associated with 
several other members of the USP family of DUBs, including USP7, USP49, USP50 and 
VCPIP1 (Sowa et al., 2009). However, according to the CRAPome repository also HUWE1 is a 
common contaminant (present in 18% of all control experiments on www.crapome.org).  
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5.3.4 USP29 and mitochondria  
As we (Figure 5.9) and others (Sowa et al., 2009) found USP29 to be associated with many 
mitochondrial proteins, including some of the inner mitochondrial membrane, such as subunits 
of the mitochondrial ATP synthase (Figure 5.9C), we wondered whether we would be able to 
find colocalisation of USP29 with mitochondrial structures. We therefore performed some 
preliminary studies and stained the mitochondria of HeLa cells transfected with GFP-USP29 
with MitoTracker (Figure 5.15). However, as shown previously, GFP-USP29 was only 
localised in the nucleus and no overlap of USP29 with mitochondrial signal was found. 
Moreover, there was no obvious change in mitochondria morphology in the presence of GFP-
USP29 as compared to GFP alone.  
 
Figure 5.15:USP29 does not colocalise with mitochondria. HeLa cells were transfected with 
GFP (upper row) or GFP-USP29 (lower row), stained with MitoTracker CM-H2XRos, fixed and 
imaged. Scale bars are 20 μm.  
Several scenarios could explain why we found interaction of USP29 with mitochondrial 
proteins. GFP-USP29 binding to mitochondrial proteins might be usually prevented by 
compartmentalisation but rendered possible after lysis during sample preparation and would 
therefore represent an artefact. We found USP29 to be bound to high amounts of heat shock 
proteins of the HSP70 family, that act as folding chaperones. While facilitating the folding of 
USP29 they might also independently be chaperoning the maturation of mitochondrial proteins 
as they emerge from the ribosome and before they get sorted to the mitochondria. However, we 
can’t exclude the possibility that there might be a small population of USP29 that localises to 
mitochondria and specifically interacts with some proteins, however our techniques might not 
be sensitive enough to detect this subpopulation.  
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5.4 Discussion 
In this chapter we present the first biochemical characterisation of the poorly studied 
deubiquitinase USP29 and its potential regulators and binding partners. We found evidence that 
additionally to its tight transcriptional regulation by imprinting (Kim et al., 2000), USP29 is 
regulated on a post-translational level. More precisely, USP29 is subjected to poly-
ubiquitination which targets USP29 for proteasomal degradation. However, this constant 
degradation is only seen for catalytically inactive USP29
C/S. USP29’s own catalytic activity is 
sufficient for auto-deubiquitination and hence USP29 escapes the proteasomal targeting.  
This proposed mechanism of auto-deubiquitination is not a novel mechanism among DUBs. For 
instance, USP19 has been described to be subjected to ubiquitination by SIAH and to 
subsequent degradation by the proteasome (Velasco et al., 2013). In analogy to what we found 
for USP29, the catalytic active form of USP19 is able to prevent the degradation through 
deconjugation of the polyubiquitin chains (Mei et al., 2011). Similarly, also UCH-L1 and USP4 
have been shown to reverse their own mono-ubiquitination, even though in both cases rather 
than affecting their stability, this did affect the DUB activity (Meray and Lansbury, 2007; 
Wijnhoven et al., 2015).  
We used mass spectrometry to identify the lysine residues in USP29 that were subjected to 
ubiquitination. As would be expected for poly-ubiquitinated proteasome substrates, the sample 
contained K48-linked polyubiquitin. Furthermore, three ubiquitinated lysine residues were 
found, K127, K599 and K668, and they turned out to be reasonably conserved throughout 
evolution with the exception of the rodent lineage. The individual or combinatorial mutation of 
the identified lysines however did not affect the protein levels of USP29
C/S
, suggesting that they 
were not exclusive determinant(s) for USP29 stability. They could however be modulating the 
catalytic activity and/or stability of USP29 by mediating or preventing further post-translational 
modifications or interactions with regulatory proteins. In this context it would be worth 
exploring the function of a specific peptide of USP29, which was consistently either 
phosphorylated or ubiquitinated. The phosphorylation might inhibit ubiquitination or vice versa. 
Such a mutually exclusive regulation has been reported for ubiquitinated or SUMOylated 
USP25, which results either in activation or inhibition of its catalytic activity, respectively 
(Denuc et al., 2009; Meulmeester et al., 2008). Furthermore, it has been suggested that DUBs 
containing ubiquitin binding domain (UBD) were regulated by mono-ubiquitination. The mono-
ubiquitin associates intra-molecularly with the UBD and hence prevents the DUB from binding 
to its ubiquitinated target proteins (Di Fiore et al., 2003; Hoeller et al., 2006). Other reports 
have shown that the ubiquitination of DUBs stimulated their ubiquitin-specific protease 
activities (Denuc et al., 2009; Todi et al., 2009). Phosphorylation of DUBs has been described 
to impact on their ability to bind to and/or deubiquitinate their substrates (Edelmann et al., 
2010; Fernandez-Montalvan et al., 2007; Hutti et al., 2007).  
We next sought to find the ubiquitin E3 ligase that was responsible for the destabilisation of 
USP29
C/S
, as well as potential downstream targets of USP29. To that end we set up an 
experiment that allowed us to identify by mass spectrometry proteins that associated with 
ectopic USP29 in cellulo. Even though the overlap with the CRAPome was substantial, 
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indicating that many proteins were rather contaminants than specific interactors, we were able 
to confirm the interaction of USP29 with PCNA, a protein that was identified in all replicates, 
by co-immunoprecipitation experiments. Interestingly, USP29 contains a canonical PCNA-
interacting protein (PIP) box within the N-terminal catalytic domain. Among the other 
identified proteins we found the ubiquitin E3 ligase HUWE1. Among HUWE1’s many 
substrates are p53, PCNA and n-myc, indicating HUWE1’s wide implication in cellular fate 
(Chen et al., 2005; Choe et al., 2016; King et al., 2016). When we depleted HUWE1 with 
siRNA, catalytic inactive USP29
C/S
 accumulated significantly and in a similar extent as it did 
upon proteasome inhibition. To our surprise however, silencing of HUWE1 not only 
accumulated poly-ubiquitinated-USP29
C/S 
but also expanded the type of conjugated Ub-chains. 
This indicated that HUWE1 rather than being a conventional Ub E3 ligase, which directly 
controls USP29 stability, might play a more complex role that needs to be further explored. For 
instance, HUWE1 might recruit a destabilising ubiquitin E3 ligase or might prevent the binding 
of a stabilising ubiquitin E3 ligase to USP29.  
Finally, we found that USP29 was able to form homo-dimers/oligomers in cells. This was not a 
surprise considering the fact that USP29 was able of remove poly-ubiquitin intermolecularly. 
Furthermore, USP29 contains a putative N-terminal homodimerisation domain, suggesting that 
the USP29 might be a functional dimer. In the case that the dimerisation of USP29 was crucial 
for its proteolytical activity towards its target proteins, the dimerisation interface could become 
a promising target, would USP29 inhibition become desirable in the future.  
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Chapter 6: Discussion 
6.1 The (dis)advantages of fluorescence microscopy 
The use of antibodies for the detection of endogenous cellular proteins is still the gold standard 
biochemical method for the analysis of localisation and behaviour of a protein of interest. The 
antibody needs to be able to bind specifically and efficiently to the protein of interest. However, 
sometimes such antibody is not available or endogenous protein levels in the model system are 
below the detection limit. Additionally, antibody staining requires fixation and permeabilisation 
of the sample. Apart from not being compatible with live cell applications, these procedures can 
also introduce major artefacts that can lead to the misinterpretation of the data (Schnell et al., 
2012).  
Fluorescence imaging in contrast, permits the investigation of protein localisation and dynamics 
in real time in living cells without the perturbations caused by harsh treatments. For this 
purpose, the protein(s) of interest need(s) to be tagged with (a) fluorescent protein tag(s). The 
green and red fluorescent protein were originally isolated from Aequorea victoria and 
Discosoma, respectively (Matz et al., 1999; Shimomura et al., 1962). Through mutations a 
broad palette of fluorescent proteins within the visible spectrum is available nowadays, which 
allows for multi-colour imaging (Day and Davidson, 2009). However, the tag needs to be fused 
to the protein of interest by molecular cloning methods and the expression plasmid needs to be 
transfected into cells. As a result, the fusion protein is likely to be expressed at levels that do not 
reflect their physiological abundance. This could be circumvented using the new CRISPR/Cas9 
genome editing technology (Jinek et al., 2012). The technology allows to specifically insert the 
sequence of a fluorescence tag in-frame with the gene of interest, resulting in the expression of 
the fluorescence-labelled endogenous protein under its own promoter. Apart from that, it should 
be noted that tags can also interfere with the behaviour of the protein of interest. The wrong 
localisation and the enhanced aggregation, as well as functional impairment of the tagged 
protein described in this thesis, are examples of such label-induced perturbations. 
Once the protein of interest has been successfully fused to a fluorescent label and the chimeric 
protein has been validated to be functional and it reproduces the cellular distribution of the 
endogenous protein, a variety of fluorescence imaging techniques can be used to explore 
properties that would be difficult to characterise using classical biochemical approaches. Rather 
than showing us simple one- or two-dimensional snap-shots of an inanimate biological system, 
modern fluorescence microscopy allows us to acquire four-dimensional data of living 
organisms. The third spatial dimension is added by z-sectioning or by using 3D imaging 
techniques such as light-sheet microscopes. Additionally, through the consecutive recording of 
the same frame, dynamic changes in the sample over time can be registered. Depending on the 
experimental setup such dynamics can range from a few milliseconds up to days and therefore 
permit us to image short and long processes, from intracellular protein diffusion and shuttling to 
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embryonic development. Furthermore, advanced fluorescence imaging techniques enable us to 
obtain highly quantitative data from the sample. FRAP, RICS and FCS can be used to measure 
the diffusion coefficients of proteins in the different compartments of the cell, for example 
(Kim et al., 2010). Apart from fluorescence live cell imaging techniques, there are currently no 
other biochemical means to obtain this information. In contrast, whether two proteins interact 
with each other, can be investigated with imaging techniques, such as FRET and FCCS as well 
as with classical biochemical methods, such as co-immunoprecipitations (co-IP) and proximity-
ligation assays (PLA). While distance-dependent photophysics are prerequisite to obtain 
positive FRET between two proteins, co-IPs and PLA can also yield positive results when the 
two proteins are both associated via a third (bridging) protein (Figure 6.1). PLA for example 
still gives a positive signal when proteins are separated by as much as 40 nm (Zatloukal et al., 
2014) and additionally the PLA signal has been shown to saturate early, resulting in only semi-
quantitative results (Mocanu et al., 2011). Hence, here imaging techniques are superior to 
biochemical ones, as they do not only have a much higher spatial resolution, but can also be 
performed in living systems, therefore accounting for dynamic changes over time. 
 
Figure 6.1: Comparison of FRET and Co-IPs to measure interaction. Whether two proteins 
(D and A) interact can be measured by FRET or Co-IP. FRET can only occur when the two 
proteins are within the Förster radius (grey circle), but not if they are physically connected, but 
spatially separated by a bridging protein (B). 
6.2 UPS and non-canonical HIF signalling 
Hypoxia signalling via HIF triggers important adaptive processes to limited oxygen availability 
that strongly impact the cell and its environment. But HIF homeostasis is not only regulated in 
an oxygen-dependent manner by the subsequent action of its canonical regulators PHD and 
pVHL and their counteracting deubiquitinases (Figure 6.2 left). Other ubiquitin E3 ligases have 
been described to poly-ubiquitinate HIF-1α, leading to its non-canonical proteasomal 
degradation or sending HIF-1α for chaperone-mediated autophagy (CMA) (Figure 6.2 right). As 
for the canonical pathway, deubiquitinases that reverse these processes have also been 
identified. Therefore, stimuli other than the oxygen tension can also modulate HIF signalling. 
And while there is growing knowledge of the identity of the responsible regulators, the 
conditions that trigger their action remain widely elusive.  
As a matter of fact, the presence of HIF-α and consequently sustained HIF signalling is a 
recognised negative prognostic factor in most cancers (Semenza, 2012b). Likewise, the 
deubiquitinases UCHL1 and USP28 have been shown to be overexpressed and to act as 
biomarkers in multiple myeloma and bladder cancer, respectively (Goto et al., 2015; Guo et al., 
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2014a). While no direct link with hypoxia signalling was established by the authors, in those 
cancers the overexpression of USP28 and UCHL1 might lead directly to HIF-1α stabilisation. 
Similarly, changes in expression levels or activity and mutations of any other of the HIF-α 
regulators could tip HIF homeostasis to one side or the other and hence cause inappropriate 
signalling. 
 
Figure 6.2: Ub E3 ligases and DUBs implicated in canonical and non-canonical HIF-1α 
regulation. Ubiquitin E3 ligases target HIF-1α for different degradation pathways by poly-
ubiquitinating them (red arrow). Deubiquitinases de-conjugate the ubiquitin (green arrow) and 
therefore stabilise HIF-1α. The grey box indicates that the two proteins antagonise each other. 
Included are only E3 ligases and DUBs whose molecular mechanism of action is sufficiently 
elucidated. 
6.3 Targeting hypoxia signalling via DUBs 
Sustained hypoxia signalling is found in many cancers and has been related to resistance to 
chemo- and radiotherapy, and hence many efforts have been made to pharmacologically inhibit 
the pathway by inhibiting HIF translation, stabilisation, dimerisation and activity (Figure 6.3) 
(Semenza, 2012b). In line with this, recent work by two groups demonstrated the specificity and 
efficacy of a small molecule that binds to HIF-2α and inhibits the dimerisation with HIF-1β in 
clear cell renal cell carcinomas in preclinincal trials in mice (Chen et al., 2016; Cho et al., 
2016).  
 
Figure 6.3: Drugs that inhibit HIF-1 signalling at different levels. From (Semenza, 2012b) 
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However, a systematic inhibition of HIF signalling might not always be beneficial as it would 
impair physiological hypoxic adaptation in other sites of the body. Therefore, targeting the de-
regulated upstream regulator of HIF could be a more promising and more cancer-specific 
approach. The rise of personalised medicine aspires to thoroughly analyse and compare each 
individual patient’s diseased and healthy tissue in the future and to be able to pin down the 
exact proteins and pathways that are deregulated in each particular case (Collins et al., 2016). 
Targeting those specifically would have a differential effect on the cancer tissue as compared to 
the healthy tissue. 
If the upregulation of a DUB is responsible for the inappropriate activation of a protein or 
signalling pathway, as we found evidence for with USP29 in prostate cancer, then targeting this 
DUB could be beneficial. Hence, DUBs are currently being explored as drug targets, both in 
academia and in industry. As they contain a conserved active site, they are potentially more 
readily targeted than their counter-players, the ubiquitin E3 ligases (D'Arcy et al., 2015). Small 
molecule inhibitors that bind to and modify the catalytic site of DUBs are being identified and 
tested, and while some DUBs can already be inhibited specifically, many drugs display low 
specificity and act as pan-inhibitors (Table 6.1).  
 
Table 6.1: Small molecule inhibitors for DUBs. From (D'Arcy et al., 2015) 
 
Apart from high-throughput compound screenings, structure-based drug discovery strategies 
could help to improve the drug development progress where structural data of the DUB to be 
targeted is available (Lionta et al., 2014). In this context, a better understanding of the structure 
and biochemistry of the DUB might also help to find alternative druggable sites, which could 
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allow for more specific targeting. The interaction of two proteins with each other could be 
interrupted by targeting the protein-protein interaction (PPI) surface with drugs. This approach 
has been successful with Nutlin-3, which binds to MDM2 and therefore prevents MDM2 from 
binding to and poly-ubiquitinating p53 (Vassilev et al., 2004). While MDM2 is an ubiquitin E3 
ligase, there is no reason why targeting a DUB’s PPI surface would not also be possible. In the 
case of USP29 it is tempting to speculate that its dimerisation might offer the possibility for 
active site-independent targeting.  
6.4 The potential role of USP29 dimerisation 
We have shown in this thesis that USP29 deubiquitinates itself and that USP29 dimers exist in 
cellulo. However, whether the USP29 dimerisation is required for its catalytical activity has not 
been investigated. Several scenarios are possible. The C-terminus of a single USP29 molecule 
could fold in, in order to complete the catalytical triad intra-molecularly (Figure 6.4A). 
However, the dimerisation of two USP29 molecules via their putative N-terminal homo-
dimerisation domains might be necessary for the conformational changes to occur. Upon 
dimerisation either one or both molecules could reconstitute their catalytical triad intra-
molecularly, creating one or two active sites, respectively (Figure 6.4B, C). Alternatively, the 
C-terminal catalytical domain of one or both molecules within the USP29 dimer could fold in 
such a way that it builds up the catalytical triad together with the cysteine of the other molecule 
(Figure 6.4D, E). This way, the dimer would form one or two inter-molecular catalytic sites, 
respectively. All hypothetical dimers could retain proteolytic activity in one active site even if 
one of the molecules contains a mutation of one of the crucial residues. Dimers consisting of the 
USP29
C/S
 mutant, however, are unable to reconstitute the required catalytical triad. 
Interestingly, the lysine residues that we found to be ubiquitinated without having a direct 
impact on USP29 stability, are located N-terminally of (K127) and just behind (K599 and 
K668) the first catalytic domain. While K127 could therefore affect USP29 dimerisation, the 
latter two are likely to be part of the hinge region that is formed when the C-terminus folds in. 
Their ubiquitination might either sterically hinder the curve formation or facilitate it by 
interacting with ubiquitin-binding domains intra- or inter-molecularly. Other post-translational 
modifications, such as phosphorylations, could similarly affect USP29 folding and/or 
dimerisation.  
As previously mentioned, if USP29 dimerisation was crucial for USP29 catalytic activity, then 
preventing the dimerisation with small molecules could be a promising approach to specifically 
reduce USP29 downstream effects. Of note, this could be more specific to USP29 than drugs 
that target USP29’s catalytic domain, as cysteine protease domains are very common. Such 
targeting of a homo-dimerisation interface with an engineered peptide has been recently 
successful in the case of estrogen receptor (Chakraborty et al., 2016).  
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Figure 6.4: Possible formations of active sites in USP29 dimers. Two USP29 molecules 
dimerise via their putative homo-dimerisation domain (grey cross), their split catalytical 
domains are coloured in green. The catalytical triad residues (C294, H840 and N857) are 
displayed as yellow stars if they form part of a complete active site or as grey stars if they don’t. 
6.5 Expression of USP29 
The expression of the USP29 gene has been described to be very low because of its selective 
transcription from the paternal allele (Kim et al., 2000). In fact, in early Northern Blot studies 
murine usp29 mRNA was detectable in brain and testis, and human USP29 mRNA was only 
present in testis tissue extracts (Kim et al., 2000). However, other’s and our data suggest that 
USP29 is also expressed in other cell types (Liu et al., 2011; Martin et al., 2015). While we 
were unable to detect endogenous USP29 protein with commercially available antibodies in 
HEK293T cells, RNAi-mediated depletion of USP29 mRNA impacted on HIF-α. Together with 
the fact that we were able to rescue this effect by re-introducing a siRNA-resistant USP29, this 
indicated that even though below the detection limit, USP29 was present and exhibited 
considerable catalytic activity. In the light of USP29 regulating not only HIF-α, but also claspin 
and p53 stability, any upregulation of USP29 expression might cause extensive perturbations of 
important cellular processes, including cell cycle progression, DNA integrity and HIF 
signalling. Accordingly, USP29 basal levels need to be limited in order for the cell to be able to 
function properly. Liu and co-workers suggest that AIMP2 induces USP29 transcription in 
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response to oxidative stress via FUSE binding protein 1 (FBP1). The alternative splice-variant 
AIMP2-DX2 was particularly successful in inducing USP29 expression (Liu et al., 2011), and 
this splice variant has been associated with lung cancer (Choi et al., 2011). Similarly, the loss of 
imprinting of the maternal USP29 allele could increase USP29 expression levels. In this regard, 
chromatin-modifying drugs that are widely used in cancer treatment, such as HDAC inhibitors 
could weaken the transcriptional repression.  
Bioinformatic analysis of an mRNA-based dataset of prostate tissue showed that USP29 
transcription was indeed upregulated in primary and metastatic tissue as compared to healthy 
prostate and that USP29 mRNA levels correlated with disease progression and severity as 
determined with the Gleason Score. Whether the USP29 up-regulation is a side effect of the 
oncogenic transformation in prostate cancer or whether it has a more decisive role in the 
transformation process remains to be investigated. In this context, it would also be important to 
confirm that the higher USP29 mRNA levels translate into higher USP29 protein levels. The 
fact that there was a positive correlation between USP29 and Ca9 mRNA levels indicates that 
this may indeed be the case. 
In order to study USP29’s function in healthy cells as well as in oncogenic transformation and 
cancer progression, there is a need for appropriate models. Mouse models are currently not 
available and given that in early studies USP29 showed different expression patterns in human 
and rodents, their usefulness needs to be scrutinised. In this regard, it is interesting to mention 
the case of bovine USP29, which shows 73% sequence identity with the human homologue 
(Kim et al., 2007). Bovine USP29 mRNA was found to be exclusively expressed in brain, 
however it has lost protein coding function and does not contain any ORF (Kim et al., 2007). 
The function of the long non-coding RNA is not well understood, however mouse data suggest 
that it might be involved in the promoter methylation status of the neighbouring zfp264 gene 
(He et al., 2016). 
6.6 USP29 - an integrator of cell signals? 
In response to oxidative stress, USP29 has been shown to stabilise p53, which subsequently 
induced apoptosis (Liu et al., 2011). Furthermore, USP29 has been reported to stabilise claspin, 
a protein that is required for replication and DNA damage repair and therefore USP29-depleted 
cells displayed delays in G1- to S-phase progression (Martin et al., 2015). In this thesis we 
established USP29 as an activator of hypoxia signalling (chapter 4). We and others also found 
USP29 to bind to PCNA, a protein crucial for DNA replication and involved in DNA damage 
response, however we did not investigate yet whether PCNA is a USP29 target protein. We 
further show that USP29 also auto-regulates its ubiquitination status and hence its stability 
(chapter 5).  
Considering its low abundance, the question arises how USP29 chooses among its different 
targets (Figure 6.5). Does USP29 bind all its ubiquitinated targets with equal affinity and is 
therefore the sole presence of the ubiquitinated substrate sufficient for USP29 binding? Or does 
USP29 have preference for a specific target which is hence stabilised preferably even in the 
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presence of other substrates? Moreover, are there USP29 modifications that modulate the 
affinity towards its target proteins? How is this whole process of substrate selection influenced 
by USP29’s own ubiquitination and/or dimerisation status? When USP29 itself is subjected to 
ubiquitination by its ubiquitin E3 ligase and hence has to auto-stabilise, is this reflected by a 
reduction of deubiquitination activity towards other targets?  
Hence, it is possible that USP29 chooses between HIF-α, p53 and claspin depending on their 
relative availabilities in the cell and USP29’s current deubiquitination potential. Furthermore, 
other regulators could interfere with the selection by modulating USP29’s catalytic activity and 
its post-translational modifications or its nuclear distribution. For example, USP29 could be 
sequestered by PCNA via its PIP-box depending on the cell cycle stage and the integrity of the 
DNA.  
By channelling the response via central transcriptional effectors such as HIF-α and p53, USP29 
could represent an integrator of various cellular signals.   
 
Figure 6.5: USP29 as an integrator of cell signals. USP29 itself and its target proteins are 
ubiquitinated (black lines) in response to various signals. USP29 removes the polyubiquitin 
(red arrows) and therefore protects them from proteasomal degradation, allowing them to 
execute their cellular functions (grey).  
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6.7 Outlook and perspective 
While we have discovered many novel regulatory mechanisms during this project, more 
fundamental regulatory principles are still to be revealed. Which ubiquitin E3 ligase(s) are 
responsible for ubiquitination of HIF-α and USP29 and which residues in USP29 are targeted? 
How does HUWE1 interfere with USP29’s ubiquitination? And do PTM’s modulate USP29’s 
ubiquitination status and/or its activity?  
Further questions are whether USP29 mRNA levels are altered or USP29 mutated in 
pathophysiological contexts other than prostate cancer and whether the alterations are 
implicated in the formation and progression of the disease or whether they occur as a 
concomitant of the cellular transformation. Depending on the answer, the next logical step 
would be the exploration of USP29 as a drug target. Is it feasible to target USP29 specifically 
and safely to manipulate HIF signalling in disease and what are the potential side effects? 
Furthermore, a new PhD project in Edurne Berra’s lab will be dedicated to investigate the basis 
and consequences of USP29’s interaction with PCNA and how this is regulated by or regulating 
DNA integrity. 
For many of these questions the use of the CRISPR/Cas9 system in model organisms could 
become a useful tool to manipulate USP29 expression levels, introduce specific mutations or 
add tags that facilitate USP29 detection. 
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Appendix 2: USP29 INTERACTOME 
Appendix Table 1: USP29 interacting proteins as determined by mass spectrometry. 
UniProt accession numbers and descriptions of the proteins that interacted with GFP-USP29 
and were at least 3-fold more enriched when compared with the GFP bait. Proteins that were 
detected in all 3 independent replicates are in grey, proteins that were detected in 2 out of the 
three replication white. 
Accession Description 
P33993 
DNA replication licensing factor MCM7 OS=Homo sapiens GN=MCM7 PE=1 SV=4 - 
[MCM7_HUMAN] 
P25705 
ATP synthase subunit alpha, mitochondrial OS=Homo sapiens GN=ATP5A1 PE=1 
SV=1 - [ATPA_HUMAN] 
P08107 
Heat shock 70 kDa protein 1A/1B OS=Homo sapiens GN=HSPA1A PE=1 SV=5 - 
[HSP71_HUMAN] 
Q9HBJ7 
Ubiquitin carboxyl-terminal hydrolase 29 OS=Homo sapiens GN=USP29 PE=2 SV=1 - 
[UBP29_HUMAN] 
P68371 
Tubulin beta-4B chain OS=Homo sapiens GN=TUBB4B PE=1 SV=1 - 
[TBB4B_HUMAN] 
P11142 
Heat shock cognate 71 kDa protein OS=Homo sapiens GN=HSPA8 PE=1 SV=1 - 
[HSP7C_HUMAN] 
P08238 
Heat shock protein HSP 90-beta OS=Homo sapiens GN=HSP90AB1 PE=1 SV=4 - 
[HS90B_HUMAN] 
P07437 Tubulin beta chain OS=Homo sapiens GN=TUBB PE=1 SV=2 - [TBB5_HUMAN] 
P12004 
Proliferating cell nuclear antigen OS=Homo sapiens GN=PCNA PE=1 SV=1 - 
[PCNA_HUMAN] 
Q9Y230 RuvB-like 2 OS=Homo sapiens GN=RUVBL2 PE=1 SV=3 - [RUVB2_HUMAN] 
O43175 
D-3-phosphoglycerate dehydrogenase OS=Homo sapiens GN=PHGDH PE=1 SV=4 - 
[SERA_HUMAN] 
Q14257 Reticulocalbin-2 OS=Homo sapiens GN=RCN2 PE=1 SV=1 - [RCN2_HUMAN] 
Q7L5D6 
Golgi to ER traffic protein 4 homolog OS=Homo sapiens GN=GET4 PE=1 SV=1 - 
[GET4_HUMAN] 
Q9UL15 
BAG family molecular chaperone regulator 5 OS=Homo sapiens GN=BAG5 PE=1 
SV=1 - [BAG5_HUMAN] 
P67809 
Nuclease-sensitive element-binding protein 1 OS=Homo sapiens GN=YBX1 PE=1 
SV=3 - [YBOX1_HUMAN] 
 USP29 interactome IX 
O15355 
Protein phosphatase 1G OS=Homo sapiens GN=PPM1G PE=1 SV=1 - 
[PPM1G_HUMAN] 
P07197 
Neurofilament medium polypeptide OS=Homo sapiens GN=NEFM PE=1 SV=3 - 
[NFM_HUMAN] 
Q9Y285 
Phenylalanine--tRNA ligase alpha subunit OS=Homo sapiens GN=FARSA PE=1 
SV=3 - [SYFA_HUMAN] 
Q07021 
Complement component 1 Q subcomponent-binding protein, mitochondrial OS=Homo 
sapiens GN=C1QBP PE=1 SV=1 - [C1QBP_HUMAN] 
P50990 
T-complex protein 1 subunit theta OS=Homo sapiens GN=CCT8 PE=1 SV=4 - 
[TCPQ_HUMAN] 
P17987 
T-complex protein 1 subunit alpha OS=Homo sapiens GN=TCP1 PE=1 SV=1 - 
[TCPA_HUMAN] 
P22695 
Cytochrome b-c1 complex subunit 2, mitochondrial OS=Homo sapiens GN=UQCRC2 
PE=1 SV=3 - [QCR2_HUMAN] 
P31943 
Heterogeneous nuclear ribonucleoprotein H OS=Homo sapiens GN=HNRNPH1 PE=1 
SV=4 - [HNRH1_HUMAN] 
P05141 
ADP/ATP translocase 2 OS=Homo sapiens GN=SLC25A5 PE=1 SV=7 - 
[ADT2_HUMAN] 
P62826 
GTP-binding nuclear protein Ran OS=Homo sapiens GN=RAN PE=1 SV=3 - 
[RAN_HUMAN] 
P23396 40S ribosomal protein S3 OS=Homo sapiens GN=RPS3 PE=1 SV=2 - [RS3_HUMAN] 
P49411 
Elongation factor Tu, mitochondrial OS=Homo sapiens GN=TUFM PE=1 SV=2 - 
[EFTU_HUMAN] 
P50402 Emerin OS=Homo sapiens GN=EMD PE=1 SV=1 - [EMD_HUMAN] 
Q9Y265 RuvB-like 1 OS=Homo sapiens GN=RUVBL1 PE=1 SV=1 - [RUVB1_HUMAN] 
P36542 
ATP synthase subunit gamma, mitochondrial OS=Homo sapiens GN=ATP5C1 PE=1 
SV=1 - [ATPG_HUMAN] 
O75190 
DnaJ homolog subfamily B member 6 OS=Homo sapiens GN=DNAJB6 PE=1 SV=2 - 
[DNJB6_HUMAN] 
P49368 
T-complex protein 1 subunit gamma OS=Homo sapiens GN=CCT3 PE=1 SV=4 - 
[TCPG_HUMAN] 
O95816 
BAG family molecular chaperone regulator 2 OS=Homo sapiens GN=BAG2 PE=1 
SV=1 - [BAG2_HUMAN] 
Q16531 DNA damage-binding protein 1 OS=Homo sapiens GN=DDB1 PE=1 SV=1 - 
X USP29 interactome 
[DDB1_HUMAN] 
O00767 Acyl-CoA desaturase OS=Homo sapiens GN=SCD PE=1 SV=2 - [ACOD_HUMAN] 
P46379 
Large proline-rich protein BAG6 OS=Homo sapiens GN=BAG6 PE=1 SV=2 - 
[BAG6_HUMAN] 
Q13263 
Transcription intermediary factor 1-beta OS=Homo sapiens GN=TRIM28 PE=1 SV=5 
- [TIF1B_HUMAN] 
P62263 
40S ribosomal protein S14 OS=Homo sapiens GN=RPS14 PE=1 SV=3 - 
[RS14_HUMAN] 
P63208 
S-phase kinase-associated protein 1 OS=Homo sapiens GN=SKP1 PE=1 SV=2 - 
[SKP1_HUMAN] 
Q96IX5 
Up-regulated during skeletal muscle growth protein 5 OS=Homo sapiens GN=USMG5 
PE=1 SV=1 - [USMG5_HUMAN] 
P43307 
Translocon-associated protein subunit alpha OS=Homo sapiens GN=SSR1 PE=1 SV=3 
- [SSRA_HUMAN] 
P19338 Nucleolin OS=Homo sapiens GN=NCL PE=1 SV=3 - [NUCL_HUMAN] 
P50991 
T-complex protein 1 subunit delta OS=Homo sapiens GN=CCT4 PE=1 SV=4 - 
[TCPD_HUMAN] 
P06733 Alpha-enolase OS=Homo sapiens GN=ENO1 PE=1 SV=2 - [ENOA_HUMAN] 
P11021 
78 kDa glucose-regulated protein OS=Homo sapiens GN=HSPA5 PE=1 SV=2 - 
[GRP78_HUMAN] 
P31689 
DnaJ homolog subfamily A member 1 OS=Homo sapiens GN=DNAJA1 PE=1 SV=2 - 
[DNJA1_HUMAN] 
Q3ZCQ8 
Mitochondrial import inner membrane translocase subunit TIM50 OS=Homo sapiens 
GN=TIMM50 PE=1 SV=2 - [TIM50_HUMAN] 
P06576 
ATP synthase subunit beta, mitochondrial OS=Homo sapiens GN=ATP5B PE=1 SV=3 
- [ATPB_HUMAN] 
P18085 
ADP-ribosylation factor 4 OS=Homo sapiens GN=ARF4 PE=1 SV=3 - 
[ARF4_HUMAN] 
P35232 Prohibitin OS=Homo sapiens GN=PHB PE=1 SV=1 - [PHB_HUMAN] 
P04181 
Ornithine aminotransferase, mitochondrial OS=Homo sapiens GN=OAT PE=1 SV=1 - 
[OAT_HUMAN] 
Q15293 Reticulocalbin-1 OS=Homo sapiens GN=RCN1 PE=1 SV=1 - [RCN1_HUMAN] 
P10809 
60 kDa heat shock protein, mitochondrial OS=Homo sapiens GN=HSPD1 PE=1 SV=2 
- [CH60_HUMAN] 
 USP29 interactome XI 
P04844 
Dolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit 2 OS=Homo 
sapiens GN=RPN2 PE=1 SV=3 - [RPN2_HUMAN] 
P39019 
40S ribosomal protein S19 OS=Homo sapiens GN=RPS19 PE=1 SV=2 - 
[RS19_HUMAN] 
Q04695 
Keratin, type I cytoskeletal 17 OS=Homo sapiens GN=KRT17 PE=1 SV=2 - 
[K1C17_HUMAN] 
P61204 
ADP-ribosylation factor 3 OS=Homo sapiens GN=ARF3 PE=1 SV=2 - 
[ARF3_HUMAN] 
P55209 
Nucleosome assembly protein 1-like 1 OS=Homo sapiens GN=NAP1L1 PE=1 SV=1 - 
[NP1L1_HUMAN] 
P38646 
Stress-70 protein, mitochondrial OS=Homo sapiens GN=HSPA9 PE=1 SV=2 - 
[GRP75_HUMAN] 
P08670 Vimentin OS=Homo sapiens GN=VIM PE=1 SV=4 - [VIME_HUMAN] 
P12236 
ADP/ATP translocase 3 OS=Homo sapiens GN=SLC25A6 PE=1 SV=4 - 
[ADT3_HUMAN] 
Q99623 Prohibitin-2 OS=Homo sapiens GN=PHB2 PE=1 SV=2 - [PHB2_HUMAN] 
P05388 
60S acidic ribosomal protein P0 OS=Homo sapiens GN=RPLP0 PE=1 SV=1 - 
[RLA0_HUMAN] 
Q9P0J0 
NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 13 OS=Homo sapiens 
GN=NDUFA13 PE=1 SV=3 - [NDUAD_HUMAN] 
Q00839 
Heterogeneous nuclear ribonucleoprotein U OS=Homo sapiens GN=HNRNPU PE=1 
SV=6 - [HNRPU_HUMAN] 
P62701 
40S ribosomal protein S4, X isoform OS=Homo sapiens GN=RPS4X PE=1 SV=2 - 
[RS4X_HUMAN] 
P27824 Calnexin OS=Homo sapiens GN=CANX PE=1 SV=2 - [CALX_HUMAN] 
P55060 Exportin-2 OS=Homo sapiens GN=CSE1L PE=1 SV=3 - [XPO2_HUMAN] 
P40227 
T-complex protein 1 subunit zeta OS=Homo sapiens GN=CCT6A PE=1 SV=3 - 
[TCPZ_HUMAN] 
P62913 
60S ribosomal protein L11 OS=Homo sapiens GN=RPL11 PE=1 SV=2 - 
[RL11_HUMAN] 
P07900 
Heat shock protein HSP 90-alpha OS=Homo sapiens GN=HSP90AA1 PE=1 SV=5 - 
[HS90A_HUMAN] 
P35998 
26S protease regulatory subunit 7 OS=Homo sapiens GN=PSMC2 PE=1 SV=3 - 
[PRS7_HUMAN] 
XII USP29 interactome 
P62269 
40S ribosomal protein S18 OS=Homo sapiens GN=RPS18 PE=1 SV=3 - 
[RS18_HUMAN] 
P11177 
Pyruvate dehydrogenase E1 component subunit beta, mitochondrial OS=Homo sapiens 
GN=PDHB PE=1 SV=3 - [ODPB_HUMAN] 
Q9Y5M8 
Signal recognition particle receptor subunit beta OS=Homo sapiens GN=SRPRB PE=1 
SV=3 - [SRPRB_HUMAN] 
P42677 
40S ribosomal protein S27 OS=Homo sapiens GN=RPS27 PE=1 SV=3 - 
[RS27_HUMAN] 
P62244 
40S ribosomal protein S15a OS=Homo sapiens GN=RPS15A PE=1 SV=2 - 
[RS15A_HUMAN] 
P62249 
40S ribosomal protein S16 OS=Homo sapiens GN=RPS16 PE=1 SV=2 - 
[RS16_HUMAN] 
O60884 
DnaJ homolog subfamily A member 2 OS=Homo sapiens GN=DNAJA2 PE=1 SV=1 - 
[DNJA2_HUMAN] 
P27348 
14-3-3 protein theta OS=Homo sapiens GN=YWHAQ PE=1 SV=1 - 
[1433T_HUMAN] 
P11441 
Ubiquitin-like protein 4A OS=Homo sapiens GN=UBL4A PE=1 SV=1 - 
[UBL4A_HUMAN] 
Q9P035 
Very-long-chain (3R)-3-hydroxyacyl-CoA dehydratase 3 OS=Homo sapiens 
GN=PTPLAD1 PE=1 SV=2 - [HACD3_HUMAN] 
P12956 
X-ray repair cross-complementing protein 6 OS=Homo sapiens GN=XRCC6 PE=1 
SV=2 - [XRCC6_HUMAN] 
Q9UBS4 
DnaJ homolog subfamily B member 11 OS=Homo sapiens GN=DNAJB11 PE=1 SV=1 
- [DJB11_HUMAN] 
P02545 Prelamin-A/C OS=Homo sapiens GN=LMNA PE=1 SV=1 - [LMNA_HUMAN] 
Q9BSD7 
Cancer-related nucleoside-triphosphatase OS=Homo sapiens GN=NTPCR PE=1 SV=1 
- [NTPCR_HUMAN] 
P17812 CTP synthase 1 OS=Homo sapiens GN=CTPS1 PE=1 SV=2 - [PYRG1_HUMAN] 
P05387 
60S acidic ribosomal protein P2 OS=Homo sapiens GN=RPLP2 PE=1 SV=1 - 
[RLA2_HUMAN] 
P61221 
ATP-binding cassette sub-family E member 1 OS=Homo sapiens GN=ABCE1 PE=1 
SV=1 - [ABCE1_HUMAN] 
Q9BQE3 
Tubulin alpha-1C chain OS=Homo sapiens GN=TUBA1C PE=1 SV=1 - 
[TBA1C_HUMAN] 
 USP29 interactome XIII 
P60709 Actin, cytoplasmic 1 OS=Homo sapiens GN=ACTB PE=1 SV=1 - [ACTB_HUMAN] 
P46782 40S ribosomal protein S5 OS=Homo sapiens GN=RPS5 PE=1 SV=4 - [RS5_HUMAN] 
P05023 
Sodium/potassium-transporting ATPase subunit alpha-1 OS=Homo sapiens 
GN=ATP1A1 PE=1 SV=1 - [AT1A1_HUMAN] 
P51149 
Ras-related protein Rab-7a OS=Homo sapiens GN=RAB7A PE=1 SV=1 - 
[RAB7A_HUMAN] 
P62857 
40S ribosomal protein S28 OS=Homo sapiens GN=RPS28 PE=1 SV=1 - 
[RS28_HUMAN] 
Q9BUF5 Tubulin beta-6 chain OS=Homo sapiens GN=TUBB6 PE=1 SV=1 - [TBB6_HUMAN] 
Q9NS69 
Mitochondrial import receptor subunit TOM22 homolog OS=Homo sapiens 
GN=TOMM22 PE=1 SV=3 - [TOM22_HUMAN] 
P51571 
Translocon-associated protein subunit delta OS=Homo sapiens GN=SSR4 PE=1 SV=1 
- [SSRD_HUMAN] 
Q13200 
26S proteasome non-ATPase regulatory subunit 2 OS=Homo sapiens GN=PSMD2 
PE=1 SV=3 - [PSMD2_HUMAN] 
P20700 Lamin-B1 OS=Homo sapiens GN=LMNB1 PE=1 SV=2 - [LMNB1_HUMAN] 
O75489 
NADH dehydrogenase [ubiquinone] iron-sulfur protein 3, mitochondrial OS=Homo 
sapiens GN=NDUFS3 PE=1 SV=1 - [NDUS3_HUMAN] 
P08134 
Rho-related GTP-binding protein RhoC OS=Homo sapiens GN=RHOC PE=1 SV=1 - 
[RHOC_HUMAN] 
Q9Y5V3 
Melanoma-associated antigen D1 OS=Homo sapiens GN=MAGED1 PE=1 SV=3 - 
[MAGD1_HUMAN] 
P11310 
Medium-chain specific acyl-CoA dehydrogenase, mitochondrial OS=Homo sapiens 
GN=ACADM PE=1 SV=1 - [ACADM_HUMAN] 
P53007 
Tricarboxylate transport protein, mitochondrial OS=Homo sapiens GN=SLC25A1 
PE=1 SV=2 - [TXTP_HUMAN] 
P07195 
L-lactate dehydrogenase B chain OS=Homo sapiens GN=LDHB PE=1 SV=2 - 
[LDHB_HUMAN] 
Q96EY1 
DnaJ homolog subfamily A member 3, mitochondrial OS=Homo sapiens 
GN=DNAJA3 PE=1 SV=2 - [DNJA3_HUMAN] 
P00403 
Cytochrome c oxidase subunit 2 OS=Homo sapiens GN=MT-CO2 PE=1 SV=1 - 
[COX2_HUMAN] 
Q00325 
Phosphate carrier protein, mitochondrial OS=Homo sapiens GN=SLC25A3 PE=1 
SV=2 - [MPCP_HUMAN] 
XIV USP29 interactome 
O43242 
26S proteasome non-ATPase regulatory subunit 3 OS=Homo sapiens GN=PSMD3 
PE=1 SV=2 - [PSMD3_HUMAN] 
P00338 
L-lactate dehydrogenase A chain OS=Homo sapiens GN=LDHA PE=1 SV=2 - 
[LDHA_HUMAN] 
Q96A26 
Protein FAM162A OS=Homo sapiens GN=FAM162A PE=1 SV=2 - 
[F162A_HUMAN] 
P0CW22 
40S ribosomal protein S17-like OS=Homo sapiens GN=RPS17L PE=1 SV=1 - 
[RS17L_HUMAN] 
Q9H3N1 
Thioredoxin-related transmembrane protein 1 OS=Homo sapiens GN=TMX1 PE=1 
SV=1 - [TMX1_HUMAN] 
Q9UG63 
ATP-binding cassette sub-family F member 2 OS=Homo sapiens GN=ABCF2 PE=1 
SV=2 - [ABCF2_HUMAN] 
Q9UJS0 
Calcium-binding mitochondrial carrier protein Aralar2 OS=Homo sapiens 
GN=SLC25A13 PE=1 SV=2 - [CMC2_HUMAN] 
O43852 Calumenin OS=Homo sapiens GN=CALU PE=1 SV=2 - [CALU_HUMAN] 
O00148 
ATP-dependent RNA helicase DDX39A OS=Homo sapiens GN=DDX39A PE=1 
SV=2 - [DX39A_HUMAN] 
Q9Y2R0 
Cytochrome c oxidase assembly factor 3 homolog, mitochondrial OS=Homo sapiens 
GN=COA3 PE=1 SV=1 - [COA3_HUMAN] 
P60468 
Protein transport protein Sec61 subunit beta OS=Homo sapiens GN=SEC61B PE=1 
SV=2 - [SC61B_HUMAN] 
P0CG48 Polyubiquitin-C OS=Homo sapiens GN=UBC PE=1 SV=3 - [UBC_HUMAN] 
O60762 
Dolichol-phosphate mannosyltransferase subunit 1 OS=Homo sapiens GN=DPM1 
PE=1 SV=1 - [DPM1_HUMAN] 
Q06210 
Glutamine--fructose-6-phosphate aminotransferase [isomerizing] 1 OS=Homo sapiens 
GN=GFPT1 PE=1 SV=3 - [GFPT1_HUMAN] 
P32119 Peroxiredoxin-2 OS=Homo sapiens GN=PRDX2 PE=1 SV=5 - [PRDX2_HUMAN] 
P82650 
28S ribosomal protein S22, mitochondrial OS=Homo sapiens GN=MRPS22 PE=1 
SV=1 - [RT22_HUMAN] 
P63244 
Guanine nucleotide-binding protein subunit beta-2-like 1 OS=Homo sapiens 
GN=GNB2L1 PE=1 SV=3 - [GBLP_HUMAN] 
Q9NX63 
MICOS complex subunit MIC19 OS=Homo sapiens GN=CHCHD3 PE=1 SV=1 - 
[MIC19_HUMAN] 
Q9UNE7 E3 ubiquitin-protein ligase CHIP OS=Homo sapiens GN=STUB1 PE=1 SV=2 - 
 USP29 interactome XV 
[CHIP_HUMAN] 
P61619 
Protein transport protein Sec61 subunit alpha isoform 1 OS=Homo sapiens 
GN=SEC61A1 PE=1 SV=2 - [S61A1_HUMAN] 
Q13185 
Chromobox protein homolog 3 OS=Homo sapiens GN=CBX3 PE=1 SV=4 - 
[CBX3_HUMAN] 
P60866 
40S ribosomal protein S20 OS=Homo sapiens GN=RPS20 PE=1 SV=1 - 
[RS20_HUMAN] 
Q7Z6Z7 
E3 ubiquitin-protein ligase HUWE1 OS=Homo sapiens GN=HUWE1 PE=1 SV=3 - 
[HUWE1_HUMAN] 
P62906 
60S ribosomal protein L10a OS=Homo sapiens GN=RPL10A PE=1 SV=2 - 
[RL10A_HUMAN] 
P62750 
60S ribosomal protein L23a OS=Homo sapiens GN=RPL23A PE=1 SV=1 - 
[RL23A_HUMAN] 
P62241 40S ribosomal protein S8 OS=Homo sapiens GN=RPS8 PE=1 SV=2 - [RS8_HUMAN] 
O94905 Erlin-2 OS=Homo sapiens GN=ERLIN2 PE=1 SV=1 - [ERLN2_HUMAN] 
P04350 
Tubulin beta-4A chain OS=Homo sapiens GN=TUBB4A PE=1 SV=2 - 
[TBB4A_HUMAN] 
P62753 40S ribosomal protein S6 OS=Homo sapiens GN=RPS6 PE=1 SV=1 - [RS6_HUMAN] 
P18621 
60S ribosomal protein L17 OS=Homo sapiens GN=RPL17 PE=1 SV=3 - 
[RL17_HUMAN] 
Q99832 
T-complex protein 1 subunit eta OS=Homo sapiens GN=CCT7 PE=1 SV=2 - 
[TCPH_HUMAN] 
Q9NZ01 
Very-long-chain enoyl-CoA reductase OS=Homo sapiens GN=TECR PE=1 SV=1 - 
[TECR_HUMAN] 
O43143 
Putative pre-mRNA-splicing factor ATP-dependent RNA helicase DHX15 OS=Homo 
sapiens GN=DHX15 PE=1 SV=2 - [DHX15_HUMAN] 
P78527 
DNA-dependent protein kinase catalytic subunit OS=Homo sapiens GN=PRKDC PE=1 
SV=3 - [PRKDC_HUMAN] 
P52597 
Heterogeneous nuclear ribonucleoprotein F OS=Homo sapiens GN=HNRNPF PE=1 
SV=3 - [HNRPF_HUMAN] 
Q92598 
Heat shock protein 105 kDa OS=Homo sapiens GN=HSPH1 PE=1 SV=1 - 
[HS105_HUMAN] 
Q15738 
Sterol-4-alpha-carboxylate 3-dehydrogenase, decarboxylating OS=Homo sapiens 
GN=NSDHL PE=1 SV=2 - [NSDHL_HUMAN] 
XVI USP29 interactome 
P26373 
60S ribosomal protein L13 OS=Homo sapiens GN=RPL13 PE=1 SV=4 - 
[RL13_HUMAN] 
P19013 
Keratin, type II cytoskeletal 4 OS=Homo sapiens GN=KRT4 PE=1 SV=4 - 
[K2C4_HUMAN] 
Q13885 
Tubulin beta-2A chain OS=Homo sapiens GN=TUBB2A PE=1 SV=1 - 
[TBB2A_HUMAN] 
P62820 
Ras-related protein Rab-1A OS=Homo sapiens GN=RAB1A PE=1 SV=3 - 
[RAB1A_HUMAN] 
P21796 
Voltage-dependent anion-selective channel protein 1 OS=Homo sapiens GN=VDAC1 
PE=1 SV=2 - [VDAC1_HUMAN] 
P17980 
26S protease regulatory subunit 6A OS=Homo sapiens GN=PSMC3 PE=1 SV=3 - 
[PRS6A_HUMAN] 
P45880 
Voltage-dependent anion-selective channel protein 2 OS=Homo sapiens GN=VDAC2 
PE=1 SV=2 - [VDAC2_HUMAN] 
O75396 
Vesicle-trafficking protein SEC22b OS=Homo sapiens GN=SEC22B PE=1 SV=4 - 
[SC22B_HUMAN] 
O00231 
26S proteasome non-ATPase regulatory subunit 11 OS=Homo sapiens GN=PSMD11 
PE=1 SV=3 - [PSD11_HUMAN] 
P61026 
Ras-related protein Rab-10 OS=Homo sapiens GN=RAB10 PE=1 SV=1 - 
[RAB10_HUMAN] 
Q16891 
MICOS complex subunit MIC60 OS=Homo sapiens GN=IMMT PE=1 SV=1 - 
[MIC60_HUMAN] 
P63104 
14-3-3 protein zeta/delta OS=Homo sapiens GN=YWHAZ PE=1 SV=1 - 
[1433Z_HUMAN] 
P61106 
Ras-related protein Rab-14 OS=Homo sapiens GN=RAB14 PE=1 SV=4 - 
[RAB14_HUMAN] 
P35613 Basigin OS=Homo sapiens GN=BSG PE=1 SV=2 - [BASI_HUMAN] 
Q9H9B4 Sideroflexin-1 OS=Homo sapiens GN=SFXN1 PE=1 SV=4 - [SFXN1_HUMAN] 
P51148 
Ras-related protein Rab-5C OS=Homo sapiens GN=RAB5C PE=1 SV=2 - 
[RAB5C_HUMAN] 
P39656 
Dolichyl-diphosphooligosaccharide--protein glycosyltransferase 48 kDa subunit 
OS=Homo sapiens GN=DDOST PE=1 SV=4 - [OST48_HUMAN] 
P62195 
26S protease regulatory subunit 8 OS=Homo sapiens GN=PSMC5 PE=1 SV=1 - 
[PRS8_HUMAN] 
 USP29 interactome XVII 
P61289 
Proteasome activator complex subunit 3 OS=Homo sapiens GN=PSME3 PE=1 SV=1 - 
[PSME3_HUMAN] 
O14828 
Secretory carrier-associated membrane protein 3 OS=Homo sapiens GN=SCAMP3 
PE=1 SV=3 - [SCAM3_HUMAN] 
P24539 
ATP synthase F(0) complex subunit B1, mitochondrial OS=Homo sapiens 
GN=ATP5F1 PE=1 SV=2 - [AT5F1_HUMAN] 
P49720 
Proteasome subunit beta type-3 OS=Homo sapiens GN=PSMB3 PE=1 SV=2 - 
[PSB3_HUMAN] 
P61019 
Ras-related protein Rab-2A OS=Homo sapiens GN=RAB2A PE=1 SV=1 - 
[RAB2A_HUMAN] 
P14625 Endoplasmin OS=Homo sapiens GN=HSP90B1 PE=1 SV=1 - [ENPL_HUMAN] 
Q15008 
26S proteasome non-ATPase regulatory subunit 6 OS=Homo sapiens GN=PSMD6 
PE=1 SV=1 - [PSMD6_HUMAN] 
P40937 
Replication factor C subunit 5 OS=Homo sapiens GN=RFC5 PE=1 SV=1 - 
[RFC5_HUMAN] 
Q9Y277 
Voltage-dependent anion-selective channel protein 3 OS=Homo sapiens GN=VDAC3 
PE=1 SV=1 - [VDAC3_HUMAN] 
Q9NWU2 
Glucose-induced degradation protein 8 homolog OS=Homo sapiens GN=GID8 PE=1 
SV=1 - [GID8_HUMAN] 
O15173 
Membrane-associated progesterone receptor component 2 OS=Homo sapiens 
GN=PGRMC2 PE=1 SV=1 - [PGRC2_HUMAN] 
P30050 
60S ribosomal protein L12 OS=Homo sapiens GN=RPL12 PE=1 SV=1 - 
[RL12_HUMAN] 
P09661 
U2 small nuclear ribonucleoprotein A' OS=Homo sapiens GN=SNRPA1 PE=1 SV=2 - 
[RU2A_HUMAN] 
Q9Y3B4 
Splicing factor 3B subunit 6 OS=Homo sapiens GN=SF3B6 PE=1 SV=1 - 
[SF3B6_HUMAN] 
Q14974 
Importin subunit beta-1 OS=Homo sapiens GN=KPNB1 PE=1 SV=2 - 
[IMB1_HUMAN] 
P60842 
Eukaryotic initiation factor 4A-I OS=Homo sapiens GN=EIF4A1 PE=1 SV=1 - 
[IF4A1_HUMAN] 
Q9UNM6 
26S proteasome non-ATPase regulatory subunit 13 OS=Homo sapiens GN=PSMD13 
PE=1 SV=2 - [PSD13_HUMAN] 
P08574 
Cytochrome c1, heme protein, mitochondrial OS=Homo sapiens GN=CYC1 PE=1 
SV=3 - [CY1_HUMAN] 
XVIII USP29 interactome 
Q02978 
Mitochondrial 2-oxoglutarate/malate carrier protein OS=Homo sapiens 
GN=SLC25A11 PE=1 SV=3 - [M2OM_HUMAN] 
O75251 
NADH dehydrogenase [ubiquinone] iron-sulfur protein 7, mitochondrial OS=Homo 
sapiens GN=NDUFS7 PE=1 SV=3 - [NDUS7_HUMAN] 
Q9NP72 
Ras-related protein Rab-18 OS=Homo sapiens GN=RAB18 PE=1 SV=1 - 
[RAB18_HUMAN] 
Q13616 Cullin-1 OS=Homo sapiens GN=CUL1 PE=1 SV=2 - [CUL1_HUMAN] 
Q8WVX9 
Fatty acyl-CoA reductase 1 OS=Homo sapiens GN=FAR1 PE=1 SV=1 - 
[FACR1_HUMAN] 
Q15773 
Myeloid leukemia factor 2 OS=Homo sapiens GN=MLF2 PE=1 SV=1 - 
[MLF2_HUMAN] 
P62333 
26S protease regulatory subunit 10B OS=Homo sapiens GN=PSMC6 PE=1 SV=1 - 
[PRS10_HUMAN] 
P62258 
14-3-3 protein epsilon OS=Homo sapiens GN=YWHAE PE=1 SV=1 - 
[1433E_HUMAN] 
P61981 
14-3-3 protein gamma OS=Homo sapiens GN=YWHAG PE=1 SV=2 - 
[1433G_HUMAN] 
P60660 
Myosin light polypeptide 6 OS=Homo sapiens GN=MYL6 PE=1 SV=2 - 
[MYL6_HUMAN] 
P28066 
Proteasome subunit alpha type-5 OS=Homo sapiens GN=PSMA5 PE=1 SV=3 - 
[PSA5_HUMAN] 
O14818 
Proteasome subunit alpha type-7 OS=Homo sapiens GN=PSMA7 PE=1 SV=1 - 
[PSA7_HUMAN] 
P62304 
Small nuclear ribonucleoprotein E OS=Homo sapiens GN=SNRPE PE=1 SV=1 - 
[RUXE_HUMAN] 
O14925 
Mitochondrial import inner membrane translocase subunit Tim23 OS=Homo sapiens 
GN=TIMM23 PE=1 SV=1 - [TIM23_HUMAN] 
P49755 
Transmembrane emp24 domain-containing protein 10 OS=Homo sapiens 
GN=TMED10 PE=1 SV=2 - [TMEDA_HUMAN] 
O95292 
Vesicle-associated membrane protein-associated protein B/C OS=Homo sapiens 
GN=VAPB PE=1 SV=3 - [VAPB_HUMAN] 
P33991 
DNA replication licensing factor MCM4 OS=Homo sapiens GN=MCM4 PE=1 SV=5 - 
[MCM4_HUMAN] 
Q9NXW2 
DnaJ homolog subfamily B member 12 OS=Homo sapiens GN=DNAJB12 PE=1 SV=4 
- [DJB12_HUMAN] 
 USP29 interactome XIX 
Q14318 
Peptidyl-prolyl cis-trans isomerase FKBP8 OS=Homo sapiens GN=FKBP8 PE=1 
SV=2 - [FKBP8_HUMAN] 
Q9BQA1 
Methylosome protein 50 OS=Homo sapiens GN=WDR77 PE=1 SV=1 - 
[MEP50_HUMAN] 
P31153 
S-adenosylmethionine synthase isoform type-2 OS=Homo sapiens GN=MAT2A PE=1 
SV=1 - [METK2_HUMAN] 
O00487 
26S proteasome non-ATPase regulatory subunit 14 OS=Homo sapiens GN=PSMD14 
PE=1 SV=1 - [PSDE_HUMAN] 
Q32P51 
Heterogeneous nuclear ribonucleoprotein A1-like 2 OS=Homo sapiens 
GN=HNRNPA1L2 PE=2 SV=2 - [RA1L2_HUMAN] 
P55735 
Protein SEC13 homolog OS=Homo sapiens GN=SEC13 PE=1 SV=3 - 
[SEC13_HUMAN] 
Q04917 14-3-3 protein eta OS=Homo sapiens GN=YWHAH PE=1 SV=4 - [1433F_HUMAN] 
P13639 Elongation factor 2 OS=Homo sapiens GN=EEF2 PE=1 SV=4 - [EF2_HUMAN] 
Q15369 
Transcription elongation factor B polypeptide 1 OS=Homo sapiens GN=TCEB1 PE=1 
SV=1 - [ELOC_HUMAN] 
O95168 
NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 4 OS=Homo sapiens 
GN=NDUFB4 PE=1 SV=3 - [NDUB4_HUMAN] 
P25788 
Proteasome subunit alpha type-3 OS=Homo sapiens GN=PSMA3 PE=1 SV=2 - 
[PSA3_HUMAN] 
P28074 
Proteasome subunit beta type-5 OS=Homo sapiens GN=PSMB5 PE=1 SV=3 - 
[PSB5_HUMAN] 
P19388 
DNA-directed RNA polymerases I, II, and III subunit RPABC1 OS=Homo sapiens 
GN=POLR2E PE=1 SV=4 - [RPAB1_HUMAN] 
P46783 
40S ribosomal protein S10 OS=Homo sapiens GN=RPS10 PE=1 SV=1 - 
[RS10_HUMAN] 
Q9BYN8 
28S ribosomal protein S26, mitochondrial OS=Homo sapiens GN=MRPS26 PE=1 
SV=1 - [RT26_HUMAN] 
P57088 
Transmembrane protein 33 OS=Homo sapiens GN=TMEM33 PE=1 SV=2 - 
[TMM33_HUMAN] 
Q92499 
ATP-dependent RNA helicase DDX1 OS=Homo sapiens GN=DDX1 PE=1 SV=2 - 
[DDX1_HUMAN] 
A0FGR8 
Extended synaptotagmin-2 OS=Homo sapiens GN=ESYT2 PE=1 SV=1 - 
[ESYT2_HUMAN] 
XX USP29 interactome 
Q12906 
Interleukin enhancer-binding factor 3 OS=Homo sapiens GN=ILF3 PE=1 SV=3 - 
[ILF3_HUMAN] 
P30837 
Aldehyde dehydrogenase X, mitochondrial OS=Homo sapiens GN=ALDH1B1 PE=1 
SV=3 - [AL1B1_HUMAN] 
P51648 
Fatty aldehyde dehydrogenase OS=Homo sapiens GN=ALDH3A2 PE=1 SV=1 - 
[AL3A2_HUMAN] 
Q96AG4 
Leucine-rich repeat-containing protein 59 OS=Homo sapiens GN=LRRC59 PE=1 
SV=1 - [LRC59_HUMAN] 
Q15645 
Pachytene checkpoint protein 2 homolog OS=Homo sapiens GN=TRIP13 PE=1 SV=2 
- [PCH2_HUMAN] 
Q16342 
Programmed cell death protein 2 OS=Homo sapiens GN=PDCD2 PE=1 SV=2 - 
[PDCD2_HUMAN] 
P43686 
26S protease regulatory subunit 6B OS=Homo sapiens GN=PSMC4 PE=1 SV=2 - 
[PRS6B_HUMAN] 
O00232 
26S proteasome non-ATPase regulatory subunit 12 OS=Homo sapiens GN=PSMD12 
PE=1 SV=3 - [PSD12_HUMAN] 
P19387 
DNA-directed RNA polymerase II subunit RPB3 OS=Homo sapiens GN=POLR2C 
PE=1 SV=2 - [RPB3_HUMAN] 
Q9BSV6 
tRNA-splicing endonuclease subunit Sen34 OS=Homo sapiens GN=TSEN34 PE=1 
SV=1 - [SEN34_HUMAN] 
Q13148 
TAR DNA-binding protein 43 OS=Homo sapiens GN=TARDBP PE=1 SV=1 - 
[TADBP_HUMAN] 
Q9Y4P3 
Transducin beta-like protein 2 OS=Homo sapiens GN=TBL2 PE=1 SV=1 - 
[TBL2_HUMAN] 
P07741 
Adenine phosphoribosyltransferase OS=Homo sapiens GN=APRT PE=1 SV=2 - 
[APT_HUMAN] 
P62330 
ADP-ribosylation factor 6 OS=Homo sapiens GN=ARF6 PE=1 SV=2 - 
[ARF6_HUMAN] 
P40616 
ADP-ribosylation factor-like protein 1 OS=Homo sapiens GN=ARL1 PE=1 SV=1 - 
[ARL1_HUMAN] 
Q8WWC4 
Uncharacterized protein C2orf47, mitochondrial OS=Homo sapiens GN=C2orf47 PE=1 
SV=1 - [CB047_HUMAN] 
O14735 
CDP-diacylglycerol--inositol 3-phosphatidyltransferase OS=Homo sapiens GN=CDIPT 
PE=1 SV=1 - [CDIPT_HUMAN] 
P24534 Elongation factor 1-beta OS=Homo sapiens GN=EEF1B2 PE=1 SV=3 - 
 USP29 interactome XXI 
[EF1B_HUMAN] 
O96000 
NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 10 OS=Homo sapiens 
GN=NDUFB10 PE=1 SV=3 - [NDUBA_HUMAN] 
P62937 
Peptidyl-prolyl cis-trans isomerase A OS=Homo sapiens GN=PPIA PE=1 SV=2 - 
[PPIA_HUMAN] 
O00743 
Serine/threonine-protein phosphatase 6 catalytic subunit OS=Homo sapiens 
GN=PPP6C PE=1 SV=1 - [PPP6_HUMAN] 
P30041 Peroxiredoxin-6 OS=Homo sapiens GN=PRDX6 PE=1 SV=3 - [PRDX6_HUMAN] 
P28072 
Proteasome subunit beta type-6 OS=Homo sapiens GN=PSMB6 PE=1 SV=4 - 
[PSB6_HUMAN] 
P51153 
Ras-related protein Rab-13 OS=Homo sapiens GN=RAB13 PE=1 SV=1 - 
[RAB13_HUMAN] 
P01111 GTPase NRas OS=Homo sapiens GN=NRAS PE=1 SV=1 - [RASN_HUMAN] 
P61353 
60S ribosomal protein L27 OS=Homo sapiens GN=RPL27 PE=1 SV=2 - 
[RL27_HUMAN] 
P52815 
39S ribosomal protein L12, mitochondrial OS=Homo sapiens GN=MRPL12 PE=1 
SV=2 - [RM12_HUMAN] 
Q96GC5 
39S ribosomal protein L48, mitochondrial OS=Homo sapiens GN=MRPL48 PE=1 
SV=2 - [RM48_HUMAN] 
Q13405 
39S ribosomal protein L49, mitochondrial OS=Homo sapiens GN=MRPL49 PE=1 
SV=1 - [RM49_HUMAN] 
P52434 
DNA-directed RNA polymerases I, II, and III subunit RPABC3 OS=Homo sapiens 
GN=POLR2H PE=1 SV=4 - [RPAB3_HUMAN] 
P62070 
Ras-related protein R-Ras2 OS=Homo sapiens GN=RRAS2 PE=1 SV=1 - 
[RRAS2_HUMAN] 
P62081 40S ribosomal protein S7 OS=Homo sapiens GN=RPS7 PE=1 SV=1 - [RS7_HUMAN] 
P14678 
Small nuclear ribonucleoprotein-associated proteins B and B' OS=Homo sapiens 
GN=SNRPB PE=1 SV=2 - [RSMB_HUMAN] 
Q9Y3D9 
28S ribosomal protein S23, mitochondrial OS=Homo sapiens GN=MRPS23 PE=1 
SV=2 - [RT23_HUMAN] 
Q9Y2Q9 
28S ribosomal protein S28, mitochondrial OS=Homo sapiens GN=MRPS28 PE=1 
SV=1 - [RT28_HUMAN] 
O75934 
Pre-mRNA-splicing factor SPF27 OS=Homo sapiens GN=BCAS2 PE=1 SV=1 - 
[SPF27_HUMAN] 
XXII USP29 interactome 
P37108 
Signal recognition particle 14 kDa protein OS=Homo sapiens GN=SRP14 PE=1 SV=2 
- [SRP14_HUMAN] 
Q9Y3D7 
Mitochondrial import inner membrane translocase subunit TIM16 OS=Homo sapiens 
GN=PAM16 PE=1 SV=2 - [TIM16_HUMAN] 
Q9BVC6 
Transmembrane protein 109 OS=Homo sapiens GN=TMEM109 PE=1 SV=1 - 
[TM109_HUMAN] 
Q9Y3A6 
Transmembrane emp24 domain-containing protein 5 OS=Homo sapiens GN=TMED5 
PE=1 SV=1 - [TMED5_HUMAN] 
Q8NGC6 
Olfactory receptor 4K17 OS=Homo sapiens GN=OR4K17 PE=2 SV=3 - 
[OR4KH_HUMAN] 
P56192 
Methionine--tRNA ligase, cytoplasmic OS=Homo sapiens GN=MARS PE=1 SV=2 - 
[SYMC_HUMAN] 
Q8N7H5 
RNA polymerase II-associated factor 1 homolog OS=Homo sapiens GN=PAF1 PE=1 
SV=2 - [PAF1_HUMAN] 
O95831 
Apoptosis-inducing factor 1, mitochondrial OS=Homo sapiens GN=AIFM1 PE=1 
SV=1 - [AIFM1_HUMAN] 
P16615 
Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 OS=Homo sapiens 
GN=ATP2A2 PE=1 SV=1 - [AT2A2_HUMAN] 
Q8IXI2 
Mitochondrial Rho GTPase 1 OS=Homo sapiens GN=RHOT1 PE=1 SV=2 - 
[MIRO1_HUMAN] 
P47897 
Glutamine--tRNA ligase OS=Homo sapiens GN=QARS PE=1 SV=1 - 
[SYQ_HUMAN] 
P13010 
X-ray repair cross-complementing protein 5 OS=Homo sapiens GN=XRCC5 PE=1 
SV=3 - [XRCC5_HUMAN] 
P68104 
Elongation factor 1-alpha 1 OS=Homo sapiens GN=EEF1A1 PE=1 SV=1 - 
[EF1A1_HUMAN] 
P13647 
Keratin, type II cytoskeletal 5 OS=Homo sapiens GN=KRT5 PE=1 SV=3 - 
[K2C5_HUMAN] 
P02533 
Keratin, type I cytoskeletal 14 OS=Homo sapiens GN=KRT14 PE=1 SV=4 - 
[K1C14_HUMAN] 
P02538 
Keratin, type II cytoskeletal 6A OS=Homo sapiens GN=KRT6A PE=1 SV=3 - 
[K2C6A_HUMAN] 
P08779 
Keratin, type I cytoskeletal 16 OS=Homo sapiens GN=KRT16 PE=1 SV=4 - 
[K1C16_HUMAN] 
Q92928 Putative Ras-related protein Rab-1C OS=Homo sapiens GN=RAB1C PE=5 SV=2 - 
 USP29 interactome XXIII 
[RAB1C_HUMAN] 
P27635 
60S ribosomal protein L10 OS=Homo sapiens GN=RPL10 PE=1 SV=4 - 
[RL10_HUMAN] 
P04843 
Dolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit 1 OS=Homo 
sapiens GN=RPN1 PE=1 SV=1 - [RPN1_HUMAN] 
Q9BVK6 
Transmembrane emp24 domain-containing protein 9 OS=Homo sapiens GN=TMED9 
PE=1 SV=2 - [TMED9_HUMAN] 
Q9UJZ1 
Stomatin-like protein 2, mitochondrial OS=Homo sapiens GN=STOML2 PE=1 SV=1 - 
[STML2_HUMAN] 
Q9UK99 F-box only protein 3 OS=Homo sapiens GN=FBXO3 PE=1 SV=3 - [FBX3_HUMAN] 
Q9NVW2 
E3 ubiquitin-protein ligase RLIM OS=Homo sapiens GN=RLIM PE=1 SV=3 - 
[RNF12_HUMAN] 
P07196 
Neurofilament light polypeptide OS=Homo sapiens GN=NEFL PE=1 SV=3 - 
[NFL_HUMAN] 
Q5W0B1 
RING finger protein 219 OS=Homo sapiens GN=RNF219 PE=1 SV=1 - 
[RN219_HUMAN] 
Q9Y3Z3 
Deoxynucleoside triphosphate triphosphohydrolase SAMHD1 OS=Homo sapiens 
GN=SAMHD1 PE=1 SV=2 - [SAMH1_HUMAN] 
Q9ULX6 
A-kinase anchor protein 8-like OS=Homo sapiens GN=AKAP8L PE=1 SV=3 - 
[AKP8L_HUMAN] 
P48643 
T-complex protein 1 subunit epsilon OS=Homo sapiens GN=CCT5 PE=1 SV=1 - 
[TCPE_HUMAN] 
O95373 Importin-7 OS=Homo sapiens GN=IPO7 PE=1 SV=1 - [IPO7_HUMAN] 
P15924 Desmoplakin OS=Homo sapiens GN=DSP PE=1 SV=3 - [DESP_HUMAN] 
P04259 
Keratin, type II cytoskeletal 6B OS=Homo sapiens GN=KRT6B PE=1 SV=5 - 
[K2C6B_HUMAN] 
P06748 Nucleophosmin OS=Homo sapiens GN=NPM1 PE=1 SV=2 - [NPM_HUMAN] 
P07910 
Heterogeneous nuclear ribonucleoproteins C1/C2 OS=Homo sapiens GN=HNRNPC 
PE=1 SV=4 - [HNRPC_HUMAN] 
P26641 
Elongation factor 1-gamma OS=Homo sapiens GN=EEF1G PE=1 SV=3 - 
[EF1G_HUMAN] 
Q96TA2 
ATP-dependent zinc metalloprotease YME1L1 OS=Homo sapiens GN=YME1L1 
PE=1 SV=2 - [YMEL1_HUMAN] 
P10599 Thioredoxin OS=Homo sapiens GN=TXN PE=1 SV=3 - [THIO_HUMAN] 
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